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There is an urgent need for developing novel approaches for cancer treatment, as 
conventional therapeutic methods such as chemotherapy and radiotherapy have a 
number of limitations and are often accompanied with many adverse side effects to 
the normal cells. That is why people are increasingly concerned about the medicinal 
values of natural products in recent years as they have been found to be less cytotoxic 
and with considerably less undesirable effects for the cancer patients. 
Conjugated linolenic acid (CLN) is a group of naturally-occurring positional and 
geometrical conjugated trienoic isomers of the C-18 polyunsaturated fatty acid, 
linolenic acid (LN). The cis- and trans- isomeric combinations of CLN have been 
found in various plant oils, including the seed oils of pomegranate, bitter gourd, 
catalpa, pot marigold and jacaranda. The conjugated double bonds of the naturally 
occurring CLN isomers are mainly found at positions A 8, 10，12- and A 9, 11, 13- of 
the fatty acid carbon chain. CLN isomers contribute to numerous physiological and 
pharmacological activities, including modulation of fat storage, promotion of the 
proliferation of normal keratinocytes, inhibition of cyclooxygenase, chemopreventive 
and anti-tumor properties etc. CLN has become the focus of the cancer research in 
recent years. Although the studies on CLN so far are promising, but the mechanisms 
by which the CLN isomers can exhibit their direct anti-tumor effects remain largely 
elusive. In particular, the anti-proliferative, apoptosis- and differentiation-inducing 
abilities of CLN isomers on human myeloid leukemia cells are poorly understood. 
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In this study, four isomers o f C L N (9Z, 1 IE, 13E-CLN, 9E, 1 IE, 13E-CLN, 8E, 
lOE, 12E-CLN and 8Z, lOE, 12Z-CLN) were examined for their modulatory effects 
on the proliferation of different well-characterized human myeloid leukemia and 
lymphoma cell lines, including HL-60, HL-60/MX2, NB-4, EoL-1, K562 and U-937. 
All CLN isomers suppressed the in vitro proliferation of leukemia and lymphoma 
cells in a dose- and time-dependent manner. Moreover, 8Z, lOE, 12Z-CLN, or jacaric 
acid, showed the most potent anti-proliferative effect among the four isomers on the 
human promyelocytic leukemia HL-60 cells. However, jacaric acid was found to have 
little, if any, cytotoxicity to murine peritoneal macrophages, murine bone marrow 
cells, human hepatocyte-like WRL 68 cells and human foreskin fibroblast Hs68 cells. 
In addition, jacaric acid could significantly reduce the in vivo tumorigenicity of 
HL-60 cells in the BALB/c nude mice. The anti-tumor effect of jacaric acid on the 
HL-60 cells is believed to be mediated through cell cycle arrest at the GQ/GI phase 
and induction of programmed cell death. 
Jacaric acid was also found to be a potent apoptosis-inducing agent. It induced 
DNA fragmentation and apoptosis in the HL-60 cells dose- and time-dependently. 
Moreover, we found that this CLN isomer induced mitochondrial membrane 
depolarization which suggested that apoptosis might be triggered in a mitochondrial-
dependent manner. Detection of the externalization of phosphatidylserine in the 
jacaric acid-treated HL-60 cells also supported the occurrence of apoptosis. The 
activation of intrinsic apoptotic pathway was indicated by an imbalanced expression 
between pro-apoptotic and anti-apoptotic Bcl-2 proteins. Using the Western blotting 
technique, elevated expression of pro-apoptotic Bcl-2 family member proteins Bak 
and Bad and reduced expression of anti-apoptotic Bel -2 family member proteins 
Bcl-2 and BC1-XL were detected in the jacaric acid-treated HL-60 cells. Cytochrome c, 
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an imperative mediator of apoptosis, was released from the mitochondria to cytosol in 
a dose-dependent manner after treatment of HL-60 cells with jacaric acid. The 
cleavage of PARP protein also supported the activation of caspase-dependent 
apoptotic pathway by jacaric acid. Interestingly, jacaric acid did not increase the 
expression of the Fas and Fas ligand proteins. Activation of the intrinsic pathway but 
not the extrinsic pathway was confirmed by studying the activation of caspases-3, -8 
and -9 activities. The “initiator” caspase of the intrinsic pathway, caspase-9, and its 
"effector" caspase, caspase-3, were activated but an "initiator" caspase of the extrinsic 
pathway, caspase-8, was not activated in the jacaric acid-treated HL-60 cells. Apart 
from the intrinsic apoptotic pathway, jacaric acid also initiated oxidative stress and 
induced apoptosis through the ROS-dependent cell death pathway. We found that 
jacaric acid enhanced superoxide anion (O2') production in the HL-60 cells. Moreover, 
the production of O2' and induction of DNA fragmentation were inhibited by the 
antioxidant N-acetylcysteine (NAC). 
Furthermore, we demonstrated that jacaric acid did not exhibit 
differentiation-inducing effect in the HL-60 cells, as judged by a number of criteria 
such as morphological and phenotypic changes in the jacaric acid-treated HL-60 cells. 
The typical morphology of differentiated cells, including an increase in cell size and 
internal complexity, could not be observed in the jacaric acid-treated HL-60 cells. 
This is supported by the fact that there was little, if any, increase in the expression of 
the cell surface markers of monocytic differentiation CDl lb and CD 14 in the HL-60 
cells after treatment with jacaric acid. 
By unravelling the signaling pathways by which jacaric acid can exert its effects 
on the myeloid leukemia cells, it is hoped that novel targets for the treatment of 
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leukemia can be identified. Our preliminary results showed that jacaric acid activated 
the JNK pathway, but not the ERK pathway of the MAPK pathways. Jacaric acid also 
triggered the NF-KB pathways, which probably play certain roles, like inducing or 
regulating apoptosis, in the HL-60 cells. It is obvious that more in-depth 
investigations are needed to reveal the molecular and signaling mechanisms 
underlying the anti-tumor activities of jacaric acid and other CLN isomers, before 
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Chapter I General Introduction 
1.1 Hematopoiesis and Leukemia 
1.1.1 An Overview on Hematopoiesis Development 
"Hematopoiesis" is originated from the ancient Greek word: haima means 
"blood"; poiesis means “to make". By considering the meaning of these two words, 
hematopoiesis means the formation of blood cellular components. In a healthy adult, 
2-2.5 X lO" erythrocytes, 1.5-2 x 10^' platelets and 1-1.5 x lO" neutrophils are 
produced everyday (Van Zant et al., 1997). 
All cellular components of the blood are derived from the hematopoietic stem 
cells (HSC). HSC are self-renewal, multi-potent and are able to differentiate to 
committed progenitor cells, and ultimately the complete range of specialized blood 
cell types, including both myeloid and lymphoid cells (Potten and Loeffler, 1990). 
Self-renewal occurs when a cell undergoes one round of mitosis in cell cycle and 
generates the daughter cells that are still at the same developmental stage of their 
parental cell. Differentiation is the sequence of the maturity of cells. Self-renewal 
capacity will be lost when lineage commitment progresses, though some regenerative 
capacity may be maintained (Warner et cd,, 2004). The differentiation process has an 
amplification effect in terms of increment of the cell numbers, thus a high blood cell 
production rate can be maintained even when the stem cell division rate is low. 
The pluripotential HSC are known as the colony forming unit-myeloid and 
lymphoid cells (CFU-M,L) or the CD34 cells. They play a central role in 
hematopoiesis to complete the whole blood and lymphoid system. The progenitor 
cells that commit to the lymphoid lineage are called lymphoid stem cells or common 
lymphoid progenitors. The progenitors further give rise to at least four types of cells: 
- 1 -
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T lymphocytes, B lymphocytes, natural killer (NK) cells and antigen-presenting 
dendritic cells (Ye and Graf, 2007). The progenitor cells that commit to the myeloid 
lineage are known as colony forming unit-granulocyte, erythrocyte, monocyte, 
megakaryocyte (CFU-GEMM) or simply common myeloid progenitors. The 
progenitors further differentiate to colony forming unit-erythroid (CFU-E), colony 
forming unit-megakaryocytic (CFU-Meg), colony forming 
iinit-granulocyte-macrophage (CFU-GM), colony forming unit-eosinophilic 
(CFU-Eo), colony forming unit-basophilic (CFU-Ba), colony forming unit-mast cell 
(CFU-Mast) and utimately give rise to red blood cells, blood platelets, macrophages, 
neutrophils, basophils, eosinophils and mast cells (Orkin, 2000; Laiosa et al., 2006). 
This character was confirmed by the studies of virally injected marrow cells that the 
viral genes were incorporated into cellular DNA genome in random. The same 
characters of virally derived genes were seen in the same region of the genome in 
both lymphocytes and blood cells (Kelly et al., 1985; Lemischka et al, 1986). The 
hematopoietic system can be viewed as a hierarchical family tree of cells (Fig. 1.1). 
- 2 -
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Fig.1.1: Hematopoiesis and development of hematopoietic stem cell (HSC) 
(Modified from Kufe et aL, 2003) 
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1.1.1.1 Hematopoietic Growth Factors 
In order to survive, divide and differentiate, it is essential for the HSC to 
intermingle with the stromal cells and different types of hematopoietic growth factors 
(Heissiq et al., 2005). Colony-stimulating factors (CSF) produced by the stromal cells 
play an important role in regulating hematopoiesis. CSF are glycoproteins that bind 
on receptor proteins of the HSC and activate intracellular signaling pathways, thereby 
promote the production of colonies of differentiated blood cells (Ogawa, 1989). For 
example, granulocyte-macrophage colony stimulating factor (GM-CSF) promotes 
non-lymphoid cells formation at the early developmental stage. Macrophage colony 
stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) 
trigger formation of monocytes and granulocytes respectively at a slightly later stage 
(Comalada et al., 2005). Erythropoietin induces terminal development and production 
of erythrocytes (Thomas, 2004). Interleukins (IL) are also imperative hematopoietic 
growth factors. Interleukin-3 (IL-3) promotes the earlier erythroid progenitor cells to 
survive and proliferate (Eder et al” 1997; Thomas et al., 2004); IL-6 stimulates B cell 
progenitors; IL-2 regulates NK cells formation and IL-7 induces the lymphoid 
progenitors to differentiate into B cell progenitors and T cell progenitors (Fry and 
Mackall, 2005; Ye and Graf, 2007). Moreover, instead of having limited effects on a 
specific cell type, some CSF and IL are involved in the development of different cell 
types and in various developmental stages (Musashi and Ogawa, 1991). The signaling 
mechanism may also involve cell-surface-attached factors. For example, 
hematopoietic precursor cells in the bone marrow display transmembrane receptors 
Notch 1 on their plasma membrane while marrow stromal cells express corresponding 
Notch ligands (Schroeder and Just, 2000). 
Until now, the central question of how a hematopoietic growth factor affects an 
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individual hematopoietic blood cell remains unclear and at least some of the CSF 
seem to act by regulating probabilities, rather than directly command the pathway that 
the cell shall go (Ogawa, 1989; Musashi and Ogawa, 1991; Bellantuono, 2004). Even 
when two sister cells are taken out immediately after a cell division and cultured apart 
under identical conditions, they frequently give rise to different types of blood cells or 
in different numbers. Differentiation paths seem to involve random events at the 
individual cell level, although it is reliable at the multicellular system. 
1.1.1.2 Site Switching of Hematopoiesis 
Human blood development system involves multiple switching in the sites of 
hematopoiesis (Tavassoli, 1991; Heissiq et al., 2005). It occurs in two phases: the 
transient embryonic (“primitive”）phase and the definitive ("adult") phase. These 
phases differ in their sites of blood cell production, the timing of hematopoiesis, the 
morphology of the cells produced and the types of globin genes used in the red blood 
cells. 
Embryonic hematopoiesis is associated with the blood islands in the ventral 
mesoderm near the yolk. In mouse, embryonic erythropoiesis is in the blood islands in 
the mesoderm surrounding the yolk sac. In chick embryos, the first blood cell is in the 
blood islands in the posterior marginal zone near the site of hypoblast initiation (Wilt, 
1974; Azar and Eyal-Giladi, 1979). The embryonic hematopoietic cell population is 
transitory. This was shown in the chick by experiments of Dieterlen-Lievre, who 
grafted the chick blastoderm onto the yolk of Japanese quail. Chick cells can be 
distinguished from quail cells as the quail cell nucleus stains much more darkly. 
Dieterlen-Lievre and Martin (1981) used the “yolk sac chimeras" to prove the yolk 
sac stem cells do not contribute cells to adult animals. 
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The definitive HSC are formed within nodes of mesoderm that line the 
mesentery and the major blood vessels. The imperative source of new blood cells in a 
4-day chick embryo was at its aortic wall and HSC were found at this site (Cormier 
and Dieterlen-Lievre, 1988). Studies in mammals also showed that the definitive HSC 
are located in a domain near the aorta, called the aorta-gonad-mesonephros (AGM) 
region. In the mouse embryo, the first blood islands appear in the mesoderm around 
the yolk sac, but by day 11, pluripotential HSC can be found in the AGM (Kubai and 
Auerbach, 1983; Godlin et al., 1993; Medvinsky et al., 1993). HSC then migrate to 
the fetal liver via bloodstream and constitute the fetal and adult circulatory system 
(Medvinsky and Dzierzak, 1996; Heissiq, 2005). Erythropoiesis is a dominant process 
in liver while granulopoiesis also occurs. At around the time of birth, the site of 
hematopoiesis is finally transferred to the bone marrow, which is predominantly 
granulopoietic, and it is the main blood cell formation site throughout adult life. 
To conclude, hematopoiesis is a highly regulated process that involves various 
signaling pathways. Hematopoietic growth factors are essential for the HSC to survive; 
the cells will undergo apoptosis in the absence of them. Our blood cells are a 
population in a steady equilibrium state that balances with the cell loss (Hay, 1966). 
Catastrophes will be resulted when the capacity of hematopoietic precursor cells to 
differentiate and die is interfered in abnormal hematopoiesis. The disorders include 
aplastic anemia, neutropenia, thrombocytopenia, myelodysplasia, myeloproliferative 
disorders, lymphoproliferative disorders and hematologic malignancies, like 
lymphoma and leukemia (Tavassoli, 1991; Orkin, 2000; Bonnet, 2005). Leukemia 
will be discussed further in the next section. 
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1.1.2 An Overview on Leukemia 
The DNA sequence can be changed by copying errors introduced by DNA 
polymerases during replication or affected by environmental agents such as mutagens, 
ultraviolet (UV) radiation and ionizing radiation (X-rays and atomic particles) and 
then leads to cancer development. The ability of ionizing radiation to cause human 
cancers, especially leukemia, was dramatically shown by the boosting number of 
leukemia patients among survivors of the atomic bombs dropped in the World War II 
(Lodish, 1999). Most people with leukemia have excess but non-functional white 
blood cells, insufficient red blood cells and blood platelets (American Cancer Society, 
2007). 
In 2007, 44,240 new cases of diagnosed leukemia are expected in the U.S.A., 
with slightly more cases of chronic (24,480 cases) than acute (19,440 cases) diseases. 
Leukemia is diagnosed 10 times more often in adults than in children. Acute 
lymphocytic leukemia (ALL) accounts for about 73% of the leukemia cases in 
childhood (ages 0-19 years). Yet, the highest incidence of leukemia in childhood 
occurs between 2 and 5 years of age. Acute myeloid leukemia (AML) (approximately 
12,700 cases) and chronic lymphocytic leukemia (CLL) (approximately 15,100 cases) 
are the most common types of leukemia in adults (American Cancer Society, 2007). 
1.1.2.1 Classification of Leukemia 
Most types of cancers are assigned numbered stages, based on the tumor size and 
how far the cancer has spread. There is no need to stage leukemia as leukemia 
involves the bone marrow, and has already spread to other organs. Leukemia is 
divided into many types and subtypes. This helps physicians to predict which types of 
treatment should be carried out. 
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Leukemia can be classified by the speed of onset into acute or chronic; and by 
the developmental cell lineage into myeloid and lymphoid. The classified groups are 
acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myeloid 
leukemia (CML) and chronic lymphocytic leukemia (CML). However, categorizing 
leukemia is difficult and controversial when the morphology of the leukemia cells is 
not so clear cut. Some acute leukemia cases show both the myeloid and lymphoid 
features. These types of acute leukemia are called ALL with myeloid markers, AML 
with lymphoid markers, or simply bi-phenotypic leukemia (American Cancer Society, 
2007). To have a better classification, the French-American-British (FAB) system was 
developed to classify the subtypes of different leukemia. 
Several years ago, an international conference of prominent hematologists/ 
oncologists specializing in leukemia treatment and pathologists specializing in 
laboratory tests was held to decide on the best system of classification of leukemia. 
For example, this group of French, American, and British doctors decided that acute 
myeloid leukemia should be divided into eight subtypes, designated MO through M7, 
based on the type of cells from which the leukemia developed. At the very beginning, 
the FAB system classified leukemia subtypes by the appearance of leukemia cells 
under microscope (American Cancer Society, 2007). The subtypes of different 
leukemia are summarized in Table 1.1. Recently, cytogenetic studies, flow cytometry, 
and molecular genetic studies have provided more information for physicians to 
classify leukemia more accurately (Vardiman et al., 2002). 
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Table 1.1 The French-American-British (FAB) classification of leukemia 
Type FAB Subtype Percentage 
of Adult 
Patients 
AML MO: Undifferentiated AML 5% 
M l : Myeloblastic leukemia with minimal maturation 15% 
M2: Myeloblastic leukemia with maturation 25% 
M3: Promyleocytic leukemia 10% 
M4: Myelomonocytic leukemia 20% 
M4eos: Myelomonocytic leukemia with eosinophilia 5% 
M5: Monocytic leukemia 10% 
M6: Erythroid leukemia 5% 
M7: Megakaryoblastic leukemia 5% 
ALL LI: T cell or pre-B cell 30% 
L2: T cell or pre-B cell 65% 
L3: Bcell ^ 
CML Chronic phase: <10% blasts/ 20% blasts & promyelocytes ™ 
Accelerated phase: >10% blasts/ >20% blasts & 
promyelocytes, but <30% blasts 
Blast phase: >30% blasts and promyelocytes 
CLL Rai classification (U.S.A.): — 
Stage 0 is low risk, stages I and II are intermediate risk, 
and stages III and IV are high risk. 
Binet staging system (Europe): 
Classification is based on the number of affected lymphoid 
tissue groups and the presence of anemia or thrombo-
cytopenia. 
(Modified from American Cancer Society, 2007) 
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1.1.2.2 Conventional Therapy of Leukemia 
There are three popular tactics for leukemia treatment: they are chemotherapy, 
radiotherapy and stem cell transplantation (SCT). Apart from those methods, 
application of monoclonal antibodies also becomes a well-known treatment 
nowadays. 
In chemotherapy, a combination of several cytotoxic drugs is given to patients 
through veins or muscle to cerebrospinal fluid, or taken by mouth for a period of time 
to ensure the cytotoxic effect and prevent relapse (American Cancer Society, 2007). 
The regimen of AML includes cytarabine (Ara-C) and anthracycline, such as 
daunorubicin and idarubicin. For ALL, the regimen is composed of cyclophosphamide, 
vincristine, dexamethasone, L-asparaginase and daunorubicin. For CML, imatinib 
mesylate, an orally available tyrosine kinase inhibitor, is able to specifically block the 
consistently activated abnormal Bcr-Abl tyrosine kinase activity in CML patients. For 
CLL, chlorambucil and cyclophosphamide are the main drugs in the regimen 
(American Cancer Society, 2007; Roboz, 2007; Usui, 2007). 
For acute promyelocytic leukemia (APL), patients have to be identified for 
different treatments as patients may develop severe blood-clotting or bleeding 
problems. Anticoagulant must be applied before transfusions of platelets or other 
blood products (Tallman et al, 2004). APL responds to a differentiating agent, so the 
treatment is not considered as a usual chemotherapy. The details are introduced in the 
later part of this section. 
Yet, chemotherapy produces serious side effects to patients, including reduction 
in blood platelet production which leads to easy bruising and bleeding, lowering the 
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white blood cell levels which boosts the infection rate and suppression of the red 
blood cell counts which contributes to anemia. Hair loss, vomiting, loss of appetite 
and nausea are other common frightening experience for many cancer patients who 
undergo the treatment (American Cancer Society, 2007). Multi-drug resistance (MDR) 
condition is the nightmare for both the patients and the physicians after a long course 
of therapy. The phenomenon is associated with the P-glycoprotein, which actively 
pumping the chemotherapeutic drugs out of the cancer cells. Many familiar 
anti-cancer drugs such as anthracyclines, mitoxantrone, bisantrene, actinomycin D, 
topotecan and epirubicin have already been on the pumping list (Ejendal and Hrycyna, 
2002; Han and Zhang, 2004). 
Radiation therapy focuses high-energy beams on the cancer by a machine. It is 
an essential part of treatment before bone marrow or peripheral blood stem cell 
transplantation. Radiation treatment also treats leukemia that has spread to the brain 
and spinal fluid or to testicles. The short-term side effects of radiotherapy include 
sunburn-like skin changes on the treated area, fatigue and reduction of infection 
resistance (American Cancer Society, 2007). 
Stem Cell Transplantation (SCT) is another major therapeutic option in treating 
leukemia. Syngeneic SCT uses identical twins as donors (Fefer et al., 1981); 
allogeneic SCT uses HLA identical siblings or HLA-matched unrelated donors (Clift 
et al., 1987; Hows et al.’ 2006), and autologous SCT uses the patient's own cells. 
Before treating with stem cell transplantation, patient usually receives both high-dose 
chemotherapy and total body irradiation. The goal is to destroy most of the leukemia 
cells and all the patient's bone marrow cells, so as to reduce the chance of stem cell 
rejection and maximize the probability of disease-free survival and cure. 
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During the past three decades, allogeneic SCT has developed from an 
experimental therapy in patients with end-stage leukemia into a well-established 
therapy. The survival rates of patients who received the treatment have also been 
increased with time. In allogeneic SCT, the stem cells can be obtained from the bone 
marrow by multiple bone marrow aspiration or from the peripheral blood by a 
procedure called leukopheresis of a donor whose tissue type is almost identical to the 
patient's tissue type. Some studies have shown that using the stem cells obtained by 
leukopheresis fastens the recovery of normal blood cell counts and reduces the relapse 
of leukemia (Visani et al., 1999). Matching suitable tissue type greatly reduces the 
chance of rejection by the patient's immune system. Although 70% patients are cured 
by this useful treatment, it is limited by identifying suitable HLA-matched family 
donors, not to say suitable unrelated donors in population. Moreover, the 
complications of life-threatening acute and chronic graft-versus-host disease (GVHD) 
are common in patients receiving stem cells from partially mismatched family donors 
or matched unrelated donors (American Cancer Society, 2007). Expensive treatment 
(more than US $100,000 nowadays) with continuously rising medical fee further 
limits the popularity of the treatment (Svahn et al, 2006). In autologous SCT, the 
patient's own stem cells are collected from his or her body before treatment and 
frozen until use (Visani et al., 1999). Due to the absence of GVHD, the treatment is 
much more tolerable and is feasible to apply for elderly patients over 60 years old. 
However, isolation of normal stem cells from leukemia cells is not an easy task. The 
improvement of the patients' condition is still an uncertainty (Thomas et al., 2007). 
After receiving the donor's stem cells, prednisone and cyclosporine are given to 
the patients to weaken their immune system and prevent tissue rejection. Supportive 
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therapies like intravenous nutrient supplementation, injection of antibiotics, red blood 
cell transfusions and platelet transfusion are also provided for better recovery. 
Monoclonal antibodies have been designed to specifically bind to the surface 
molecules on the AML cells. Monoclonal antibodies may link with radioactive 
chemicals or cell poisons to kill the target cells. Gemtuzumab ozogamicin (Mylotarg), 
an anti-CD33 monoclonal antibody linked with a poison, has recently been approved 
for use in old adults with relapsed AML (Aribi et al., 2007). 
1.1.2.3 Novel Approaches to Leukemia Therapy: Apoptosis and Differentiation 
Induction 
A concept of viewing cancer as a disease of deregulated cell proliferation has 
changed to the aberrant control of apoptosis in cells (Cheung et al., 2006). By 
increasing the understanding of the underlying molecular mechanisms by which 
cancer cells escape the tightly regulated process, scientists believe inducing apoptosis 
of leukemia cells is a new prospective of cancer therapy. Different small molecules 
have already been designed to target the abnormal molecules, including death 
receptors, caspases, Bcl-2 family proteins and transcription factors such as NF-KB, 
that are involved in apoptosis deregulation in leukemia (Fischer and Schulze-Osthoff, 
2005; Mazars et al., 2005; Reed and Pellecchia, 2005). Mitochondrion is a central 
organelle that triggers the caspase-dependent pathway and apoptosis by mitochondrial 
membrane transition (Nijhuis et al, 2006). 
All-rra/75-retinoic acid (ATRA) is a typical example of differentiation-induction 
therapy which treats APL effectively (Fenaux et al., 2001; Tallman et al., 2002; 
Fenaux et al., 2007). APL (M3 of AML) has distinctive morphologic, clinical, 
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cytogenetic features. The marrow is replaced by blasts that resemble unusually 
heavily granulated progranulocytes in most APL patients. Round nuclei, with obvious 
nucleoli and the cytoplasm that filled with multiple, large, and coalesced azurophilic 
granules are the remarkable morphologic features (American Cancer Society, 2007). 
Class II human leukocyte antigens (HLA DR) which are found in all hematopoietic 
precursors are usually absent in progranulocytes (Griffin et al., 1986). However, 
CD33 is strongly expressed. APL is usually co-related to hypofibrinogenemia, 
depletion of certain coagulation factors, elevation of fibrin degradation products and 
increase in endogenous and transfused platelets consumption. Most APL patients have 
a chromosomes 15 and 17 [t (15;17)(q22;ql2)] translocation (Larson et al, 1984). 
This abnormality may be associated with other cytogenetic abnormalities, like trisomy 
8. In fact, the chromosome translocation of t(15;17)(q22;q21) is one of the factors 
causing APL. The breakpoint in chromosome 17 is in the intron of the retinoic acid 
receptor alpha gene. The gene that encodes a protein with DNA-binding capability 
called PML in chromosome 15 is translocated to the breakpoint to form a fusion 
protein that blocks the transcription of genes controlled by RAR-a, probably by 
raising nuclear co-repressor activity. The fusion protein blocks differentiation of 
myeloid cells and inhibits apoptosis of the cells. The ATRA treatment reduces the 
co-repression activity and allows transcription of genes for differentiation to take 
place (de The et cil.. 1991; Grignani et al, 1998; He et al, 1998; Melnick and Licht, 
1999). Nowadays, ATRA therapy is further combined with daiinorubicin and 
anthracycline. APL is uniquely sensitive to the combined therapy and initial drug 
resistance is rare. 
Searching natural products having apoptosis-inducing and differentiation-
inducing abilities on tumor cells, especially on leukemia cells, is one of the major 
- 1 4 -
Chapter I General Introduction 
directions of anti-cancer drug development. For example, it has been reported that 
arsenic trioxide (AS2O3), a compound in traditional Chinese medicine, and resveratrol, 
a compound from red wine, demonstrate potent apoptosis- and 
differentiation-inducing effects on AML (Davison et al., 2004; Tedesco et al., 2005; 
Ramos et al,, 2006) and on relapsed APL (Kwong et al., 2001; Aribi et al., 2007) 
through many well-known mechanistic pathways. Other natural products including 
isoflavonoid (Hunakova et al., 1994), vitamin D3 (Koschmieder et al., 2007), and 
green tea catechin (Cooper et al., 2006) were reported to have a potent 
differentiation-inducing effect on leukemia cells. Moreover, numerous cytokines such 
as ILs and GM-CSF are applied to induce the differentiation of leukemia cells to 
various lineages (Leung et al., 2005). 
The objective of this M. Phil, project is to identify novel or more potent 
candidate(s) for leukemia treatment from the naturally occurring conjugated 
polyunsaturated fatty acids. Over the past two years, we have studied the anti-cancer 
activities of conjugated linolenic acid (CLN) in human myeloid leukemia cells. Some 
hints on the mechanisms that can suppress leukemia cell growth have been revealed. 
The details will be delineated in Chapter 3, 4 and 5 of this M. Phil, dissertation. 
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1.2 Polyunsaturated Fatty Acids 
1.2.1 An Overview on Polyunsaturated Fatty Acids 
A fatty acid is a carboxylic acid with a long unbranched aliphatic carbon chain 
that is either saturated or unsaturated. Unsaturated fatty acid means the carbon chain 
of a fatty acid is "unsaturated" with hydrogen atoms. Two hydrogen atoms are 
eliminated where a double bond (-CH=CH-) is formed. A polyunsaturated fatty acid is 
a kind of unsaturated fatty acid in which there are two or more double bonds in the 
fatty acid carbon chain. Once a double bond is located at the fatty acid chain, the 
orientation of those carbon atoms involved in the bond are fixed; either cis- or trans-
configuration is resulted. A cis- configuration is defined as the two hydrogen atoms 
are on the same side of the double bond. Rigid cis- configuration forces the chain to 
bend and lowers the chain flexibility. The specific geometry plays an important role in 
many biological processes and cellular structures, like cell membrane fluidity 
increases when more unsaturated fatty acids are present in the membrane. In trans-
configuration, the hydrogen atoms are fixed at the opposite sides of the bond, so the 
shape of the chain does not change much. Though huge number of fatty acids can be 
named based on different combinations, most of the naturally occurring 
polyunsaturated fatty acids have even number of carbons and limited double bonds 
with commonly cis- configuration. 
As different forms of fatty acids can be found in nature or formed artificially, a 
clear and simplified naming system is essential for effective communication on the 
international basis. For example, linoleic acid (LA) can be written as 18:2(n-6), which 
indicates this 18 carbon fatty acid has two double bonds and the first double bond is 
the sixth carbon counting from methyl end of the carbon chain. To specifically 
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identify carbon atoms, each of them was labeled by Greek alphabets based on the 
distance away from the carboxylic acid end. The one next to the carboxylic group is 
the alpha (a) carbon, the second closest one is the beta (p) carbon and the last carbon 
at the methyl end of the chain is the omega (oo) carbon, etc. By counting the double 
bond on the xth carbon-carbon bond from the co carbon, alpha linolenic acid (ALA) is 
defined as an co-S fatty acid while gamma linolenic acid (GLA) is an (0-6 fatty acid. 
Another way of naming the fatty acid is denoted by the "cis-/trans- A^", where the xth 
carbon-carbon bond counting from the carboxyl terminus is the double bond. For 
example, the chemical name of LA can be represented as cis,cis-I^ 
octadecadienoic acid. 
1.2.2 An Overview on Essential Fatty Acids 
Essential fatty acids are polyunsaturated fatty acids that cannot be synthesized de 
novo in mammals and must be ingested from the dietary plant material. Mammalian 
hepatocytes can readily introduce double bonds at the Apposition of the fatty acids but 
not in the positions between C-10 and the methyl-terminal end. Both plants and 
bacteria have the desaturases that introduce double bonds at A^^  A'^ positions. The 
essential fatty acids are divided into the (JO-3 and the AJ-6 families. ALA, 
eicosapentaenoic acid (EPA) and docosaheptaenoic acid (DHA) are the major oj-3 
fatty acids that are most commonly used by our bodies; whereas GLA and arachidonic 
acid are the major co-6 fatty acids (Das, 2006). 
1.2.2.1 Alpha Linolenic Acid (ALA) 
ALA is an 18-C polyunsaturated fatty acid containing three cis- double bonds 
(Fig. 1.2). Its systematic chemical name is aH-cis-9,12,15-octadecatrienoic acid. Its 
molecular formula is C18H30O2 and its molar mass is 278.43 g/mol. Seed oils are rich 
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in alpha linolenic acid. The sources include rapeseed (canola), soybeans, walnuts, 
flaxseed and perilla. ALA was used as a control in assays for comparison with the 
bioactivities of conjugated linolenic acids (CLN) in this M. Phil, study. 
H〇〇C 八 A A . . , , CH3 
Fig. 1.2 Structure of alpha linolenic acid (ALA) 
ALA is converted to EPA and DHA and they are more readily used by the human 
bodies, as they are involved in the synthesis of eicosanoids (prostaglandins, 
leukotrienes, and thromboxanes). Both EPA and DHA are found to possess anti-tumor 
effects and anti-arrhythmogenic activities (Riipp et ah, 2004; Breslow, 2006). EPA 
also modulates the NK cell activity in normal humans (Thies et al., 2001). 
ALA was found to lower plasma triacylglycerol level in rats by suppressing the 
hepatic synthase (Kim, 2004). Some studies also suggest that ALA alone has 
beneficial electrophysiological and anti-arrhythmic effects, so it can protect against 
cardiovascular diseases and reduces coronary death (Landmark and Aim, 2006). 
However, some reviews regarded that the effects are not potent enough when 
compared with LA (Sanderson et al., 2002; Breslow, 2006). 
1.2.2.2 Gamma Linolenic Acid (GLA) 
GLA is a 18-C polyunsaturated fatty acid containing three cis- double bonds (Fig. 
1.3). Its systematic chemical name is all-cis-6,9,12-octadecatrienoic acid. It is an 
isomer of alpha linolenic acid. It was also used as a control in assays for comparison 
w ith the bioactivities of conjugated linolenic acids (CLN) in this M. Phil, study. 
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Fig. 1.3 Structure of gamma linolenic acid (GLA) 
GLA can be found in blackcurrant seed oil, borage oil and hemp seed oil. Trace 
amounts of GLA are also found in green leafy vegetables and nuts. Our bodies also 
produce GLA from LA by A^-desaturase, which creates a double bond on the sixth 
carbon counting from the carboxyl terminus. 
Arachidonic acid, a 20:4 fatty acid derived from GLA, is a major precursor of 
several classes of signal molecules: prostaglandins, prostacyclins, thromboxanes, and 
leukotrienes. Prostaglandin (PG) is a 20-carbon fatty acid containing a 5-carbon ring. 
PG with two double bonds, such as PGE2, are derived from arachidonic acid; the other 
two double bonds of this precursor are lost in forming a five-meinbered ring. 
Prostacyclin and thromboxanes are related compounds that arise from a nascent 
prostaglandin. Short-lived prostaglandins and other eicosanoids affect either on the 
cells producing them or their neighbors through seven transmembrane receptors, so 
I hey act as messengers and local hormones (Das, 2006). The effects vary in differenl 
types of cells and signaling pathways, ranging from modulating inflammatory 
response, blood How regulation, changing ion transport across membrane and 
synaptic transmission and affecting the gene expression of various bioactive 
molecules (Kapoor and 丨 luang. 2006). 
Some studies suggest that high oj-6 talt\ acid to ('>3 fatty acid ratios (modern 
Western diet has a high ratio of about 10: 1) may promote pro-inflammatory cytokine 
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production and enhance the occurrence of both inflammatory diseases and depression 
in old adults (Kiecolt-Glaser et al., 2007). 
1.2.3 An Overview on Conjugated Fatty Acids: Conjugated Linoleic Acid (CLA)， 
Conjugated EPA and Conjugated DHA 
One of the most well-known conjugated fatty acids is conjugated linoleic acid 
(CLA). CLA is a group of positional and geometrical conjugated dienoic isomers of 
LA. There are two major isomers, the cis-% trans-11 and trans-lQ, cis-\2 CLA (Fig. 
1.4 and Fig. 1.5). It has been reported that CLA isomers possess pro-apoptotic, 
pro-differentiation and anti-tumorigenic, anti-obese and anti-diabetic effects etc. 
(Nagao and Yanagita, 2005). 
Fig. 1.4 Structure of cis-9, trans-\ \ conjugated linoleic acid (CLA) isomer 
Fig. 1.5 Structure of trans-W, cis-12 conjugated linoleic acid (CLA) isomer 
Conjugated fatty acids (CFA) can be obtained naturally from different sources. 
CLA has been found in milk fat, cheese product and ruminant meat (Sehat et aL, 
1998). The cis-9, trans-11 CLA isomer is produced naturally by rumenal bacteria 
Butyrvibrio fibrisolvens during the incomplete biohydrogenation of unsaturated fatty 
acids (Kepler et al., 1966). CLA can be absorbed into the digestive tract, and then 
transported to the mammary gland and becomes a component of milk fat. Apart from 
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absorption, lactating cow can also synthesize CLA from trans fatty acids by 
A9-desaturase in its mammary gland (Griinari et al., 2000; Kelly, 2001). The enzyme 
introduces a c/5'-double bond at carbon 9 of the trans-11 fatty acid to form the cis-9, 
trans-11 CLA isomer. For trans-10, cis-\2 CLA production, Propionibacter can 
convert linolenic acid to trans-10, cis-12 CLA (Pariza et al, 2001). It has also been 
reported that many conjugated trienoic and tetraenoic acids occur naturally. For 
example, conjugated linolenic acid (CLN) is rich in some seed oils and more details 
will be introduced in the next section. Red seed, Ptilota filicna, is a good example of a 
natural source of tetraenoic acid, which contains trans-5, trans-1 trans-9, cisAA, 
cis-17 conjugated EPA and trans-5, trans-1 trans-9, cis-XA, cisAl conjugated EPA 
(Fig. 1.6 and Fig. 1.7) (Lopez and Gerwick, 1987). 
It is known that CLA is not only non-toxic to human body, but also modulates 
our physiological activities and possesses anti-obese, hypolipidemic, 
anti-atherosclerotic, anti-diabetic, immunomodulatory, hypotensive and anti-tumor 
properties and is beneficial to our health. Some clinical trials have shown that CLA 
does not exert toxic effects to the liver. Aspartate aminotransferase (ASAT), alanine 
aminotransferase (ALAT) and y-glutamyltransferase (y-GT) levels were not changed 
after 12 week-CLA treatment (1.7-6.8g/day) in both male and female volunteers 
(Blankson et al., 2000). The anti-obese and hypolipidemic properties of CLA are 
some of the earliest known health benefits to animals. They had been revealed since 
early 1970s and more supporting evidences were reported in the 1990s. A 0.5% CLA 
diet reduced 60% body fat coupled with more than 10% increase in lean body mass in 
mice as CLA can modulate the fatty acid uptake and fat storage in adipocytes 
(Holman, 1951; Park et al., 1997). Recently, it has been reported that dietary 
supplementation of 1% CLA reduces abdominal white adipose tissue, serum 
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triglyceride and liver triglyceride levels on obese model Otsuka Long-Evans 
Tokushima fatty (OLETF) rats. This is achieved by enhancing y^-oxidation of fatty 
acid and suppressing fatty acid synthesis in the liver of rats (Rahman et al., 2001; 
Nagao et al., 2003). Some studies showed that CLA also promotes fatty acid 
y^-oxidation in brown adipose tissue and muscle and increases oxygen consumption 
and energy use in OLETF rats (Rahman et al., 2001; Nagao et al., 2003). Besides the 
animal studies, a clinical trial conducted in Norway had tested for the 
body-fat-lowering effect of CLA in human volunteers. After taking CLA mixture (1.8 
g/day) for 3 months, there was a 4% drop of the body fat content of the volunteers 
(Thorn et al., 2001). Anti-atherogenic effect of CLA has been reported in different 
animal models. The aortic fatty streak area was reduced in the rabbit and hamster 
models after feeding with CLA (0.5g/day) for 22 weeks and 1% CLA-supplemented 
diet for 13 weeks respectively (Lee et al, 1994; Nicolosi et al., 1997). Interestingly, 
the LDL cholesterol to HDL cholesterol ratio and total cholesterol to HDL cholesterol 
ratio were significantly reduced in CLA-fed rabbits (Lee et al., 1994). Anti-diabetic 
effect of CLA has been reported in many studies using obese diabetic rat models. 
Feeding of rats with 1.5% transAO, cis-12 CLA diet showed significant anti-diabetic 
effect and the effect was similar to that of the pharmaceutical agent troglitazone 
(Houseknecht et al, 1998). CLA also promotes immunomodulation. 1% CLA diet 
increases the immunoglobulin A (IgA), IgG and IgM production but decreases the IgE 
production in the rat spleen (Sugano et al., 1998; Yamasaki et al., 2000). CLA shows 
hypotensive property in many studies. The trans-\0, cis-12 CLA isomer prevents the 
development of obesity-induced hypotension in the diabetic Zucker rats and the obese 
OLETF rats (Nagao et al., 2003; Nagao et al., 2003). CLA also prevents the 
development of essential hypertension in the non-obese spontaneously hypertensive 
rats (Inoue et al., 2004). CLA has also shown to have potent anti-tumor activities. It 
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can act as a cytotoxic agent and inhibit the in vitro growth of a variety of cancer cells, 
including myeloid leukemia (WEHI-3B JCS) (Lui et al., 2005), colon carcinoma 
(HT-29 and HCT116) (Cho et al., 2003; Kemp et al., 2003), hepatoma (HepG2) 
(Igarashi and Miyazawa, 2001), breast cancer (MCF-7) (Durgam et al., 1997; Chujo 
et al., 2003) and lung adenocarcinoma cells (A-427, SK-LU-1 and A549) (Sch0nberg 
and Krohan, 1995) etc. The underlying mechanisms of the anti-tumor effects of CLA 
have also been elucidated. It can up-regulate the expression of TNF-«, YL-Xp and 
IFN-7 genes in WEHI-3B JCS cells, which play an instrumental role in triggering the 
monocytic differentiation of myeloid leukemia cells (Lui et al., 2005). 
Both CLA and EPA have been found to have an anti-tumor activity (Petrik et al, 
2000; Lui et al, 2005). Hence, some investigators hypothesized that a combination of 
conjugated double bonds and an n-3 polyunsaturated fatty acid produced stronger 
anti-tumor activity (Tsuzuki et al., 2004). Recently, conjugated EPA (Fig. 1.6 and Fig. 
1.7) and conjugated DHA (Fig. 1.8) have been demonstrated to have higher 
cytotoxicity when compared with the CLA isomers (Petrik et al., 2000; Lui et al., 
2005). 
H��V^/WWV=A=AH3 
Fig. 1.6 Structure of trans-5, trans-1 trans-9, CM-14, cis-17 conjugated 
eicosapentaenoic acid (EPA) isomer 
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Fig. 1.7 Structure of cis-5, trans-1 tram-9, CM-14, cis-17 conjugated eicosapentaenoic 
acid (EPA) isomer 
Fig. 1.8 Structure of cisA, cis-1 trans-% trans-11, cw-13, cis-\6, cis-19 conjugated 
docosaheptaenoic acid (DHA) isomer 
Conjugated EPA and conjugated DHA have been shown to cause cell death via 
lipid peroxidation and apoptosis in the absence of alpha-tocopherol in HepG2, A549, 
MCF-7 and MKN-7 cells (Igarashi and Miyazawa, 2000). Other studies showed that 
conjugated EPA and conjugated DHA triggered apoptosis by inducing DNA 
condensation and fragmentation in the human colorectal cancer DLD-1 cells both in 
vivo and in vitro. The mechanism might involve up-regulation of expression of genes 
induced by p53 and activation of the mitochondrial apoptosis pathway via Bax and 
the death pathway via TRAIL (Tsuzuki et al., 2007). 
1.2.4 Conjugated Linolenic Acid (CLN) 
Once the diverse effects and health benefits of the CLA isomers were revealed, 
scientists started to investigate the polyunsaturated fatty acids with more than two 
conjugated bonds to see how our bodies or cancer cells are affected by this type of 
fatty acids. People also pay attention to prepare highly purified CLN isomers for the 
growing markets. 
CLN is a group of positional and geometrical conjugated trienoic isomers of 
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C-18 linolenic acid, which are the major components of some plant seed oils. The 
major naturally occurring CLN isomers are listed in Table 1.2. Many studies have 
been focused on the identification, preparation and synthesis of highly purified CLN 
isomers. Recently, more and more studies have been carried out to examine the 
potential of CLN isomers in different biological and medical aspects. The structures 
of various CLN isomers with different cis-/trans-conY\g\xmX\ons are shown in Fig. 1.9 
to Fig. 1.15. 
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Table 1.2 Major CLN isomers and their naturally occurring sources 
Name of CLN Structure of the Source(s) (Plant Seeds) 
isomer 
Punicic acid cis-9, trans-11, cis-13 Pomegranate (Punica granatum) 
a-eleostearic acid cis-9, trans-11, Tung seed (Aleurites fordii)\ 
trans-13 Bitter gourd {Momordica charantia) 
y^-eleostearic acid trans-9, trans-\\, Cata lpa�Cat lp a bignonoides); 
trans-13 Bitter gourd {Momordica charantia) 
Catalpic acid trans-9, trans-\\, Catalpa {Catalpa bignonoides) 
cis-13 
a-calendic acid trans-込,trans-W, Pot marigold {Calendula officinalis) 
cis-12 
y^-calendic acid trans-込,trans-10, Pot marigold {Calendula officinalis) 
trans-12 
Jacaric acid cis-^, trans-10, cis-12 Jacaranda {Jacaranda mimosifolis) 
(Modified from Ozgul-Yucel, 2006) 
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H〇〇C A 八 八 A 
Fig. 1.9 Structure of cis-% trans-11, cis-13 conjugated linolenic acid (CLN) isomer 
H � � W \ A / ^ V V V ^ C H 3 
Fig. 1.10 Structure of cis-9, trans-11, trans-\3 conjugated linolenic acid (CLN) 
isomer 
h � � c w \ A / W W ^ h 3 
Fig. 1.11 Structure of trans-9, trans-11, trans-13 conjugated linolenic acid (CLN) 
isomer 
h � � V w \ / W ^ v / V H 3 
Fig. 1.12 Structure of trans-9, trans-11, cw-lS conjugated linolenic acid (CLN) 
isomer 
Fig. 1.13 Structure of trans-名,trans-10, cis-12 conjugated linolenic acid (CLN) 
isomer 
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Fig. 1.14 Structure of tram-込,trans-XO, trans-12 conjugated linolenic acid (CLN) 
isomer 
丄\/\/\广•」、/• 
Fig. 1.15 Structure of c/^-8, transAQ, cis-12 conjugated linolenic acid (CLN) isomer 
1.2.4.1 Identification and Production of CLN 
To identify the detailed compositions of the fatty acids in the seed oil mixtures 
containing two or more conjugated octadecatrienoic acids, open-tubular gas liquid 
chromatography (GLC) and reversed-phase high performance liquid chromatography 
(HPLC) are needed. An open-tubular column coated with a non-polar liquid phase 
OV-1 is used to obtain an effective GLC separation whereas the HPLC method 
separates the conjugated octadecatrienoic acid isomers on the basis of number of the 
cis- and trans- double bonds (Takagi and Itabashi, 1981). 
Conjugated trienoic acids can be produced chemically or biologically using ALA, 
GLA or other fatty acids as precursors. Conjugated trieonic fatty acids can be 
prepared chemically by two ways: acid-catalyzed methods and base-catalyzed 
methods. Six different methods, three for acid-catalyzed and three for base-catalyzed, 
were proposed for preparation of conjugated trienoic acids artificially (Igarashi et al., 
2004). The BF3/MeOH method was the best method among them for the methylester 
preparation of conjugated trienoic fatty acids in terms of preventing artificial 
isomerization, preventing byproducts formation and being able to apply to both food 
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and biological samples. Researchers maximized conjugated dienoic fatty acids 
productivity successfully using lactic acid bacteria {Lactobacillus plantarum AKU 
1009a) (Kishino et al.’ 2002). This gave hints to scientists to use lactic acid bacteria as 
conjugated trienoic fatty acid producing factories (Ogawa et al” 2005). Though the 
method is still on trial to enhance its efficiency and specificity, it is a right step 
towards mass production of designed polyunsaturated fatty acids. 
1.2.4.2 Metabolism of CLN 
The CLN isomers were orally administered into the animals, and the distribution 
and metabolism of CLN isomers were investigated. One of the direct methods for 
investigation of the metabolism of CLN in the rat model was to remove the rat organs 
and tissues after CLN administration. Surprising, low levels of a-eleostearic acid 
(C/5-9, trans-11, trans-13 CLN isomer) were detected, but relatively high cis-9, 
trans-11 CLA levels and coenzyme (NADPH) level were detected in rat liver, kidneys 
and small intestine mucosa homogenates by HPLC (Tsuzuki et al., 2004). It was 
believed that the CLN isomer was converted to the CLA isomer by a A'^-saturation 
reaction carried out by an NADPH-dependent enzyme (Tsuzuki et al, 2003; 2004). 
White Leghorn hens were another study model of the CLN metabolism. It was proved 
that a-eleostearic acid (cis-9, trans-11, trans-13 CLN isomer) was almost not 
deposited in the tissues and egg yolk of hens; however, CLA was significantly 
detected in adipose tissues, liver, heart and breast muscle (Lee et al., 2002). 
Low proportions of CLN can incorporate into the neutral lipid of the mammalian 
models. The free fatty acid form and triacylglycerols of CLN isomers have the same 
ability to incorporate into tissues and undergo bioconversion. CLN isomer mixtures 
can be totally absorbed in rats and low levels of CLN are present in plasma 
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phospholipids (Plourde et al., 2006). 
1.2.4.3 Anti-Obese and Hypolipidemic Effect of CLN 
CLN isomers were found to modulate fat storage and bioconversion of lipid 
related biomoleciiles. CLN isomers significantly reduced the perirenal and epididymal 
adipose tissue weights. CLN, but not CLA, increased serum and liver triglyceride 
levels of rats (Koba et al., 2002). It was probably due to the increase of y^^oxidation in 
liver mitochondria (Koba et al., 2002). Moreover, CLN isomers decreased hepatic 
cholesterol levels in hamsters, but the concentrations of total cholesterol, 
HDL-cholesterol, and non-HDL-cholesterol in plasma, heart and kidneys were not 
affected (Yang et al., 2005). In contrast, different results were obtained in the 
CLA-treated hamsters, and the level of LDL-cholesterol in the plasma of hamster was 
significantly reduced (Ledoux et al., 2007). Although the mechanisms behind are not 
clear at present, these findings indicate that CLN isomers can modulate the body fat 
and lipid metabolism somehow differently from CLA isomers. Apart from that, CLN 
isomers also lowered the plasma lipid peroxidation and showed antioxidant activity in 
normal rats (Dhar et al,, 1999). Another study had shown that cis-9, trans-11, 
CLN isomer could significantly reduce apolipoprotein BlOO secretion in the human 
hepatoma HepG2 cells when compared with linolenic acid. This is the first study to 
demonstrate CLN isomer has the hypolipidemic activity (Arao et al., 2004). 
1.2.4.4 Anti-Proliferative Effect of CLN 
a-eleostearic acid {cis-9, trans-11, trans-13 CLN isomer in bitter gourd seed) 
was one of the earliest conjugated trienoic fatty acids that ignited the scientists' 
interests. A group of Japanese researchers was curious about why the elderly who 
regularly had bitter gourd in their diet generally lived longer. They showed 
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a-eleostearic acid possibly had chemopreventive activity in the early phase for the 
formation of colon cancer cells (Kohno et al., 2002). They became one of the groups 
which actively studying on the anti-tumor activity of different CLN isomers. They 
showed that administration of a CLN isomer extracted from pomegranate seed oil 
{cis-9, trans-11, cis-13 CLN isomer) in the diet of male F344 rats would significantly 
reduce the incidence and multiplicity of azoxymethane (AOM)-induced colonic 
aberrant crypt foci (ACF) (Kohno, 2004). The inhibition of colon adenocarcinoma 
was associated with an increasing level of cis-9, trans-11 CLA isomer in the lipid 
fraction of the rat colonic mucosa and liver. The gene expression level of peroxisome 
proliferator receptor gamma (PPARy) in the colonic mocosa was also elevated (Kohno 
et al,, 2004; Chuang et al., 2006). a-eleostearic acid (cis-9, trans-11, trans-13 CLN 
isomer) and catalpic acid (jrans-9, trans-W, cw-H CLN isomer) were similarly 
studied both in vivo and in vitro and these conjugated trienoic fatty acids also showed 
suppression on colon cancer development through p53 apoptosis-inducing pathways 
(Yasui et al., 2005; Suzuki et al., 2006). The involvement of PPARy in the underlying 
mechanism was further proved by demonstrating that troglitazone, a synthetic PPARy 
ligand, had a chemotherapeutic effect on HT-29, DLD-1 and Caco-2 colon cancer 
cells. It was found that HT-29 cells which endogenously expressed high PPARy levels 
responded more vigorously to both troglitazone and a-eleostearic acid {cis-9, trans-11, 
trans-13 CLN isomer) than Caco-2 cells with low PPARy expression levels (Yasui et 
al., 2006). Apart from colorectal cancer cells, CLN isomer also showed potent 
anti-tumor effect on a wide range of human cancer cells, including hepatoma (HepG2), 
lung adenocarcinoma (A549), breast adenocarcinoma (MCF-7) and stomach tubular 
adenocarcinoma (MKN-7) (Igarashi and Miyazawa, 2000). 
-31 -
Chapter 1 General Introduction 
Whether the positions and cis-/trans- configurations of CLN isomers might play 
a role in their anti-proliferative effect on tumor cells had been investigated. The 
cytotoxicity of a-eleostearic acid {cis-9, trans-11, trans-13 CLN), punicic acid (cis-9, 
trans-11, cis-13 CLN), catalpic acid {trans-9, trans-11, cLs-13 CLN) and «-calendic 
acid (trans-^, trans-XQ, cis-\2 CLN) were compared (Suzuki et al., 2001) and the 
preliminary data showed that the 9,11,13 CLN isomers were generally more potent 
than the 8,10,12 CLN isomer, yet the results were still controversial. The mechanism 
of the cytotoxicity of those four trienoic fatty acids somehow involved, at least 
partially, lipid peroxidation (Suzuki, 2001; Tsuzuki, 2004). a-eleostearic acid {cis-9, 
trans-\\, trans-13 CLN), /?-eleostearic acid (trans’-9, trans-11, trans-13 CLN), 
c(-calendic acid { trans-� , trans-W, cis-12 CLN) andy^-calendic acid (Jrans-名,trans-lO, 
trans-12 CLN) were compared to check the importance of cis-/trans- configuration on 
their anti-tumor effects (Yasui et al, 2006). It was believed that all-trans CLN 
isomers exerted greater growth inhibitory effects and induction of DNA fragmentation 
on colorectal cancer Caco-2 cells than the cis-CLN isomers. The anti-apoptotic gene, 
bcl-2, was down-regulated whereas the pro-apoptotic gene, bax, was up-regulated at 
the mRNA level. Moreover, the cytotoxic effects of /?-eleostearic acid acid and 
y^-calendic acid were not counteracted completely by ^-tocopherol, an antioxidant, 
whereas the effects of a-eleostearic and a-calendic acids were greatly reduced when 
the cells were co-treated with a-tocopherol. It was suggested that the all-trans trienoic 
fatty acids might have different signaling pathways to inhibit the tumor cell viability. 
1.2.4.5 Other Novel Effects of CLN 
Pomegranate seed oil (rich in cis-9, trans-\\, cis-13 CLN isomer) was found to 
promote normal skin cell proliferation. This conjugated trienoic fatty acid also 
enhanced regeneration of human epidermal keratinocytes without affecting their 
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normal function (Aslam et al., 2006). Other conjugated trienoic acids have not been 
investigated in this aspect and they might be of great potential for cosmeceutical use. 
Moreover, naturally occurring jacaric acid {cis-^, trans-XO, cis-12 CLN isomer) and 
synthetic c/^'-S, trans-10, trans-12 CLN isomer were found to be potent inhibitors of 
cyclooxygenase (COX) as they inhibited the prostaglandin synthesis (Nugteren and 
Christ-Hazelhof, 1987). 
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1.3 Aims and Scopes of This Investigation 
Conjugated linolenic acids (CLN) are fatty acids that are widely distributed in 
many plant seed oils and they have been demonstrated to possess diverse biological 
and pharmacological effects on various cell lines, and in animal models and humans, 
as described in Section 1.2. However, the anti-tumor effects and action mechanisms of 
CLN on human myeloid leukemia cells remain elusive. Therefore, the aims of my 
project were to investigate the anti-tumor activities of CLN against human myeloid 
leukemia and attempts were made to elucidate the cellular and molecular mechanisms 
governing their anti-leukemic activities. 
In this study, the anti-proliferative effect of four CLN isomers on a 
well-characterized and subcloned human promyelocytic leukemia cell line, HL-60, 
was compared. The isomers examined include oc-eleostearic acid {cis-9, trans-11, 
trans-13 CLN isomer), /?-eleostearic acid {trans-9, trans-11, trans-13 CLN isomer), 
/?-calendic acid {trans-^, trans-10, trans-12 CLN isomer) and jacaric acid (c/^-8, 
trans-XO, cis-12 CLN isomer). Apart from the HL-60 cells, different human leukemia 
and lymphoma cell lines, including NB-4, EoL-1, K562, U-937, HL-60/MX2 were 
used to show that the growth inhibitory effect of CLN was not restricted to a single 
leukemia cell line. The kinetics and reversibility of CLN with respect to their 
anti-proliferative effect on HL-60 cells were assessed. MTT assay, ^H-thymidine 
incorporation assay and trypan blue exclusion assay were used to evaluate the 
anti-proliferative and cytotoxic effects of CLN. The cell cycle kinetics of HL-60 cells 
after CLN treatment was detected by flow cytometry. The ability of CLN isomer to 
induce apoptosis was measured by a range of methods, including the DNA 
fragmentation assay, cell death ELISA kit and annexin V-GFP PI double staining 
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assay. The expression of apoptosis-associated proteins was detected by the Western 
blotting. Moreover, the induction of caspase activities and mitochondrial membrane 
depolarization were measured to elucidate the possible apoptotic pathway(s). The 
effect of CLN isomer on the in vivo tumorigenicity of HL-60 cells was also studied in 
BALB/c nude mice. 
Finally, the differentiation-inducing activities of CLN on HL-60 cells were 
assessed by a number of criteria, including their morphological and phenotypic 
alterations after CLN treatment. The morphological changes were studied by flow 
cytometry. The phenotypic changes were assessed by antibody staining of surface 
differentiation markers and analyzed using flow cytometry. 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Animals 
Inbred female BALB/c (haplotype H-2^) mice and BALB/c nude mice aged 6 to 
8 weeks old were bred at the University Laboratory Animal Services Centre of The 
Chinese University of Hong Kong under a specific pathogen-free condition. They 
were fed with animal diet (Chow 5001, Rodent Laboratory) and tap water ad libitum. 
2.1.2 Human Cell Lines 
1) HL-60 
HL-60 is a human promyelocytic leukemia cell line established from a 
36-year-old Caucasian female with acute promyelocytic leukemia (Collins et al, 
1977). It was purchased from the American Type Culture Collection (ATCC), U.S.A. 
2) HL-60/MX2 
HL-60/MX2 is a mitoxantrone resistant derivative of the HL-60 cell line which 
was obtained from peripheral blood leukocytes by leukopheresis from a patient with 
acute promyelocytic leukemia (Harker et al., 1991). It was purchased from ATCC, 
U.S.A. 
3) NB-4 
NB-4 is a human acute promyelocytic leukemia cell line established from the 
bone marrow of a 23-year-old female with acute promyelocytic leukemia in second 
relapse (Lanotte et al., 1991). The cell line was kindly provided by Prof. K.P. Fung, 
Department of Biochemistry, The Chinese University of Hong Kong, Hong Kong, 
China. 
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4) EoL-1 
EoL-1 is a human eosinophilic leukemia cell line established from the peripheral 
blood of a patient with Philadelphia chromosome-negative eosinophilic leukemia (EL) 
(Saito e t a l , 1985). This cell line was kindly provided by Prof. C. K. Wong, 
Department of Chemical Pathology, The Chinese University of Hong Kong, China. 
5) K562 
K562 is a human chronic myelogenous leukemia cell line originated from the 
pleural effusion of a 35-year-old female with chronic myelogenous leukemia in 
terminal blast crises (Lozzio and Lozzio, 1975). It was purchased from ATCC, U.S.A. 
6) U-937 
U-937 is a human histiocytic lymphoma cell line established from a 37-year-old 
Caucasian male with histiocytic lymphoma (Sundstrom and Nilsson, 1976). The cell 
line was kindly provided by Prof. W.K. Liu, Department of Anatomy, The Chinese 
University of Hong Kong, Hong Kong, China. 
7) Hs68 
Hs68 is a human foreskin fibroblast cell line derived from an apparently normal 
Caucasian newborn male in 1969 (Yeh and Hu, 2001). The cell line was kindly 
provided by Prof. K.R Fung, Department of Biochemistry, The Chinese University of 
Hong Kong, Hong Kong, China. 
8) WRL 68 
WRL 68 is a human hepatocyte-like cell line with functional properties of 
normal hepatocytes (Apostolov, 1976). The cell line was kindly provided by Prof. K.R 
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Fung, Department of Biochemistry, The Chinese University of Hong Kong, Hong 
Kong, China. 
2.1.3 Cell Culture Medium, Buffers and Other Reagents 
1) Cell Culture Medium 
The powdered form of RPMI 1640 medium (Invitrogen Life Technologies Inc.), 
supplemented with 25 mM N-2-hydroxy-ethyl-piperazine-N'-2-ethane-sulfonic acid 
(HEPES) and 2 mM L-glutamine was used for the preparation of culture medium. The 
powdered medium was dissolved in deionized water and buffered with 2 g sodium 
bicarbonate (NaHCOa) (Sigma-Aldrich Co.) per litre. The medium was adjusted to pH 
7.15 by either 1 M HCl or 1 M NaOH (Sigma-Aldrich Co.). The medium was 
sterilized by membrane filtration through a 0.22 jLim Millipore filter and stored in dark 
at 4°C until use. 
"Plain RPMI medium" was prepared by supplementing RPMI medium with 1% 
antibiotics (PSF or PSN). "Complete RPMI medium" prepared by supplementing 
plain RPMI medium with 10% fetal bovine serum (FBS) was used for sub-culturing 
the human and murine cells in this study, with the exception of HL-60 cells and 
HL-60/MX2 cells which used plain RPMI medium supplemented with 20% FBS 
instead. Heat inactivated (HI)-FBS was used to supplement plain RPMI medium when 
bioassays were performed. 
2) Serum Supplements 
Fetal Bovine Serum (FBS) (Invitrogen Life Technologies Inc.) was stored as 50 
ml and 20 ml aliquots. Heat-inactivated fetal bovine serum (HI-FBS) was prepared by 
heating the FBS at 56°C for 30 minutes in a water bath. Both the serum aliquots were 
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stored at -20°C until use. 
3) Antibiotic Solutions 
Two types of antibiotic solution were used in alternate periods: they were 
Antibiotic Antimycotic Solution (PSF) [10,000 units/ml penicillin G (sodium salt), 
10,000 jug/ml streptomycin sulfate and 25 jag/ml amphotericin B as Fungizone in 
0.85% saline] and Penicillin-Streptomycin-Neomycin Antibiotic Mixture (PSN) 
[5,000 |Lig/ml penicillin G sodium, 5,000 \ i g / m \ streptomycin sulfate and 10,000 jug/ml 
neomycin sulfate in 0.85% saline]. Stock solutions (lOOX) were purchased from 
Invitrogen Life Technologies Inc. and they were stored at -20°C as 5 ml aliquots. 
4) Phosphate-Buffered Saline (PBS) 
Phosphate-buffered saline was prepared by dissolving 8 g NaCl (137 mM), 0.2 g 
KCl, 0.2 g KH2P04(1.4 mM) and 1.15 g Na2HP04 (4.3 mM) in one litre deionized 
water. The chemicals were purchased from Sigma-Aldrich Co. The pH of the solution 
was adjusted to 7.2 by adding either 1 M HCl or 1 M NaOH and then sterilized by 
autoclaving at 121°C for 20 minutes. 
5) Trypsin-EDTA solution 
Trypsin-EDTA solution was purchased from Invitrogen Life Technologies Inc. 
The solution was made up of 0.25% trypsin together with 1 mM EDTA-tetrasodium in 
HBSS without Ca^^ and Mg2+. It was stored at -20°C as 5 ml aliquots until use. 
6) MatrigefM Basement Membrane Matrix 
The MatrigelTM Basement Membrane Matrix (BD Biosciences) is a solubilized 
basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) 
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mouse sarcoma, a tumor rich in extracellular matrix (ECM) proteins. Its major 
components are laminin, collagen IV, heparan sulfate proteoglycans, ectactin, nidogen 
and some growth factors which are found naturally in the EHS tumor. The matrix 
significantly increases the incidence of successful xenograft transplantation of human 
tumors into immuno-suppressed mice. The stock solutions (5 ml) were divided into 
150 |Lil aliquots and were stored at -20°C. 
7) ACK Lysis Buffer 
The buffer was prepared by dissolving 8,3 g NH4CI, 1 g KHCO3 in deionized 
water together with 1.8 ml 5% EDTA to produce one litre solution. The pH was 
adjusted to 7.2 - 7.4 by adding either 1 M HCl or 1 M NaOH and then sterilized by 
filtration. NH4CI and KHCO3 were purchased from Sigma-Aldrich Co. while EDTA 
was bought from USB Corporation. 
8) Conjugated Linolenic Acids (CLN) 
CLN and other polyunsaturated fatty acids used in the present study were 
purchased from Larodan Fine Chemicals AB. and they were listed in Table 2.1. The 
solid compounds were dissolved in 100% ethanol to give 0.2 M stock solutions. All 
stock solutions were stored at -20°C and used within three months. 
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Table 2.1 Four conjugated linolenic acid (CLN) isomers and other 
polyunsaturated fatty acids used in this study 
Common Name Chemical Name Estimated Stock 
Purity (%) Concent-
ration (M) 
a-eleostearic Acid 9(Z), 11 (E), 13(E)-octadecatrienoic Acid 97+ 0.2 
y^-eleostearic Acid 9(E), 11 (E), 13(E)-octadecatrienoic Acid 97+ 0.2 
y^-calendic Acid 8(E), 10(E), 12(E)-octadecatrienoic Acid 97+ 0.2 
Jacaric Acid 8(Z), 10(E), 12(Z)-octadecatrienoic Acid 97+ 0.2 
a-linolenic Acid 9(Z), 12(Z), 15(Z)-octadecatrienoic Acid 99+ 0.2 
7-linolenic Acid 6(Z),9(Z), 12(Z)-octadecatrienoic Acid 99+ 0.2 
I I I 
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9) All Trans-Retinoic Acid (ATRA) 
ATRA powder purchased from Sigma-Aldrich Co. was dissolved in DMSO to 
prepare 0.2 M stock solution. The yellow chemical was protected from light and was 
stored at -20°C as 250 |il aliquots. ATRA is well known for regulating growth and 
differentiation of both normal and malignant cells (Fenaux et al., 2001). 
10) Vitamin D3 
Powdered form vitamin D3 bought from CalBiochem was dissolved in DMSO to 
prepare 0.2 mM stock solution. The chemical should be protected from light and was 
stored at -20°C as 250 |il aliquots. Vitamin D3 is able to induce differentiation in 
many different types of cells (Yoshida et al., 1995). 
11) Methylthiazoletetrazolium (MTT) 
MTT powder was purchased from USB Corporation. The powder was dissolved 
in sterile PBS to prepare the stock solution at a concentration of 4 mg/ml. Thirty 
microlitres stock solution was added to each well of the 96-well flat-bottomed 
microplate. 
12) [Methyl-3Hj Thymidine ([^H]-TdR) 
The stock solution with specific activity of 2 Ci/mmol was purchased from 
Amersham Life Science Ltd. and was stored at 4°C as 500 jul aliquots. The stock 
solution was diluted with complete RPMI medium to give a working solution of 25 
)LiCi/ml before use. In proliferation assays, 20 jil working solution was added to each 
well of the 96-well flat-bottomed microplate. 
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13) Liquid Scintillation Cocktail 
The OptiPhase “Hisafe，，2 liquid scintillation cocktail was purchased from 
Perkin-Elmer Co. The cocktail was based on biodegradable solvents with dioctyl 
sulfosuccinate, sodium salts and poly(ethyleneglycol)mono(4-nonylphenyl)-ether. The 
ready-to-use cocktail was stored in dark at room temperature. 
14) Thioglycollate (TG) (3%, w/v) Broth 
Thioglycollate (TG) (3%, w/v) broth was prepared by adding 3 g dehydrated 
thioglycollate powder (Difco Laboratories) in 100 ml deionized water. The solution 
was heated until the powder was completely dissolved and was sterilized by 
autoclaving at 121�C for 20 minutes. It was stored in dark for at least one month at 
room temperature before use. 
15) Dye Solutions 
a) Hemacolor Staining Solutions 
Hemacolor staining solutions were purchased from Merck Biosciences. The 
solution set is essential for staining cells on microscopic glass slides after 
cytocentrifugation. The set consists of three different solutions: Hemacolor Solution 1 
(methanol) is used for cell fixation, Solution 2 is a buffered red color reagent and 
solution 3 is a buffered blue color reagent. They were stored in dark at room 
temperature. 
b) 0.4% (w/v) Trypan Blue Solution 
Trypan blue solution was purchased from Sigma-Aldrich Co. It contains 0.4% 
(w/v) trypan blue dissolved in a solution of 0.817% (w/v) NaCl and 0.06% (w/v) 
KH2PO4. The solution was stored at room temperature. 
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2.1.4 Reagents and Buffers for Flow Cytometry 
1) Propidium Iodide (PI) DNA Staining Buffer 
The PI DNA staining buffer was freshly prepared by mixing 40 jug/ml propidium 
iodide (Sigma-Aldrich Co.) and 8 )ig/ml RNase A (USB Corporation) in PBS. The 
PBS and PI stock solution were stored at 4°C while RNase A stock solution was 
stored at -20°C. 
2) Annexin V-GFP 
Annexin V-GFP was kindly supplied by Prof. S.K. Kong, Department of 
Biochemistry, The Chinese University of Hong Kong, Hong Kong, China. Annexin V 
is a 35kDa phospholipid-binding protein that has a high affinity for 
phosphatidylserine and it is a sensitive probe to detect early apoptosis. The 50X 
reagent was stored in dark at -20°C and was diluted with annexin V binding buffer 
before use. 
3) Annexin V Binding Buffer 
It consists of 10 mM HEPES (4-(2-hydroxyethyl)-1 -piperazineethanesulfonic 
acid) at pH 7.4, with 140 mM NaCl and 2.5 mM CaCl� . The chemicals were ordered 
from USB Corporation. The buffer was filtered and then stored at 4°C until use. 
4) JC-1 Staining Solution 
5,5',6,6'-tetrachloro-1,1 ',3,3'-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) 
was purchased from Molecular Probes Inc. JC-1 is a lipophilic and cationic 
fluorescent dye that selectively accumulates in mitochondria. It acts as a marker for 
detecting mitochondrial membrane potential of cells, as indicated by a fluorescence 
emission shift from red (590 nm- J aggregate form) to green (525 nm- monomeric 
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form) upon excitation at 488 nm. JC-1 stock solution concentration was 5 mg/ml in 
DMSO. The dye was stored at - 2 0 � C and diluted to 10 juM in PBS before use. 
5) 2',7'-Dichlorodihydrofluorescein Diacetate (H2DCFDA) 
H2DCFDA (Calbiochem) is a cell-permeable fluorogenic probe for detecting 
reactive oxygen species (ROS) and nitric oxide (•NO) and it is commonly used for 
determining the degree of overall oxidative stress. The stock solution (20 mg/ml) was 
prepared by dissolving 20 mg powder per ml of DMSO and was stored at -20°C in 
dark. The light-sensitive working solution was freshly prepared by diluting the stock 
solution with warm culture medium to a concentration of 200 jug/ml. 
6) Superoxide Dismutase (SOD) 
Superoxide dismutase, purchased from Sigma-Aldrich Co., catalyzes the 
dismutation of superoxide radicals to hydrogen peroxide and molecular oxygen and 
against the effects of oxygen radicals. SOD working solution (200 units/ml) was 
prepared by dissolving 30,000 units/ml SOD powder in 150 ml RPMI medium 
supplemented with 20% HI-FBS. The solution is stable in 4°C up to 3 months. 
7) N-Acetyl-L-Cysteine (NAC) 
N-acetyl-L-cysteine, purchased from Sigma-Aldrich Co., is an antioxidant. NAC 
working solution (15 mM) was prepared by dissolving O.lg NAC powder in 40.85 ml 
RPMI supplemented with 20% HI-FBS. It is stable in 4°C up to 3 months. 
8) 75% (v/v) Ethanol 
Analytical grade absolute ethanol was purchased from Merck Biosciences. By 
mixing 75 ml absolute ethanol together with 25 ml autoclaved deionized water, 75% 
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(v/v) ethanol was prepared. It was stored at 4°C and used for fixing cells in cell cycle 
analysis. 
9) 1% (w/v) Paraformaldehyde 
One gram paraformaldehyde powder purchased from Sigma-Aldrich Co. was 
completely dissolved in 50 ml deionized water by heating to 60°C with constant 
stirring for 1 hour in a fume hood. A few drops of 1 M NaOH were added to facilitate 
the dissolution of paraformaldehyde powder. Once the clear solution was obtained, it 
was cooled to room temperature. 2X PBS solution (50 ml) was added to the solution 
to give the 1% (w/v) paraformaldehyde. The solution was stored in dark at 4°C until 
use. 
10) FACS Medium 
FACS medium consists of 2% (v/v) HI-FCS and 0.05% (w/v) sodium azide in 
PBS. It was used for washing and re-suspending cells in FACS analysis. Sodium azide 
was added to inhibit internalization of cell-bound antibodies, patching and capping of 
the cells. The FACS medium was stored at 4°C. 
11) FACS Flow Sheath Fluid 
The sheath fluid is a ready-to-use solution purchased from Becton Dickinson. It 
is a balanced electrolyte solution containing sodium chloride, potassium chloride, 
disodium EDTA, sodium fluoride and an anti-microbial agent. It was stored at room 
temperature. 
12) Antibodies for Flow Cytometry 
a) Mouse Anti-Human Macrophage Differentiation Antigen C D l l b (Integrin 
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alpha M, Mac-1 alpha) Monoclonal Antibody (clone: ICRF44; isotype: mouse IgGi) 
It was purchased from eBioscience, Inc. The ICRF44 monoclonal antibody reacts 
with the human CDl lb, a 165 kDa adhesion molecule. Small volume aliquots of the 
antibody were stored at -70°C until use. Once the antibody was thawed, it was kept at 
4°C. 
b) Mouse Anti-Human Macrophage Differentiation Antigen CD 14 Monoclonal 
Antibody (clone: M5E2; isotype: mouse IgG2a) 
It was purchased from BD Pharmingen. The antibody reacts with the human 
CD 14 antigen. Small volume aliquots of the antibody were stored at -70°C until use. 
Once the antibody was thawed, it was kept at 4°C. 
c) Mouse IgG and Human IgG 
Mouse IgG (10 mg/ml) and human IgG (10 mg/ml) were purchased from 
Sigma-Aldrich Co. The antibodies are used to block the non-specific binding of 
immunoglobulins to the Fc receptors of the cells. They were stored in aliquots at 
-20�C. 
2.1.5 Reagents for DNA Extraction 
1) IGEPAL CA-630 Lysis Buffer 
The lysis buffer was prepared in 50 mM Tris [hydroxylmethyl] amino methane 
(Tris)-HCl, pH 7.5 with 3% non-ionic detergent IGEPAL CA-630 ((Octylphenoxy) 
polyethoxyethanol) and 20 mM EDTA. IGEPAL CA-630 lysis buffer components 
were purchased from Sigma-Aldrich, Inc. and IGEPAL is a registered trademark of 
Phone-Poulenc, Inc. The lysis buffer was stored at room temperature. 
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2) Proteinase K 
Proteinase K is a USB Corporation product. It is a highly active and stable 
endopeptidase purified from the fungus Tritirachium album and is used in a wide 
range of applications. By dissolving the proteinase powder in autoclaved TioEo.i 
buffer, the stock solution (20 mg/ml) was prepared and it was stored as 500 )il 
aliquots at -20°C. 
3) RNase A 
The bovine pancreatic RNase A was purchased from USB Corporation. By 
dissolving RNase powder in TioEo.i buffer, the stock solution (10 mg/ml) was 
prepared. The solution was boiled for 15 minutes to denature any contaminated 
DNase. It was stored as 500 |LI1 aliquots at -20°C. 
4) 3M Sodium Acetate Solution (NaOAc) (pH 5.2) 
Sodium acetate powder was purchased from Sigma-Aldrich Co. The 3M stock 
solution was prepared by dissolving 24.61 g sodium acetate in 100 ml deionized water 
and adjusted the pH to 5.2 with glacial acetic acid. It was then sterilized by 
autoclaving at 121 °C for 20 minutes. The solution was stored at room temperature. 
5) T.oEo.I Buffer 
The buffer consists of 10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA in deionized 
water. It was stored at room temperature. 
2.1.6 Cell Death Detection ELISA*"^^^ 
This ELISA kit is a user-friendly product produced by Roche Applied Science. 
The kit was stored at It contains the following reagents: 
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1) Anti-Histone-Biotin Antibody 
It is a monoclonal antibody from mouse (clone HI 1-4). It is able to bind to the 
histone component of the nucleosomes and captures the immunocomplex 
simultaneously via biotin to the streptavidin-coated microplate. The lyophilized 
antibody was reconstituted in 0.45 ml deionized water and stored at 4°C up to 2 
months. 
2) Anti-DNA-POD Antibody 
It is a peroxidase conjugated Fab-fragment derived from mouse monoclonal 
antibody (clone MCA-33). The antibody recognizes the DNA components of the 
nucleosomes and produces the color reaction with ABTS. The lyophilized antibody 
was reconstituted in 0.45 ml deionized water and stored at 4°C up to 2 months. 
3) Lysis Buffer 
It is a ready-to-use solution. The stock buffer was stored at 4°C until use. It was 
used to lyse cells and freed the DNA components from the cells. 
4) Incubation Buffer 
It is a ready-to-use solution. The stock buffer was stored at 4°C until use. The 
immunoreagent was prepared by mixing of 1 volume anti-histone-biotin and 1 volume 
anti-DNA-POD with 18 volumes incubation buffer. 
5) Substrate Buffer 
It is a ready-to-use solution for dissolving the ABTS tablets. The stock buffer 
was stored at 4°C until use. 
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6) ABTS Tablets 
One tablet was dissolved in 5 ml substrate buffer to give the ABTS solution. The 
solution is light sensitive and was stored in dark at 4°C for 1 month. 
7) Microplate 
The plate provides a suitable base for the reaction. The wall of the plate was 
coated with streptavidin which could bind to anti-histone-biotin antibody, and thus 
linked with other reagents for color detection. It was stored in dark at 4°C. 
8) Pan-caspase Inhibitor III 
It is a cell-permeable, irreversible, broad-spectrum caspase inhibitor purchased 
from CalBiochem. The off-white semi-solid was dissolved in DMSO in 1 mM 
concentration and stored at -20°C. 
2.1.7 Reagents for Measuring Caspase Activity 
1) Cell Lysis Buffer 
The lysis buffer contains 1% IGEPAL-CA 630 (Sigma), 150 mM NaCl, 50 mM 
Tris-HCl (pH 7.5) and complete'^^ protease inhibitor cocktail (Roche Applied Science) 
in 50 ml deionized water. It was stored at 4°C. 
2) 2X Reaction Buffer 
2X reaction buffer contains 20 mM HEPES-KOH (pH 7.0), 80 mM 
P-glycerophosphate, 100 mM NaCl, 4 mM MgCb, 10 mM EGTA, 0.2% CHAPS, 200 
|ag/ml BSA and 20 mM DTT. It was stored at 4°C. 
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3) Dithiothreitol (DTT) 
IM stock solution was prepared by dissolving DTT in deionized water. It was 
stored at -20°C. It was added to the 2X reaction buffer to a final concentration of 20 
mM just before use for maintaining full caspase activity. 
4) Bradford Reagent 
It is a 5X solution purchased from Bio-Rad Laboratories. One volume Bradford 
reagent was mixed with 4 volumes protein samples for protein quantification. The 
Bradford reagent was stored at 4°C. 
5) Caspase-3 Substrate, Ac-DEVD-AMC 
Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) 
(Sigma-Aldrich Co.) is a caspase-3 specific fluorogenic substrate. The 2 mM stock 
solution in DMSO was stored at -20°C. 
6) Caspase-3 Inhibitor, Ac-DEVD-CHO 
Acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO) (Alexis Biochemicals) is a 
specific reversible inhibitor of caspase-3. It was dissolved in sterile deionized water as 
a 10 mM stock solution. The stock solution was diluted to give a 1 mM working 
solution using RPMI medium. Both the stock and the diluted solutions were stored at 
-20�C. 
7) Caspase-8 Substrate, Ac-IETD-AMC 
N-Acetyl-Ile-Glu-Thr-Asp-7-Amido-4-methylcoumarin (Ac-IETD-AMC) 
(Alexis Biochemicals) is a specific fluorogenic substrate for caspase-8 and granzyme 
B. The 1 mM stock solution in DMSO was stored at -20°C. 
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8) Caspase-8 Inhibitor, Ac-IETD-CHO 
Acetyl-Ile-Glu(OMe)-Thr-Asp(OMe)-CHO (Ac-IETD-CHO) (Alexis 
Biochemicals) is a potent, cell permeable and irreversible inhibitor of caspase-8 and 
granzyme B. It was dissolved in DMSO as a 10 mM stock solution. The stock 
solution was diluted to give a 1 mM working solution using RPMI medium. Both the 
stock and the diluted solutions were stored at -20°C. 
9) Caspase-9 substrate, Ac-LEHD-AFC 
N-Acetyl-Leu-Glu-His-Asp-7-amido-4-trifluoromethylcoumarin (Ac-LEHD-
AFC) (Alexis Biochemicals) is a caspase-9 specific fluorogenic substrate. The 5 mM 
stock solution in DMSO was stored at -20°C. 
10) Caspase-9 inhibitor, Ac-LEHD-CHO 
Acetyl-Leu-Glu(OMe)-His-Asp(OMe)-aldehyde (Ac-LEHD-CHO) (Alexis 
Biochemicals) is a potent, cell permeable and irreversible inhibitor of caspase-9. It 
was dissolved in DMSO as a 10 mM stock solution. The stock solution was diluted to 
give a 1 mM working solution using RPMI medium. Both the stock and the diluted 
solutions were stored at -20°C. 
11) 7-Amino-4-MethyI Coumarin (AMC) 
7-Amino-4-methyl coumarin (AMC) purchased from Sigma-Aldrich Co. is a 
standard marker for the quantification of caspase-3 and caspase-8 activities. It was 
dissolved in DMSO as a 50 mM stock solution. The working solution in 100 fiM was 
prepared by dilution with the lysis buffer. Both the stock and diluted solutions were 
stored at 4°C. 
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12) 7-Amino-4-TrifluoromethyI Coumarin (AFC) 
7-Amino-4-trifluoromethyl coumarin (AFC) was purchased from Sigma-Aldrich 
Co. It is a standard marker for the quantification of caspase-9 activity. It was 
dissolved in methanol as a 20 mM stock solution. By diluting with lysis buffer, the 
working solution in 80 juM was prepared. Both the stock and diluted solutions were 
stored at 4°C. 
2.1.8 Reagents for Fast Activated Cell-based (FACETM) ELISA Kit 
Two FACE™ ELISA kits were purchased from Active Motif. They were the 
FACETM J N K ELISA kit and FACE'^^ NF-KB p65 profiler. The kits were stored at 
-20°C. Most of the reagents are common for the two kits and they included the 
following: 
1) IX PBS 
IX PBS was prepared by adding 1 volume lOX PBS to 9 volumes deionized 
water and mixed thoroughly. 
2) Washing Buffer (0.1% Triton X-100) 
It was prepared by 100-fold dilution of 10% Triton X-100 solution using IX 
PBS. 
3) Quenching Buffer 
Quenching buffer is a washing buffer containing 0.1% fresh sodium azide 
(Sigma-Aldrich Co.) and 1% fresh hydrogen peroxidase (Merck Biosciences). It was 
used to inactivate the cells' endogenous peroxidase activity. 
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4) Fixing Buffer (8% Formaldehyde) 
It was prepared by adding 36.5% stock formaldehyde (Sigma-Aldrich Co.) to IX 
PBS. Formaldehyde (8%) was used with non-adherent cells for cell fixation. 
5) IX Antibody Blocking Buffer 
The buffer was supplied as a ready-to-use solution. 
6) IX Antibody Dilution Buffer 
The buffer was supplied as a ready-to-use solution. 
7) Chemiluminescent Reagent 
The light-sensitive developing dilution was supplied as a ready-to-use solution 
and it was warmed to room temperature before use. 
8) Stop Solution 
Sulphuric acid was supplied as a ready-to-use solution. The acid was used to stop 
the reaction. 
The antibodies in two kits include the following: 
9) Anti-Rabbit HRP-Conjugated IgG 
The supplied antibody was diluted 2000 times in antibody dilution buffer before 
use. The HRP-conjugated secondary antibody was used to detect bound primary 
antibodies. 
10) Phospho-JNK Antibody (T183/Y185) ( F A C E ™ JNK ELISA kit only) 
The supplied antibody was diluted 500 times in antibody dilution buffer before 
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use. It only recognizes the phosphorylated form of the JNK protein. 
11) Total-JNK Antibody (FACE^^ JNK ELISA kit only) 
The supplied antibody was diluted 250 times in antibody dilution buffer before 
use. It recognizes both the phosphorylated and non-phosphorylated forms of the JNK 
protein. 
12) Phospho-NF-KB p65 Antibodies (S468 and S536) (FACE^^ N F - K B p65 
profiler only) 
The supplied antibody was diluted 500 times in antibody dilution buffer for use. 
Two specific antibodies (S468 and S536) that recognize the phosphorylated form of 
the NF-KB p65 protein were used in this study. 
13) Total-NF-KB p65 Antibody (FACE^^ N F - K B p65 profiler only) 
The supplied antibody was diluted 500 times in antibody dilution buffer before 
use. It recognizes both the phosphorylated and non-phosphorylated forms of the 
NF-KB p65 protein. 
2.1.9 Reagents for Western Blotting 
1) Cell Lysis Buffer for Total Protein Extraction 
The lysis buffer contains 1% IGEPAL-CA 630 (Sigma), 150 mM NaCl, 50 mM 
Tris-HCl (pH 7.5) and complete™ protease inhibitor cocktail (Roche Applied Science) 
in 50 ml deionized water. It was stored at 4°C. 
2) Cell Lysis Buffer for Cytosolic and Mitochondrial Protein Extraction 
The lysis buffer consists of 2 portions. The first part of the solution (4/10 volume 
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of the lysis buffer) contains 75 mM NaCl, 1 mM NaH2P04, 8 mM Na2HP04, 250 mM 
sucrose and complete'^^ protease inhibitor cocktail (Roche Applied Science) in 50 ml 
deionized water. The second part (6/10 volume of the lysis buffer) was prepared by 
0.02g/ ml digitonin solution. For separating the cytosolic fraction of the cell, 1/24 
volume of the stock digitonin was diluted with 23/24 volume of deionized water 
before freshly mixing with the first part of solution. For separating mitochondrial 
fraction, 1/3 volume of the stock digitonin was diluted with 2/3 volume of deionized 
water before mixing with the first portion of the lysis buffer. Both the stock solutions 
were stored at 4°C. 
3) Cell Lysis Buffer for Phosphorylated Protein Extraction 
The lysis buffer consists of 2 parts. The first part of the solution (896/1000 
volume of the buffer) contains 100 mM Tris, 0.1 M NaCl, 5 mM EDTA, 67 mM 
sodium pyrophosphate and 1% Triton X-100. The second part (104/1000 volume of 
the buffer) contains 0.1 M sodium orthovandate, 0.5 M 1,4-dithiothreitol and 
completeTM protease inhibitor cocktail. Both the stock solution were stored at 4°C and 
only freshly mixed before use. 
4) Bradford Reagent 
It is a 5X solution purchased from Bio-Rad Laboratories. 1/5 volume Bradford 
reagent was mixed with 4/5 volume protein samples for protein quantification. The 
reagent was stored at 4°C. 
5) Bovine Serum Albumin (BSA) 
BSA (Sigma-Aldrich Co.) powder was dissolved in sterilized deionized water 
and made up to 2 mg/ml stock aliquots. The powder was stored at 4°C while the 
- 5 6 -
Chapter 2 Materials and Methods 
aliquots were kept at -20°C. The BSA standard curve was constructed using 0 jug/ml, 
2 |ig/ml, 4 |ig/ml, 6 |ig/ml, 8 |Lig/ml and 10 |ig/ml filtered water diluted-BSA solutions. 
6) Lower Buffer 
1.5 M Tris (Sigma-Aldrich Co.) was dissolved in deionized water to prepare the 
buffer (pH had to be adjusted to 8.8). It was stored at 4°C. 
7) Upper Buffer 
0.5 M Tris (Sigma-Aldrich Co.) was dissolved in deionized water to prepare the 
buffer (pH had to be adjusted to 6.8). It was stored at 4°C. 
8) 10% Sodium Dodecyl Sufate (SDS) Solution 
SDS powder was purchased from Sigma-Aldrich Co. 10% SDS solution (w/v) 
was prepared by dissolving 10 g SDS in 100 ml deionized water and kept at room 
temperature. 
9) Acrylamide Stock Solution 
30% (w/v) acrylamide/ bis stock solution was produced by Bio-Rad Laboratories. 
The 500 ml solution contains 146.1 g acrylamide and 3.9 g N,N，-methylene-
bis-acrylamide at a total monomer to crosslinker ratio of 37.5:1. It was stored at 4°C. 
10) 10% Ammonium Persulfate (APS) 
APS was purchased from Bio-Rad Laboratories. The 10% APS solution (w/v) 
was prepared by dissolving 0.5 g APS in 5 ml deionized water. The solution was kept 
at -20°C. 
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11) N,N,N,N'-Tetra-Methyl-ethylenediamine (TEMED) 
TEMED stock solution 5 (ml) was bought from Bio-Rad Laboratories. 
12) 4X SDS Loading Buffer 
By mixing 0.4 ml 0.05% bromophenol blue, 2 ml upper buffer, 2 ml glycerol, 2 
ml 10% SDS, 0.2 ml 2-mercaptoethanol and 1.4 ml deionized water together, 8 ml 
concentrated loading buffer was produced. All reagents were bought from 
Sigma-Aldrich Co. except 2-mercaptoethanol which was purchased from GIBCO 
BRL Life Technologies Inc. The loading buffer was kept at 4°C. 
13) lOX SDS Running Buffer 
The buffer contains 0.25 M Tris base (pH 8.6), 1.92 M glycine (USB 
Corporation) and 1% SDS in deionized water. The working buffer was 10-fold diluted 
from the lOX stock solution. The buffer was stored at 4°C. 
14) lOX Transfer Buffer 
The buffer contains 0.25 M Tris base (pH 8.6) and 1.92 M glycine. lOX transfer 
buffer (40 ml) was mixed with 360 ml deionized water and 100 ml methanol (Merck 
Biosciences) to produce 500 ml IX buffer. It was stored at 4°C. 
15) 1 OX Washing Buffer 
The buffer was made up of 100 mM Tris (pH 7.5), 1 M NaCl and 1% Tween 20 
(Sigma-Aldrich Co.) in deionized water. The buffer was stored at 4°C. 
16) Kaleidoscope Prestained Standards 
The Bio-Rad Laboratories standards are mixtures of well-characterized 
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proteins that are used as a reference to determine the molecular weight of proteins of 
interest identified by the antibody probes. They contain seven individually coloured 
proteins, including myosin (199,000 Da), p-galactosidase (128,000 Da), bovine serum 
albumin (85,000 Da), carbonic anhydrase (41,700 Da), soybean trypsin inhibitor 
(32,100 Da), lysozyme (18,300 Da) and aprotinin (7,500 Da). The standard prepared 
in 33% (v/v) glycerol, 3% SDS, 10 mM Tris (pH 7), 10 mM DTT, 2 mM EDTA and 
0.01% NaNs was stored at -20°C. 
丁\f 
17) BioTrace Polyvinylidene Fluoride Transfer Membrane 
The 3 meter roll PVDF membrane with pore size of 0.45 fim was purchased from 
Pall Corporation. It was cut into 8.5 cm x 5.5 cm sized transfer membranes and stored 
at room temperature. 
18) Filter Paper 
Chromatography paper (3 mm) was purchased from Whatman International Ltd. 
One hundred sheets sized 46 cm x 57 cm papers were cut to small filter paper sized 
8.5 cm X 5.5 cm. 
19) Blocking Agent 
One gram non-fat milk powder was dissolved in 20 ml IX washing buffer to give 
5% blocking agent. 
20) Primary Antibodies 
a) Mouse Anti-p-actin Monoclonal Antibody (catalog number: A5316) 
The mouse IgG purchased from Sigma-Aldrich Co. is a monoclonal antibody 
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(mouse IgG2a isotype) derived from the AC-74 hybridoma that was produced by the 
fusion of mouse myeloma cells and splenocytes from an immunized mouse. It 
recognizes an epitope located on the N-terminal end of the P-isoform of actin. The 
antibody labelled p-actin (42 kDa) in a wide variety of tissues and species. The 
product was supplied as ascites fluid containing 0.1% sodium azide as a preservative. 
b) Rabbit Anit-Bad Polyclonal Antibody (catalog number: AAP-020) 
The rabbit IgG purchased from StressGen Biotechnologies Corporation is a 
synthetic peptide corresponding to amino acid residues 19 to 35. It detects a 23 kDa 
band, corresponding to the expected molecular mass of Bcl-2-antagonist of cell death 
(Bad). The 100 |ug antibody was stored in borate buffered saline (25 mM sodium 
borate, 100 mM boric acid, 75 mM NaCl and 5 mM disodium EDTA, pH 8.2, at -20 
c) Rabbit Anti-Bak (H-211) Polyclonal Antibody (catalog number: sc-7873) 
The rabbit anti-Bak IgG, purchased from Santa Cruz Biotechnology, was raised 
against amino acids 1-211 representing the full length Bak of human origin. Each vial 
contains 200 |Lig IgG in 0.1 ml of PBS with less than 0.1% sodium azide and 0.1% 
gelatine. The antibody reacts with Bak of mouse, rat and human origin. The product 
was stored at 4°C. 
d) Rabbit Anti-Bid (FL-195) Polyclonal Antibody (catalog number: sc-11423) 
The rabbit anti-Bid IgG, purchased from Santa Cruz Biotechnology, was raised 
against amino acids 1-195 representing the full length Bid of human origin. Each vial 
contains 200 jig IgG in 0.1 ml of PBS with less than 0.1% sodium azide and 0.1% 
gelatine. The antibody reacts with Bid of mouse, rat and human origin. The product 
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was stored at 
e) Rabbit Anti-Bci-Xs/t (L-19) Polyclonal Antibody (catalog number: sc-1041) 
The rabbit anti-Bcl-X IgG, purchased from Santa Cruz Biotechnology, was raised 
against a peptide mapping at the C-terminal of BC1-XS/L of human origin. Each vial 
contains 200 |ig IgG in 0.1 ml of PBS with less than 0.1% sodium azide and 0.1% 
gelatine. The antibody reacts with BC1-XS/L of mouse, rat and human origin. The 
product was stored at 4°C. 
f) Mouse Anti-Bcl-2 (C-2) Monoclonal Antibody (catalog number: sc-7382) 
The mouse anti-Bcl-2 IgG, purchased from Santa Cruz Biotechnology, was raised 
against amino acids 1-205 of Bcl-2 of human origin. Each vial contains 200 jiig IgG in 
0.1 ml of PBS with less than 0.1% sodium azide and 0.1% gelatine. The antibody 
reacts with Bcl-2 of mouse, rat and human origin. The product was stored at 4°C. 
g) Rabbit Anti-PARP (H-250) Polyclonal Antibody (catalog number: sc-7150) 
The rabbit anti-PARP IgG, purchased from Santa Cruz Biotechnology, was raised 
against amino acids 764-1014 mapping at the C-terminus of PARP-1 of human origin. 
Each vial contains 200 |ig IgG in 0.1 ml of PBS with less than 0.1% sodium azide and 
0.1% gelatine. The antibody reacts with PARP of mouse, rat and human origin. The 
product was stored at 4°C. 
h) Rabbit Anti-Fas (FL-335) Polyclonal Antibody (catalog number: sc-7886) 
The rabbit anti-Fas IgG, purchased from Santa Cruz Biotechnology, was raised 
against amino acids 1-335 representing the full length Fas of human origin. Each vial 
contains 200 )ig IgG in 0.1 ml of PBS with less than 0.1% sodium azide and 0.1% 
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gelatine. The antibody reacts with Fas of mouse, rat and human origin. The product 
was stored at 4"C. 
i) Rabbit Anti-Fas Ligand (C-178) Polyclonal Antibody (catalog number: 
sc-6237) 
The rabbit anti-Fas ligand IgG, purchased from Santa Cruz Biotechnology, was 
raised against amino acids 100-278 mapping at the C-terminus of Fas-L of rat origin. 
Each vial contains 200 jLig IgG in 0.1 ml of PBS with less than 0.1% sodium azide and 
0.1% gelatine. The antibody reacts with Fas-L of mouse, rat and human origin. The 
product was stored at 4°C. 
j) Rabbit Anti-ERK 1 (K-23) Polyclonal Antibody (catalog number: sc-94) 
The rabbit anti-ERKl IgG, purchased from Santa Cruz Biotechnology, was raised 
against a peptide mapping subdomain XI of ERK of rat origin. Each vial contains 200 
jig IgG in 0.1 ml of PBS with less than 0.1% sodium azide and 0.1% gelatine. The 
antibody reacts with ERK 1 p44 and ERK 2 p42 of mouse, rat and human origin. The 
product was stored at 4°C. 
k) Rabbit Anti-Phospho-p44/p42 MAP Kinase (T202/Y204) Monoclonal 
Antibody (catalog number: 4374) 
The rabbit anti-phospho-p44/p42 MAP kinase IgG, purchased from Cell 
Signaling Technology, was produced by immunizing mice with a synthetic 
phosphor-peptide corresponding to residues surrounding Thr202/Tyr204 of human 
p44 MAP kinase. The product was supplied in PBS (pH 7.2) with 0.1% sodium azide 
and 2.0 mg/ml BSA. The antibody detects phosphorylated ERK 1 p44 and ERK 2 p42; 
it does not cross-react with the corresponding phosphorylated residues of either 
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SAPK/JNK or p38 MAP kinase. The product was stored at 4°C. 
I) Mouse Anti-Cytochrome c Monoclonal Antibody (catalog number: 556433) 
The mouse anti-cytochrome c IgG, purchased from BD Biosciences PharMingen, 
is a monoclonal antibody (mouse IgG2b isotype) derived from the clone 7H8.2C12. 
Clone 7H82C12 recognizes an epitope within amino acids 93-104 of pigeon 
Cytochrome c (Cyt c). Synthetic peptides corresponding to amino acids 1-80, 81-104 
and 66-104 of pigeon Cyt C were used as immunogens. The IgG was dissolved in 0.1 
ml of aqueous buffered solution with less than 0.09% sodium azide. The antibody 
reacts with Cyt C of mouse, rat and human origin. The product was stored at 4°C. 
21) Secondary Antibodies 
a) Anti-Rabbit Ig, Horseradish Peroxidase Linked Whole Antibody 
The antibody was purchased from Amersham Biosciences UK Limited with the 
concentration of 1 mg/ml. It was used at 1:1,000 concentration. The antibody was 
stored at 4 T . 
b) Anti-Mouse Ig, Horseradish Peroxidase Linked Whole Antibody 
The antibody was purchased from Amersham Biosciences UK Limited with the 
concentration of 1 mg/ml. It was used at 1:1,000 concentration. The antibody was 
stored at 4°C. 
22) Western Blotting Luminol Reagent A and B 
The Western blotting luminol reagents (Nalgene) consist of reagent A (125 ml) 
and B (125 ml). Equal volume of reagent A and B was mixed freshly to produce a 
detection reagent. Five hundred microlitres mixture was used for wetting one 
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membrane.The reagents were stored in dark at 4°C. 
23) Fuji Medical X-ray Film 
The film was produced by Fuji Photo Film Co. Ltd. It was stored in dark at 4°C. 
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2.2 Methods 
2.2.1 Culturing the Tumor Cell Lines 
1) Suspension Cells 
Most of the human leukemia cell lines (NB-4, EoL-1, K562 and U-937) in this 
study were cultured in 10% complete RPMI medium as suspension cultures while 
HL-60 and HL-60/MX2 cells were grown in RPMI medium supplemented with 20% 
FBS. All cells were incubated at 37°C in a humidified incubator supplied with 5% 
carbon dioxide (CO2) for continuous growth. In general, sterilized 25, 75 or 150 cm^ 
tissue culture flasks were used to culture cells. The cells in exponential growth phase 
were either chosen for performing assays or for long-term storage of cell lines by 
cryopreservation in liquid nitrogen (the composition of cryopreservation medium was 
50% FBS and 10% DMSO in RPMI medium). Depending on the doubling time of 
each cell line, cells were sub-cultured at 2 to 4 day intervals to maintain a desirable 
cell population and prevent over-growth. 
2) Adherent Cells 
For sub-culturing human adherent cell lines (WRL 68 and Hs68), the growth 
medium was discarded and the cells on flask surface were rinsed once with warm 
sterilized PBS before trypsinization. The cells were incubated with 2 ml (for 25 cm^ 
2 7 
culture flask), 4 ml (for 75 cm culture flask) or 6 ml (for 150 cm culture flask) warm 
0.25% trypsin-1 mM EDTA solution at 37°C for 2 to 3 minutes. It was followed by 
adding 10% complete RPMI medium to stop the trypsinization process. An 
appropriate amount of cells was transferred to a new culture flask containing fresh 
complete medium. 
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2.2.2 Isolation, Preparation and Culturing of Murine Peritoneal Macrophages 
and Bone Marrow Cells 
1) Murine Peritoneal Macrophages 
BALB/c mice aged 6 to 8 weeks were injected intraperitoneally (i.p.) with 1 ml 
3% thioglycollate broth and sacrified 3 days later by cervical dislocation. The mice 
were placed facing upward vertically on a clean plastic surface. The abdominal skin 
of the disinfected mice was cut and pulled apart to expose the peritoneal membrane. 
Air ( � 3 ml) was first injected to inflate the peritoneal cavity. Plain RPMI medium ( � 3 
ml) was injected into the cavity using a 5 ml syringe fitted with a 20-gauge needle for 
washing out the peritoneal exudate cells (PEC). The washing process was repeated 
three times to maximize the efficiency of cell isolation. PEC were resuspended in the 
10% complete RPMI medium. 
The PEC (1 X 10^ cells/ml) were seeded in a 96-well flat-bottomed microplate 
and incubated at 37°C for 3 hours to allow macrophages to attach onto the plastic 
surface of wells. The wells were then washed once with plain RPMI medium to 
remove the suspension cells. The RPMI medium supplemented with 10% HI-FBS was 
added to wells and the macrophages were ready for performing assays. 
2) Murine Bone Marrow Cells 
To obtain the mouse bone marrow cells, 6 to 8 weeks old BALB/c mice were 
sacrificed by cervical dislocation. The skin of mice was wetted with 70% ethanol. The 
femurs were removed with aseptic techniques and put into a petri dish containing 10% 
complete RPMI medium. Two ends of the bones were cut and cells were flushed out 
using a 2 ml syringe fitted with a 25 G needle containing 10% complete RPMI 
medium. The cells were resuspended in ACK buffer for 5 minutes in order to lyse red 
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blood cells so as to obtain the bone marrow cells. The cells were then resuspended in 
complete RPMI medium. For performing assays, the cells were resuspended in RPMI 
medium supplemented with 10% HI-FBS. 
2.2.3 Anti-proliferation Assays 
1) MTT Reduction Assay 
Leukemia cells (1 x 10^ cells/ml) were first incubated with different 
concentrations of conjugated linolenic acid (CLN) in 96-well flat-bottomed 
microplates at 37°C for 24, 48 and 72 hours in a humidified 5% CO2 incubator. Thirty 
microlitres MTT (5 mg/ml) was then added to the drug-treated cells for 2 hours. After 
centrifuging the plate at 400 x g for 5 minutes, the medium was aspirated. DMSO (50 
|Lil) was added to dissolve the blue formazan deposited in the cells or acted as the 
blank. The absorbance was measured at 540 nm by a microplate reader (Bio-Rad 
Laboratories). The results were expressed as the mean percentage cell viability 土 
standard error (S.E.) of quadruplicate samples. The percentage viability was 
calculated as follows: 
Percentage to control = [OD540 of test sample / OD540 of control] x 100% 
As controls, the effects of other polyunsaturated fatty acids on leukemia cells 
(HL-60 cells) and the effects of CLN on normal primary cells were also investigated 
using this assay. 
2) [^H]-TdR Incorporation Assay 
Leukemia cells (1 x 10^ cells/ml) were incubated with different concentrations of 
CLN in 96-well flat-bottomed microplates at 37°C for 24, 48 and 72 hours in a 
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humidified 5% CO2 incubator. The drug-treated cells were pulsed with 0.5 \iC\ 
^H]-TdR (in 20 |LI1 complete medium) for 6 hours and put in a -20°C freezer. The cells 
were thawed and harvested onto a glass microfiber filter (Skatron Instrument) by cell 
harvester (Molecular Device). The radioactivity, in counts per minute (cpm), was 
measured by the liquid scintillation Analyzer Tri-Carb® 2900TR (Packard Instrument 
Company). The results were expressed as the mean percentage inhibition of [^H]-TdR 
incorporation 士 S.E. of quadruplicate samples. The untreated cells were used as a 
control. The percentage inhibition was calculated by the following equation: 
Percentage inhibition = [(cpm of control — cpm of test sample)/cpm of control] x 
100% 
2.2.4 Cell Viability Determination 
Trypan blue exclusion assay was carried out to determine cell viability. The 
viability is distinguished by the ability of cells to exclude trypan blue dye as only the 
viable cells with integral plasma membrane can exclude the dye. Viable cells are 
visible as clear cell bodies while dead cells are stained in blue. The leukemia cells at a 
concentration of 1 x 10^ cells/ml were incubated with different concentrations of CLN 
at 37°C. The viability of cells was determined after 24, 48, 72 and 96 hours of 
incubation. Ten microlitres cell suspension was mixed with 10 jul 0.4% trypan blue 
solution, and 10 |ul mixture was then taken out and loaded in a hemocytometer to 
count the number of viable and dead cells. The results were expressed as the mean 
percentage of cell viability 士 S.E. of triplicate cultures. The percentage viability was 
calculated by the following equation: 
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Percentage of cell viability = (number of viable cells/number of total cells counted) x 
100% 
2.2.5 Determination of Anti-leukemic Activity In Vivo (In Vivo Tumorigenicity 
Assay) 
Human leukemia HL-60 cells (1 x 10^ cells/ml) were incubated with different 
concentrations of jacaric acid for 16 hours at 37°C. The drug-treated cells were 
collected and washed twice with PBS. After performing viable cell counting, HL-60 
cells (3 X lO?) in 100 |LI1 matrigel matrix were injected i.p. into each nude mouse in 
groups of five. The tumor size was continuously monitored at a 2 to 4 days interval up 
to a month. 
2.2.6 Cell Cycle Analysis by Flow Cytometry 
i) Cell Preparation 
HL-60 cells (1 x 10^ cells/ml) were synchronized in RPMI medium 
supplemented with 1% HI-FBS overnight. The leukemia cells were then resuspended 
in RPMI medium supplemented with 20% HI-FBS and incubated with different 
concentrations of jacaric acid at 37°C for different periods of time. The cells were 
washed once with PBS and centrifuged at 400 x g for 5 minutes. They were fixed with 
1 ml 70% ethanol at 4 � C for at least 30 minutes. 
ii) PI Staining and Cell Cycle Analysis 
Before staining the DNA contents within cells, the ethanol had to be removed 
completely. That was achieved by first spinning the samples at 400 x g for 10 minutes 
to remove most of the ethanol and then washing the cells once again with PBS and 
centrifuging the cells down at the same conditions. Each sample was mixed with 1 ml 
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fresh Pl-containing DNA staining solution in dark at 37°C for 30 minutes. The stained 
cells were subjected to FACS analysis using the FACSCanto flow cytometer (Becton 
Dickinson). The excitation wavelength was at 488 nm and the emission wavelength 
was at 590 nm for measuring red fluorescence intensity. Ten thousands events were 
collected for each sample determination. The data were analyzed using ModFit 3.0 
program (Verity Software House) to produce the cell cycle profile. The DNA contents 
in GQ/G], S, and G2/M phases of various samples were compared. 
2.2.7 Detection of Apoptosis 
1) Detection of Mitochondrial Membrane Potential Changes 
JC-1 staining method is a common method to determine the mitochondrial 
membrane potential (Avj/m) of cells. Jacaric acid-treated and untreated HL-60 cells (1 
X 106 cells) were collected after various time periods. The cells were resuspended in 
the working JC-1 solution and incubated for 15 minutes at 37°C. The stained cells 
were subjected to flow cytometric analysis using BD FACSCanto flow cytometer. The 
excitation wavelength was at 488 nm and the emission wavelengths of red (590 nm) 
and green (525 nm) fluorescence were measured simultaneously (Mason, 1993). 
2) Detection of DNA Fragmentation by Agarose Gel Electrophoresis 
There were 3 major steps in this assay: 
i) Cell Preparation 
HL-60 cells (1 x 10^ cells/ml) were incubated with various concentrations of 
jacaric acid for different time periods at 37°C. The cells were collected and washed 
once with cold PBS by spinning at 400 x g for 5 minutes. Cell counting with 0.4% 
trypan blue was carried out to determine the cell number and cell viability. 
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ii) Collecting DNA Fragments 
DNA fragments were isolated from the apoptotic cells according to the method 
described by Herrmann e t a l (1994). HL-60 cells (2 x 10^ cells) were collected after 
cell counting and treated with 200 |LI1 IGEPAL CA-630 lysis buffer for 10 minutes in a 
37°C water bath. The samples were centrifuged at 6,000 x g for 5 minutes in order to 
collect the supernatants that contained the apoptotic DNA fragments. The 
supernatants were transferred to new microcentrifuge tubes and 50 |LI1 5% SDS was 
added to each sample. Ten microlitres DNase-free RNase A (10 mg/ml) was then 
added and incubated with the samples at 56°C for 90 minutes to remove the cellular 
RNA. Twenty microlitres proteinase K (20 mg/ml) was added and incubated with the 
samples at the same temperature for another 90 minutes to remove all proteins 
including RNase A. The DNA fragments were precipitated with 0.1 volume (30 jul) of 
3 M sodium acetate (pH 5.2) and 2.5 volumes (750 of 4°C absolute ethanol. After 
centrifugation at 20,000 x g at 4°C for 30 minutes, the pellets were resuspended with 
4°C 70% ethanol. The pellets were spun down at 20,000 x g at 4°C for 5 minutes and 
the supernatants were discarded. The washing steps were repeated using 4°C absolute 
ethanol to replace 70% ethanol. Once the pellets were air-dried for about 10 minutes, 
a milky layer should be observed on the walls of microcentrifuge tubes. TioEo.i buffer 
(20 )Lil) was added to dissolve the milky layer of the DNA fragments. 
iii) Detection of the DNA Fragments 
The samples were incubated at 65°C for 5 minutes to denature any DNA 
secondary structures before carrying out agarose gel electrophoresis. The samples 
were chilled on ice for 3 minutes. 5X gel loading buffer (5 jul) was mixed with each 
sample. Twenty-five microlitres dye containing samples were loaded into the wells of 
2% agarose gel and subjected to electrophoresis at 80 volts. After about 90 minutes, 
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the gel was stained with ethidium bromide (1 |Lig/ml) for 3 minutes and destained with 
deionized water for 15 minutes. The DNA bands were detected under UV illumination 
by the Gel Doc 2000 UV transilluminator (Bio-Rad Laboratories). 
3) Detection of Cytoplasmic Histone-Associated-DNA-Fragments by Cell 
Death ELISA Kit 
There were 3 major steps in the cell death ELISA kit: 
i) Sample Preparation 
Exponentially growing HL-60 cells were diluted in RPMI medium supplemented 
with 20% HI-FBS to a concentration of 1 x 10^ cells/ml. The HL-60 cells were 
incubated with various concentrations of jacaric acid (together with or without the 
pan-caspase inhibitor III) in the wells of a microplate for 4 hours at 37°C in a total 
volume of 200 |il. The microplate was then centrifuged at 200 x g for 10 minutes. The 
medium was discarded and the cell pellet was resuspended in 200 )il ready-to-use 
lysis buffer for 30 minutes at room temperature. The lysate was centrifuged at 200 x g 
for 10 minutes. Twenty microlitres supernatant (cytoplasmic fraction of cells) was 
transferred into the streptavidin-coated microplate for analysis immediately. The 
samples were prepared in triplicates. 
ii) Detection of Cytoplasmic Histone-Associated-DNA-Fragments 
Samples (20 |LI1) including lysates from drug-treated cells, negative control 
(lysate of untreated cells), background control (incubation buffer only) and positive 
control were transferred to streptavidin-coated microplate and mixed with 80 jil 
immunoreagent. The immunoreagent was prepared by blending 1 volume 
anti-DNA-POD and 1 volume anti-histone-biotin with 18 volumes incubation buffer. 
The plate was covered with an adhesive cover foil and incubated for 2 hours at room 
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temperature with gentle shaking (300 rpm). After removing the solution thoroughly by 
suction, the wells were rinsed with 300 |il incubation buffer for 3 times. Each washing 
step took 5 minutes and the plate was shaken gently. ABTS solution (100 |il) was 
pipetted to each well for color development in dark. By measuring the absorbance at 
405 nm against ABTS solution as a blank (with a reference wavelength of 490 nm) 
using a microplate reader, the colour change was analyzed. 
iii) Calculation 
The average absorbance values for different samples were measured. The values 
were then subtracted from the background value of the immunoassay. The specific 
enrichment factor for the mono- and oligo-nucleosomes released into the cytoplasm 
was calculated by the following equation: 
Enrichment factor = micro Unit (mU) of the sample/ mU of the corresponding 
negative control (cells without treatment) 
4) Early Apoptosis Detection by Annexin V-GFP-PI Double Staining 
The HL-60 cells at a concentration of 1 x 10^ cells/ml were incubated with 
different concentrations of jacaric acid for various time periods. The drug-treated cells 
and the control cells (1 x 10^) were collected and washed once with PBS. Each sample 
was kept on ice in dark for 15 minutes after resuspending in 100 j^ l reaction buffer 
(prepared by mixing 2 )il annexin V-GFP and 2 |LI1 PI (50 jig/ml) with 96 |il annexin V 
binding buffer). Another 400 |LI1 binding buffer was added to each sample before 
recording the cellular fluorescent signals by the BD FACSCanto flow cytometer. The 
data were analyzed using ModFit 3.0 program (Verity Software House) to produce dot 
plots. The x-axis was FL-1 while the y-axis was FL-2. 
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5) Early Detection of Reactive Oxygen Species (ROS) Generation 
The cellular ROS level was measured by staining the cells with 
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA). HL-60 cells were divided 
into two groups: one group was treated with different concentrations of jacaric acid 
and another group was pre-incubated with 15 mM N-acetyl-L-cysteine (NAC) or 200 
units/ml superoxide dismutase (SOD) for 3 hours and then treated with the same drug 
concentrations after washing NAC or SOD away. Total cells (1 x 10^) were collected 
in each sample and resuspended in 0.5 ml staining solution containing 10 \iM 
H2DCFDA at 37°C for 30 minutes. BD FACSCanto flow cytometer was used to detect 
the oxidative conversion by measuring the change of red fluorescence intensity. The 
excitation wavelength was 488 nm and the emission wavelength was 590 nm. 
2.2.8 Assessment of Differentiation-associated Characteristics 
1) Morphological studies 
HL-60 cells (5 x cells/ml) were incubated with different concentrations of 
jacaric acid at 37°C for 3 days. Cells (1 x 10)) were collected and fixed onto a clean 
microscopic glass slide by cytocentrifugation at 500 rpm for 5 minutes using the 
Shandon Cytospin 3 centrifuge (Shandon Scientific Ltd., U.K.). Once the cells were 
air-dried, they were stained with Hemacolor staining solution in the order of Solution 
1, 2 and 3. Each step lasted for 15 seconds and the cells had to be destained with 
running water gently. The air-dried cells were mounted with a neutral mounting 
medium, Canada Balsam (Sigma-Aldrich Co.). The cell morphology was studied 
under the Axioskop Plus II light microscope (Carl Zeiss, Inc). 
2) Side Scatter (SSC) and Forward Scatter (FSC) Analysis by Flow Cytometry 
HL-60 cells (2.5 x 10^ cells/ml) were incubated with different concentrations of 
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CLN isomers at 37°C for 3 days. The cells were collected and the culture flasks were 
shaken vigorously to detach any differentiated cells attached on the inner surfaces of 
the flasks. The flasks were washed once with cold PBS and the remaining cells were 
collected. Cells (1 x 10^) were analyzed by the BD FACSCanto flow cytometer to 
detect the granularity (indicated by SSC) and the size (indicated by FSC) of the cells. 
Density plots were constructed using the data collected. 
3) Surface Antigen Immunophenotyping by Flow Cytometry 
HL-60 cells (2.5 x cells/ml) were incubated with different concentrations of 
jacaric acid and positive control (vitamin D3) at T f C for 4 days. The cells were 
collected and the culture flasks were shaken vigorously to detach any differentiated 
cells attached on the inner surfaces of the flasks. The flasks were washed once with 
cold PBS and the remaining cells were collected. HL-60 cells (4 x 10^ cells per 
sample) were washed with 10 ml ice-cold FACS medium and centrifuged at 400 x g 
for 5 minutes. The supernatant was discarded and the cells were resuspended in 0.2 ml 
FACS medium containing human IgG (10 jug/ml) and mouse IgG (10 |Lig/ml) in a 
microcentrifuge tube. The IgG can bind to the Fc receptors on the HL-60 cells, so as 
to block the non-specific binding. The samples were chilled on ice for 30 minutes 
with occasional shaking before washing once with the FACS medium. The pellets 
were resuspended in 50 jul FACS medium and transferred to a new microcentrifuge 
tube. One microgram primary antibody (mouse anti-human macrophage 
differentiation antigen C D l l b monoclonal antibody or mouse anti-human macrophage 
differentiation antigen CD 14 monoclonal antibody) was added to the cell suspensions. 
For the control group, mouse IgG was added instead. After incubating the samples at 
4°C for 30 minutes in dark, they were washed twice with the FACS medium by 
spinning at 400 x g for 5 minutes at 4°C. The cells were resuspended in 100 jul FACS 
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medium containing FITC-conjugated goat anti-mouse IgG antibody (1 jug). After 
another 30 minutes of dark incubation at 4°C, the cells were washed twice with the 
FACS medium by spinning at 400 x g for 5 minutes at 4°C. The cell pellet was 
resuspended in 0.6 ml 1% paraformaldehyde. The green fluorescence intensity of 
samples was measured using the BD FACS Canto flow cytometer, with an excitation 
wavelength of 488 nm and an emission wavelength of 525 nm. 
2.2.9 Measurement of Caspase Activities 
There were 3 stages for measuring caspase activities: 
i) Treatment of Cells and Extraction of Proteins 
The caspase activities of jacaric acid-treated cells were measured using the 
method described by Mack et al. (2000). Briefly, HL-60 cells (1 x lO; cells/ml) were 
treated with the indicated concentrations of jacaric acid at 37°C for different time 
periods. The cell pellets were collected and washed twice with cold PBS by 
centrifuging at 400 x g for 5 minutes at 4°C. The lysis buffer (100 jul) was added to 2 
X 10^ cells and the mixture was incubated on ice for 10 minutes to free the 
cytoplasmic proteins. The mixture was then shaken vigorously by vortexing and 
centrifuged at 20,000 x g for 10 minutes at 4°C. The caspases-containing supernatants 
were collected for next two steps. 
ii) Protein Quantification 
Bradford protein assay was carried out to determine the protein concentrations of 
the cell lysates. Bovine serum albumin (BSA) standard solutions were prepared by 
diluting 2 mg/ml BSA stock solution with deionized water to 2, 4, 6, 8 and 10 |Lig/ml. 
Two microlitres protein samples were diluted with 798 |LI1 deionized water to give 800 
|al diluted samples. BSA standards or protein samples (800 |LI1) were mixed with 200 
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Bradford reagent (Bio-Rad Laboratories) thoroughly. The 1 ml mixtures were then 
incubated at room temperature for 3 minutes. The absorbance at 595 nm was 
measured using 200 |LI1 Bradford reagent in 800 |LI1 deionized water as the blank. A 
standard curve was constructed by the BioPhotometer (Eppendorf) and the protein 
concentrations of the cell lysates were determined. 
iii) Fluorometric Measurement of Caspase Activities 
Fluorescent signal-generating caspase substrates were used for the detection of 
caspase activities. The specificity of detection was ensured by comparing the caspase 
activities in the presence of specific caspase inhibitors in the jacaric acid treated cells. 
Fifty microlitres cell lysate (the volume was adjusted with cell lysis buffer) was 
mixed with an equal volume of 2X reaction buffer, with or without 1 |il caspase 
inhibitor (1 ^iM Ac-DEVD-CHO for caspase 3 inhibition, 1 jiiM Ac-IETD-CHO for 
caspase 8 inhibition and 1 |uM Ac-LEHD-CHO for caspase 9 inhibition) and the 
mixtures were incubated for 30 minutes at 37°C. All the samples were incubated with 
1 \x\ of the corresponding caspase-specific substrates (Ac-DEVD-AMC for caspase-3 
activity detection, Ac-IETD-AMC for caspase-8 and Ac-LEHD-AFC for caspase-9) 
for 1 hour at 37°C. The fluorescence intensity generated by the cleaved products was 
quantified by the Polarizon fluorescent plate reader (Tecan Group). The caspase 
activity was directly proportional to the product's fluorescent intensity. Standard 
curves of AMC and AFC had to be plotted by serial dilution of AMC or AFC solution 
with lysis buffer to 4 jaM, 2 juM, 1 |LIM, 0.5 |uM and 0.25 juM concentrations. The 
fluorescence intensity of the cleaved products can be quantified by reference to the 
standard curves of free fluorescence units. The caspase activity converted from the 
fluorescent unit (FU) was calculated as follows: 
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Caspase activity = FU / slope of standard curve 
2.2.10 Protein Expression Study 
There were 4 stages in the protein expression study: 
i) Treatment of Cells and Protein Extraction 
HL-60 cells (1 x 10^ cells/ml, total 20 ml) were treated with different 
concentrations of jacaric acid for different time periods at 37°C. The cells were 
washed once with PBS, 1 x 10^ cells were collected by centrifuging at 400 x g for 5 
minutes at 4°C. The cell pellet was resuspended in 50 |il lysis buffer and then shaken 
vigorously by vortexing. The cell lysates were chilled on ice for 30 minutes to free all 
proteins. Other components of cells were spun down at 20000 x g for 5 minutes at 4°C 
and the supernatants were then collected. 
For extracting phosphorylated proteins, a lysis buffer with unique ingredients 
was used. The same procedures were carried out as described before. Each treatment 
was duplicated so the results of phosphorylated proteins and total target proteins could 
be compared. 
The composition of the lysis buffer was modified for separately extracting 
cytosolic and mitochondrial proteins. Once the cells were harvested, 50 jil digitonin 
containing lysis buffer (first lysis buffer) was added to resuspend the cell pellet for 
collecting the cytosolic fraction. The mixture was vortexed for 30 seconds before 
centrifuging at 10000 x g for 1 minute at 4°C. After the supernatant was collected to a 
new Epperdorf tube, the cell pellet was resuspended in 50 \i\ second lysis buffer for 
mitochondrial fraction collection. The mixture was vortexed for exactly 30 seconds 
and followed by centrifuging at 10000 x g for 1 minute at 4°C. The second 
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supernatant was transferred to another Eppendorf tube. 
ii) Protein Quantification 
The Bradford protein assay was carried out to determine the protein 
concentrations of the cell lysates. BSA standard solutions at various concentrations (0, 
2, 4, 6, 8 and 10 |ig/ml) were prepared by diluting 2 mg/ml BSA stock solution with 
deionized water. Protein samples (2 jul) were diluted with 798 |ul deionized water to 
give 800 fil diluted samples. BSA standards or protein samples (800 jal) were mixed 
with 200 |Lil Bradford reagent (Bio-Rad Laboratories) thoroughly. The 1 ml mixtures 
were then incubated at room temperature for 3 minutes. The absorbance at 595 nm 
was measured using 200 fil Bradford reagent in 800 fil deionized water as the blank. A 
standard curve was constructed by the BioPhotometer (Eppendorf) and the protein 
concentrations of the cell lysates were determined. The protein concentration of the 
samples was adjusted to 1 jug/jil with lysis buffer. Twenty microlitres protein samples 
were subjected to SDS-PAGE. 
iii) Western Blotting Analysis 
To perform SDS-PAGE, a gel was set first. The gel consisted of two parts: the 
running gel that located at the lower region for separating proteins according to their 
molecular size; and the stacking gel that positioned at the upper region for sample 
loading and for the formation of highly concentrated protein bands. The percentage of 
acrylamide in the running gel was determined by the size of protein being studied. 
The larger the molecular weight of the proteins, the lower percentage of acrylamide 
was used. The composition of the chemicals for setting the running gels was 
summarized in Table 2.2. The protein sizes and their corresponding percentages of 
acrylamide used for separation were shown in Table 2.3. 
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Table 2.2 Composition of the SDS-Polyacrylamide Gel 
Stacking Running Gel (5 ml) 
Gel (3 ml) 
Gel percentage 5% 7.5% 10% 12% 15% 
Deionized Water 1.65 ml 2.4 ml 2 ml 1.65 ml 1.15ml 
Lower Buffer --- 1.25 ml 1.25 ml 1.25 ml 1.25 ml 
Upper Buffer 0.75 ml — — — … 
Acrylamide Stock 0.5 ml 1.25 ml 1.665 ml 2 ml 2.5 ml 
10% SDS 30^11 25 III 25 |il 25 i^l 25 i^l 
10% APS 40 |Lil 75 |Lil 75 III 75 jiil 75 i^l 
TEMED 3 III 2 III 2 2 |il 2 
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Table 2.3 Protein sizes and their corresponding 
percentages of acrylamide used for separation 
Protein Molecular Running Gel (% Acrylamide) 
Mass (kDa) 7.5% 10% 15% 
p-actin 42 v^  
Bad 23 v^  
Bak 30 “ 
Bid 22 V 
PARP 116/85 V 
Bcl-2 26 V 
BC1-XS/L 18 /30 V 
Fas 48 Z 
Fas L 40 v^  
ERK 44 V 
Phospho ERK 42 Z 
Cytc 15 v^  
L i 
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Twenty microlitres protein samples (20 fig) were mixed with 5 )il 4X protein 
loading buffer and boiled for 5 minutes. The boiled mixtures (25 jLil) and 8 jul 
Kaleidoscope prestained protein standards were loaded to different wells of the 
SDS-polyacrylamide gel. The gel was run under constant voltage of 100 volts for 
about 2 hours. 
The stacking gel was removed after electrophoresis and the protein containing 
running gel was immersed into deionized water for washing away any SDS remained 
that could hinder protein transfer. The washed gel was soaked in IX transfer buffer for 
3 minutes before protein transfer. Six pieces of 3 mm filter papers and one piece of 
PVDF membrane activated with 100% methanol were soaked in IX transfer buffer 
completely for 5 minutes. Three pieces of filter papers were taken out first and 
stacked on the clean surface of a semi-dry electroblotter (Bio-Rad Laboratories). The 
PVDF membrane was on the top of the papers. The running gel was carefully placed 
on the membrane for protein transfer and then covered by the last 3 pieces of wet 
filter papers. It was noted that all air bubbles were excluded by rolling a glass tube on 
the surface of wet filter papers and the surrounding buffer was dried before 
electroblotting. A voltage of 16 volts was applied for 30 minutes to force the proteins 
to transfer from the gel to the PVDF membrane. The protein attached membrane was 
washed with IX washing buffer for 10 minutes. The membrane was rotated with 5 ml 
5% milk blocking agent on an orbital shaker at room temperature for an hour to block 
non-specific sites for probing. Primary antibody for the target protein was added to 
the milk solution at a ratio of 1:1,000 and the solution was rotated for an extra 1 hour 
at room temperature. By washing the membrane with IX washing buffer for 5 
minutes for 3 times, the primary antibody was removed. The corresponding 
horseradish peroxidase-linked secondary antibody at a 1:1,000 dilution in washing 
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buffer was rotated with the membrane for an hour at room temperature. The 
membrane was then washed 3 times with IX washing buffer and taken for ECL 
detection. 
vi) ECL Detection 
Western blotting luminol reagent A and B were mixed and poured onto the 
PVDF membrane. After removing the excessive solution, the membrane was 
sandwiched in transparent plastic sheets and a X-ray film was placed above the 
membrane in a dark room. The film cassette was closed for different time periods for 
exposure, ranging from 15 seconds to 3 minutes. Specific protein bands were 
visualized on the film once the film was developed. The protein size was determined 
by comparing with the standards, in order to verify the identity of protein being 
detected. Band intensity was quantified by the ImageQuant software (Molecular 
Dynamics). The relative intensity of each protein band was compared with the control, 
after normalization with respect to the house-keeping protein, p-actin. 
2.2.11 Detection of Phosphorylation of JNK by FACE^^ JNK ELISA Kit 
There were 3 main stages in the detection of phosphorylated protein expression: 
i) Culturing, Fixing and Blocking of Cells 
A 96-well culture plate was treated with poly-L-lysine for 30 minutes at 37°C. 
The plate was washed twice for 5 minutes with PBS. One hundred microlitres HL-60 
cells (1 X 105 cells/ml) were seeded to the plate and treated with jacaric acid for 
various time periods. By replacing the growth medium with 100 |LI1 8% formaldehyde 
for 20 minutes, the cells were fixed. Formaldehyde solution was removed and the 
cells were washed 3 times with 200 |il washing buffer. Each washing step took 5 
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minutes with gentle shaking. The washing buffer was replaced by 100 jil quenching 
buffer and incubated with the samples for 20 minutes. The cells were washed twice 
with washing buffer in order to remove the quenching buffer. After removal of 
washing buffer, 100 |il antibody blocking buffer was added and incubated with the 
samples for 1 hour at room temperature. 
ii) Binding Primary and Secondary Antibodies 
The blocking buffer containing wells were washed twice with 200 jiil washing 
buffer. Depending on experimental design, some wells were incubated with diluted 
phosphor-JNK antibody, some with total-JNK antibody and some with secondary 
antibody alone (negative control). Diluted primary antibody (40 |il) was added to the 
cells after removal of washing buffer. Negative control was prepared by incubating 
the samples with 40 |LI1 antibody dilution buffer instead of primary antibody. A 10 cm 
X 18 cm parafilm was placed over the sample containing wells and the plate was 
covered with a lid to protect from evaporation. The plate was placed at 4°C overnight. 
The primary antibody was removed and the cells were washed 3 times for 5 minutes 
with washing buffer. The cells were then incubated with 100 jLil diluted secondary 
antibody for 1 hour at room temperature. During this incubation time, the developing 
solution was transferred into a secondary container and kept in dark at room 
temperature for a least an hour. 
iii) Colorimetric Reaction 
To remove the secondary antibody, the wells were washed three times with 
washing buffer and twice with PBS. Developing solution (100 |LI1) was added to each 
well when the PBS was discarded. The light protected samples were incubated for 2 
to 20 minutes at room temperature with constant monitoring for blue color 
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development. The reactions were stopped when the darkest-staining wells were turned 
to medium- or dark-blue. Stop solution (100 jiil) was added and the sample changed 
from blue to yellow for absorbance measurement. The reading was recorded within 5 
minutes at 450 nm with a reference wavelength of 655 nm. 
2.2.12 Detection of Phosphorylation of N F - K B by F A C E ^ ^ N F - K B p65 Profiler. 
The F A C E T M NF-KB ELISA kit was produced by the Active Motif company and 
based on the same experimental principles to detect different targets. The procedures 
of this kit were the same as the FACE™ JNK ELISA kit. The only difference was the 
provision of NF-KB primary antibodies and the corresponding secondary antibody. 
2.2.13 Statistical Analysis 
Each experiment was performed at least two to three times and the results of 
only one representative experiment were presented in the thesis. The data were 
expressed as arithmetic mean 土 standard error. Experimental data were processed 
using Microsoft Excel program. The Student's t-test was used for statistical analysis 
and calculated by SPSS 14.0 program (SPSS, Inc.). Normally, P-value (p) < 0.05 was 
regarded as statistically significant different. 
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3.1 Introduction 
Conjugated fatty acids (CFA) refer to the positional and geometrical isomers of 
polyunsaturated fatty acids with conjugated double bonds in the molecules. They have 
attracted considerable attention in recent years because of their potentially beneficial 
effects on human health (Nagao and Yanagita, 2005). Among the various CFA, 
conjugated linoleic acid (CLA) with two conjugated double bonds has been studied 
most intensively. Dietary CLA has been reported to reduce carcinogenesis, 
atherosclerosis and body fat (Badinga and Greene, 2006; Bhattacharya et al., 2006). 
Recently, similar effects are found in the conjugated trienoic acids (Nagao and 
Yanagita, 2005). Conjugated linolenic acid (CLN) is a group of naturally-occurring 
positional and geometrical conjugated trienoic isomers of the C-18 polyunsaturated 
fatty acid, linolenic acid (LN). Cis- and trans- isomeric combinations of CLN have 
been found in various seed oils. For example, punicic acid (9Z, HE, 13Z CLN) 
occurs naturally in pomegranate seed oil; «-eleostearic acid (9Z, HE, 13E CLN) in 
bitter gourd seed oil and tung seed oil; catalpic acid (9E, HE, 13Z CLN) in catalpa 
seed oil; a-calendic acid (8E, lOE, 12Z CLN) in pot marigold seed oil; and jacaric 
acid (8Z, lOE, 12Z CLN) in blue jacaranda (Takagi and Itabashi, 1981; Nagao and 
Yanagita, 2005; Narayan et al., 2006). Accumulating evidence has shown that CLN 
isomers exhibit anti-carcinogenic, hypolipidemic and anti-oxidative properties. 
However, their modulatory effects on myeloid cells remain poorly understood. 
As mentioned in Chapter 1, CLN isomers are potent suppressor on the growth of 
a wide range of human cancer cell lines in vitro, including hepatoma (HepG2), lung 
adenocarcinoma (A549), breast adenocarcinoma (MCF-7), stomach tubular 
adenocarcinoma (MKN-7) and colon carcinoma (HT-29, DLD-1 and Caco-2) 
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(Igarashi and Miyazawa, 2000; Yasui et al, 2006). Yet, there are very few in vivo 
studies for the anti-tumor effects of CLN isomers and these studies are primarily 
limited on their chemopreventive effects on colon carcinogenesis in rats (Kohno et al., 
2002; Kohno et al., 2004) and their direct suppressive effect on the growth of human 
colon cancer in nude mice (Tsuzuki et al., 2004). Until now, few data are available to 
show the anti-tumor effects of CLN isomers on leukemia cells, both in vitro and in 
vivo. 
In the present study, the anti-proliferative effect of four CLN isomers on the 
human promyelocytic leukemia cell line, HL-60, was compared. The isomers chosen 
for this study were a-eleostearic acid {cis-9, trans-11, trans-13 CLN isomer or 9Z, 
HE, 13E CLN), y^-eleostearic acid {trans-9, trans-11, trans-13 CLN isomer or 9E, 
HE, 13E CLN), y^-calendic acid (trans-�, trans AO, trans-\2 CLN isomer or 8E, lOE, 
12E CLN) and jacaric acid (c/5-8, trans-lQ, cis-\2 CLN isomer or 8Z, lOE, 12Z CLN). 
Different human leukemia and lymphoma cell lines, including the acute 
promyelocytic leukemia (NB-4, HL-60/MX2), eosinophilic leukemia (EoL-1), 
chronic myelogenous leukemia (K562), histiocytic lymphoma (U-937), were used to 
show that the growth inhibitory effect of CLN was not restricted to a single leukemia 
cell line. The kinetics and reversibility of CLN with respect to their anti-proliferative 
effect on HL-60 cells were also assessed. MTT assay, ^H-thymidine incorporation 
assay and trypan blue exclusion assay were used to evaluate the anti-proliferative and 
cytotoxic effects of CLN. The cell cycle kinetics of HL-60 cells after CLN treatment 
was detected by flow cytometry. Apart from the in vitro studies, the ability of CLN to 
suppress the in vivo tumorigenicity of HL-60 cells in xenogeneic inbred female 
BALB/c nude mice was also examined. 
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3.2 Results 
3.2.1 Anti-proliferative Activity of CLN Isomers on Various Myeloid Leukemia 
and Lymphoma Cell Lines In Vitro 
The anti-proliferative activity of four CLN isomers, a-eleostearic acid (9Z, HE, 
13E CLN), /?-eleostearic acid (9E, HE, 13E CLN), y^-calendic acid (8E, lOE, 12E 
CLN) and jacaric acid (8Z, lOE, 12Z CLN), on the human promyelocytic leukemia 
HL-60 cells was first evaluated by the standard colorimetric MTT assay. HL-60 cells 
(1 X 10^ cells/ml) were incubated with different concentrations of CLN isomers at 
37°C for 24, 48 and 72 hours. Thirty microlitres MTT (5 mg/ml) was then added to 
the drug-treated cells for 2 more hours. The mechanism behind this experiment is that 
the MTT salt is metabolized by the mitochondrial dehydrogenases of living cells and 
a deep color compound is produced. The amount of colored product reflects the viable 
cell number of HL-60 cells after different treatments. Apart from HL-60 cells, 
different human leukemia and lymphoma cell lines, including the acute promyelocytic 
leukemia (NB-4, HL-60/MX2), eosinophilic leukemia (EoL-1), chronic myelogenous 
leukemia (K562) and histiocytic lymphoma (U-937), were also studied. Moreover, the 
anti-proliferative effect of CLN was compared with the natural unconjugated isomers, 
alpha linolenic acid (ALA) and gamma linolenic acid (GLA). 
As shown in Fig. 3.1, the growth of HL-60 cells was inhibited dose-dependently 
by the CLN isomers to different extent, with >95% inhibition of cell proliferation at a 
concentration of 10 jiM for three CLN isomers. The growth inhibitory effect was not 
due to the solvent (ethanol), as the highest concentration (0.02% v/v) of ethanol used 
in the studies exhibited insignificant growth inhibitory effect on the HL-60 cells after 
48 hours of incubation (Fig. 3.1). It can be seen that the corresponding unconjugated 
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isomers, ALA and GLA, did not demonstrate any anti-proliferative activity up to a 
concentration of 40 \xM (Fig. 3.2). The estimated IC50 values of different isomers on 
the HL-60 cells were summarized in Table 3.1. Jacaric acid was found to have the 
most potent anti-proliferative effect. Other three CLN isomers were less potent, with 
2-4 fold higher IC50 values when compared with jacaric acid. Similar 
anti-proliferative effect was observed when various human cancer cell lines were 
cultured with jacaric acid (Fig. 3.3). Table 3.2 shows the IC50 values of jacaric acid on 
various leukemia and lymphoma cell lines. From this Table, the human promyelocytic 
leukemia HL-60 cells were found to be one of the most sensitive cell lines to the 
anti-proliferative activity of the CLN. Moreover, due to the relatively short doubling 
time and well-characterized features, the HL-60 cell line was chosen as the human 
leukemia cell model for further mechanistic studies. 
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Fig. 3.1: Growth-inhibitory effect of «-eleostearic acid (9Z, HE, 13E CLN) 
/?-eleostearic acid (9E, HE, 13E CLN), )9-calendic acid (8E, lOE, 12E CLN) and 
jacaric acid (8Z, lOE, 12Z CLN) on the human promyelocytic leukemia HL-60 
cells as determined by the MTT assay. HL-60 cells (1 x 10^ cells/ml) were 
incubated with different concentrations of the four CLN isomers ( 0 - 1 0 juM) or 
ethanol (0 - 0.02%) at 3 7 � C for 48 hours. The cells were then treated with 30 MTT 
solution for 2 hours. DMSO (50 |al) was added after removing the medium. Results 
were expressed as percentage of cells, using untreated cells as a control. Each point 
represents the mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.2: Effect of a-linolenic acid (9Z，12Z, 15Z LN) and ^linolenic acid (6Z，9Z， 
12Z LN) on the growth of human promyelocytic leukemia HL-60 cells as 
determined by the MTT assay. HL-60 cells (1 x 10^ cells/ml) were incubated with 
different concentrations (0 — 40 |iM) of a-linolenic acid or y-linolenic acid at 37°C for 
48 hours. The cells were treated with 30 |LI1 MTT solution for 2 hours. DMSO (50 |LI1) 
was added after removing the medium. Results were expressed as percentage of cells, 
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Table 3.1: The estimated IC50 values of different CLN isomers and their 
unconjugated isomers on the HL-60 cells at 48 hour incubation 
CLN or LN Isomer Estimated IC50 Value (^iM) 
cc-eleostearic acid (9Z, 11E, 13E CLN) 
y^-eleostearic acid (9E, 11E, 13E CLN) ^ 
/?-calendic acid (8E, lOE, 12E CLN) ^ 
Jacaric acid (8Z, lOE, 12Z CLN) ^ 
a-linolenic acid (9Z, 12Z, 15Z LN) ^ 
7-linolenic acid (6Z，9Z, 12Z LN) 
IC50 value is the estimated concentration of CLN or LN that causes 50% inhibition on 
the in vitro growth of HL-60 cells under the specified experimental conditions. 
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Fig. 3.3: Growth-inhibitory effect of jacaric acid (8Z, lOE, 12Z CLN) on the 
human eosinophilic leukemia EoL-1 cells, human histocytic lymphoma U-937 
cells, human chronic myelogenous leukemia K562 cells, mitoxantrone 
resistant-human acute promyelocytic leukemia HL-60/MX2 cells, human acute 
promyelocytic leukemia HL-60 and NB-4 cells as determined by the MTT assay. 
The tumor cells (1 x 10^ cells/ml) were incubated with different concentrations ( 0 - 1 0 
juM) of jacaric acid at 37°C for 48 hours. The cells were then treated with 30 MTT 
solution for 2 hours. DMSO (50 jiil) was added after removing the medium. Results 
were expressed as percentage of cells, using untreated cells as a control. Each point 
represents the mean 土 S.E. of quadruplicate cultures. 
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Table 3.2: The estimated IC50 values of jacaric acid (8Z, lOE, 12Z CLN) on 
various types of leukemia and lymphoma cell lines at 48 hour incubation 
Human Tumor Cell Line Estimated IC50 Value 
( _ ) 
Acute promyelocytic HL-60 � 2 
leukemia 
HL-60/MX2 � 4 
NB-4 � 2 . 5 
Eosinophilic leukemia EoL-1 � 2 . 5 
Chronic myelogenous K562 � 3 
leukemia 
Histiocytic monoblast-like U-937 � 2 
lymphoma 
IC50 value is the estimated concentration of jacaric acid which causes 50% inhibition 
on the in vitro growth of leukemia or lymphoma cells under the specified 
experimental conditions. 
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3.2.2 Direct Cytotoxic Effect of Jacaric Acid on HL-60 Cells In Vitro 
The direct cytotoxicity of jacaric acid on the human promyelocytic leukemia 
HL-60 cells was examined by the trypan blue exclusion assay. By incubating with 
jacaric acid for different time periods, it was found that jacaric acid exhibited 
negligible cytotoxic effect on the human promyelocytic leukemia HL-60 cells. Fig. 
3.4 shows that the percentage of viable cells remained high (>90%) after different 
treatment time while Fig. 3.5 shows that the actual numbers of viable HL-60 cells 
decreased in a dose- and time-dependent manner. The findings indicate that the 
anti-proliferative effect was unlikely to be attributable to the direct cytotoxic effect of 
jacaric acid, but other mechanism(s), such as cell cycle arrest and/or induction of 
apoptosis might be involved. 
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Fig. 3.4; Effect of jacaric acid (8Z, lOE, 12Z CLN) on the viability of human 
promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^  cells/ml) were incubated 
with different concentrations of jacaric acid ( 0 - 5 |iM) at 37°C for 1, 2 and 3 days. 
The numbers of viable and non-viable cells were counted by trypan blue exclusion 
test using a hemocytometer. Results were expressed as mean percentage of viable 
cells 土 S.E. of triplicate cultures. 
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Fig. 3.5: Effect of jacaric acid (8Z，lOE, 12Z CLN) on the in vitro growth of 
human promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^ cells/ml) were 
incubated with different concentrations of jacaric acid ( 0 - 5 juM) at 37°C for 1, 2, 3 
and 4 days. The number of viable cells was counted by trypan blue exclusion test 
using a hemocytometer. Results were expressed as mean percentage of viable cells 土 
S.E. of triplicate cultures. 
- 97 -
Chapter 3 A nti-proli ferative Effects 
3.2.3 Cytotoxic Effect of Jacaric Acid on Primary Murine Cells and Human 
Normal Cell Lines In Vitro 
To ensure the safety of a novel medication for clinical trials, the cytotoxicity of 
the drug on normal cells must be checked. The thioglycollate-elicited murine 
peritoneal macrophages and murine bone marrow cells were cultured with various 
concentrations of jacaric acid at 37°C for 24 hours. The viability of the cells was 
measured by the MTT assay. As shown in Fig. 3.6, jacaric acid exhibited only a slight 
cytotoxic effect (<25% cytotoxicity) on the cells over a wide range of concentrations, 
up to a relatively high concentration of 40 jiM. Other CLN isomers also demonstrated 
similar results (data not shown). Two normal human cell lines, the hepatocyte-like 
WRL 68 cells and foreskin fibroblast Hs68 cells, were also tested. Similar to the 
results of normal murine cells, jacaric acid exhibited little, if any, cytotoxic effect on 
the two normal human cell lines up to a concentration of 40 jiiM (Fig. 3.7). The 
percentage of viable cells after jacaric acid treatment was maintained at about 80%. 
Collectively, our results suggest that CLN isomers are relatively non-toxic to normal 
cells. 
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Fig. 3.6: Effect of jacaric acid (8Z，lOE，12Z CLN) on the growth of murine 
peritoneal macrophages and bone marrow cells as determined by the MTT assay. 
The murine normal cells (1 x 10^ cells/ml) were incubated with different 
concentrations (0 — 40 liM) of jacaric acid at 37°C for 24 hours. The cells were then 
treated with 30 jil MTT solution for 2 hours. DMSO (50 jil) was added after removing 
the medium. Results were expressed as percentage of cells, using untreated cells as a 
control. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.7: Effect of jacaric acid (8Z, lOE, 12Z CLN) on the growth of human 
hepatocyte-like WRL 68 cells and foreskin fibroblast Hs68 cells as determined by 
the MTT assay. WRL 68 cells and Hs68 cells (1 x 10^ cells/ml) were incubated with 
different concentrations (0 一 40 |LIM) of jacaric acid at 37°C for 24 hours. The cells 
were then treated with 30 |LI1 MTT solution for 2 hours. DMSO (50 jil) was added after 
removing the medium. Results were expressed as percentage of cells, using untreated 
cells as a control. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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3.2.4 Kinetics and Reversibility Studies of the Anti-proliferative Effect of Four 
CLN Isomers on the Human Promyelocytic Leukemia HL-60 Cells 
The MTT assay was used for studying the kinetics of anti-proliferative effect of 
a-eleostearic acid, y^-eleostearic acid, /?-calendic acid and jacaric acid on the human 
promyelocytic leukemia HL-60 and NB-4 cells. The leukemia cells (HL-60 cells or 
NB-4 cells) were cultured with various concentrations of CLN isomers at 37°C for 24, 
48 and 72 hours. Fig. 3.8A, 3.8B, 3.8C and 3.8D show the kinetic studies of the 
anti-proliferative effect of CLN isomers on the human promyelocytic leukemia HL-60 
cells. Similarly, the kinetic studies of the anti-proliferative effect of CLN isomers on 
the human promyelocytic leukemia NB-4 cells were shown in Fig. 3.9A, 3.9B, 3.9C 
and 3.9D. The results indicate that all CLN isomers inhibited the in vitro growth of 
HL-60 and NB-4 cells in a dose- and time-dependent manner. In line with our 
previous results shown in Section 3.2.1, jacaric acid was found to display the most 
potent anti-proliferative activity among the four CLN isomers tested. 
The tritiated thymidine (^H-TdR) incorporation assay is another sensitive in vitro 
method to study the anti-proliferative effect of a test compound. As the amount of 
radioactive labeled DNA precursor, ^H-TdR, incorporated into the DNA of the cells is 
directly proportional to the extent of cell proliferation, the growth-inhibitory effect of 
a test compound can be quantified by measuring the incorporated radioactivity of the 
cells. Only jacaric acid was chosen for this test because of the relatively high potency 
of this compound. Both the HL-60 and NB-4 cells were cultured with various 
concentrations of jacaric acid at 37°C for 24, 48 and 72 hours, and all proliferation 
was measured by the ^H-TdR incorporation assay. As shown in Fig. 3.1 OA and 3.1 OB, 
jacaric acid significantly inhibited the in vitro proliferation of the HL-60 and NB-4 
cells in a dose- and time-dependent manner. The IC50 values at 48 hours of incubation 
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for the HL-60 and NB-4 cells were 3.5 [iM and 3 |LIM respectively, which were very 
similar to the results obtained in the MTT assay (Table 3.2). 
To test the reversibility of the anti-proliferative effect of jacaric acid on the 
HL-60 cells, the leukemia cells were treated with jacaric acid at 2 )LIM, 3 |LIM, 5 |LIM 
and 10 JIM for 16, 24 and 48 hours, then the CLN isomer was washed away by 
removing the medium. Drug-free fresh complete medium was then added to the cells 
and the mixture was further incubated up to a total of 48 hours. Fig.3.11 shows that 
the growth-inhibitory effect of jacaric acid was less than 20% after 16 hours of 
incubation at all the concentrations tested. The percentage of inhibition was increased 
after 24 hours of treatment and at higher concentrations of jacaric acid. The 
percentage of inhibition reached up to 65% and 75% after 48 hours of treatment with 
5 jiM and 10 \xM of jacaric acid respectively. The results indicate that the 
growth-inhibitory effect of jacaric acid was partially reversible at 16 hours of 
incubation. However, the reversibility of jacaric acid on the growth inhibition of 
HL-60 cells was time-dependent. The longer the exposure time to jacaric acid, the less 
reversibility the anti-proliferative effect was. 
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Fig. 3.8A: Kinetic study on the growth-inhibitory effect of «-eIeostearic acid (9Z, 
HE, 13E CLN) on the human promyelocytic leukemia HL-60 cells as determined 
by the MTT assay. HL-60 cells (1 x 10^ cells/ml) were incubated with different 
concentrations ( 0 - 1 0 juM) of a-eleostearic acid at 37°C for 24, 48 and 72 hours. The 
cells were then treated with 30 \i\ MTT solution for 2 hours. DMSO (50 was added 
after removing the medium. Results were expressed as percentage of cells, using 
untreated cells as a control. Each point represents the mean 土 S.E. of quadruplicate 
cultures. 
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Fig. 3.8B: Kinetic study on the growth-inhibitory effect of y^-eleostearic acid (9E, 
HE, 13E CLN) on the human promyelocytic leukemia HL-60 cells as determined 
by the MTT assay. HL-60 cells (1 x 10^  cells/ml) were incubated with different 
concentrations (0—10 |LIM) of Y^-eleostearic acid at 37°C for 24, 48 and 72 hours. The 
cells were then treated with 30 |li1 MTT solution for 2 hours. DMSO (50 jil) was added 
after removing the medium. Results were expressed as percentage of cells, using 
untreated cells as a control. Each point represents the mean 士 S.E. of quadruplicate 
cultures. 
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Fig. 3.8C: Kinetic study on the growth-inhibitory effect of y^-calendic acid (8E, 
lOE, 12E CLN) on the human promyelocytic leukemia HL-60 cells as determined 
by the MTT assay. HL-60 cells (1 x 10^  cells/ml) were incubated with different 
concentrations ( 0 - 1 0 |LIM) of Y^-calendic acid at 37°C for 24, 48 and 72 hours. The 
cells were then treated with 30 |LI1 MTT solution for 2 hours. DMSO (50 |LI1) was added 
after removing the medium. Results were expressed as percentage of cells, using 
untreated cells as a control. Each point represents the mean 士 S.E. of quadruplicate 
cultures. 
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Fig. 3.8D: Kinetic study on the growth-inhibitory effect of jacaric acid (8Z, lOE， 
12Z CLN) on the human promyelocytic leukemia HL-60 cells as determined by 
the MTT assay. HL-60 cells (1 x 10^ cells/ml) were incubated with different 
concentrations ( 0 - 5 jiM) of jacaric acid at 37°C for 24, 48 and 72 hours. The cells 
were then treated with 30 jul MTT solution for 2 hours. DMSO (50 jLil) was added after 
removing the medium. Results were expressed as percentage of cells, using untreated 
cells as a control. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.9A: Kinetic study on the growth-inhibitory effect of «-eleostearic acid (9Z, 
HE, 13E CLN) on the human promyelocytic leukemia NB-4 cells as determined 
by the MTT assay. NB-4 cells (1 x 10^  cells/ml) were incubated with different 
concentrations (0—10 |iM) of a-eleostearic acid at 37°C for 24, 48 and 72 hours. The 
cells were then treated with 30 \il MTT solution for 2 hours. DMSO (50 |LI1) was added 
after removing the medium. Results were expressed as percentage of cells, using 
untreated cells as a control. Each point represents the mean 士 S.E. of quadruplicate 
cultures. 
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Fig. 3.9B: Kinetic study on the growth-inhibitory effect of y9-eleostearic acid (9E, 
HE, 13E CLN) on the human promyelocytic leukemia NB-4 cells as determined 
by the MTT assay. NB-4 cells (1 x 10^ cells/ml) were incubated with different 
concentrations (0—10 |LIM) of Y^-eleostearic acid at 37°C for 24, 48 and 72 hours. The 
cells were then treated with 30 |il MTT solution for 2 hours. DMSO (50 was added 
after removing the medium. Results were expressed as percentage of cells, using 
untreated cells as a control. Each point represents the mean 士 S.E. of quadruplicate 
cultures. 
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Fig. 3.9C: Kinetic study on the growth-inhibitory effect of y^-calendic acid (8E， 
lOE, 12E CLN) on the human promyelocytic leukemia NB-4 cells as determined 
by the MTT assay. NB-4 cells (1 x 10^  cells/ml) were incubated with different 
concentrations ( 0 - 1 0 |LIM) of Y^-calendic acid at 37°C for 24, 48 and 72 hours. The 
cells were then treated with 30 |LI1 MTT solution for 2 hours. DMSO (50 j^l) was added 
after removing the medium. Results were expressed as percentage of cells, using 
untreated cells as a control. Each point represents the mean 士 S.E. of quadruplicate 
cultures. 
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Fig. 3.9D: Kinetic study on the growth-inhibitory effect of jacaric acid (8Z, lOE, 
12Z CLN) on the human promyelocytic leukemia NB-4 cells as determined by 
the MTT assay. NB-4 cells (1 x 10^ cells/ml) were incubated with different 
concentrations ( 0 - 5 jiM) of jacaric acid at 37°C for 24, 48 and 72 hours. The cells 
were then treated with 30 fil MTT solution for 2 hours. DMSO (50 j^l) was added after 
removing the medium. Results were expressed as percentage of cells, using untreated 
cells as a control. Each point represents the mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.10A: Kinetic study on the growth-inhibitory effect of jacaric acid (8Z, lOE, 
12Z CLN) on the human promyelocytic leukemia HL-60 cells as determined by 
the tritiated thymidine incorporation assay. HL-60 cells (1 x 10^  cells/ml) were 
incubated with different concentrations (0 - 10 ^iM) of jacaric acid at 37°C for 24, 48 
and 72 hours. The cells were then pulsed with 0.5 iiiCi of ^H-TdR for 6 hours. 
Radioactivity expressed as counts per minutes (cpm) was measured using a Beckman 
liquid scintillation counter. Results were expressed as percentage inhibition of 
^H-TdR incorporation, using untreated cells as a control. Each point represents the 
mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.10B: Kinetic study on the growth-inhibitory effect of jacaric acid (8Z, lOE, 
12Z CLN) on the human promyelocytic leukemia NB-4 cells as determined by 
the tritiated thymidine incorporation assay. NB-4 ceJJs (1 x 10^ cells/ml) were 
incubated with different concentrations ( 0 - 1 0 juM) of jacaric acid at 37°C for 24, 48 
and 72 hours. The cells were then pulsed with 0.5 juCi of ^H-TdR for 6 hours. 
Radioactivity expressed as counts per minutes (cpm) was measured using a Beckman 
liquid scintillation counter. Results were expressed as percentage inhibition of 
^H-TdR incorporation, using untreated cells as a control. Each point represents the 
mean 士 S.E. of quadruplicate cultures. 
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Fig. 3.11: Reversibility study on the growth-inhibitory effect of jacaric acid (8Z， 
lOE, 12Z CLN) on the human promyelocytic leukemia HL-60 cells. HL-60 cells (1 
X 10^ cells/ml) were incubated with four different concentrations (2, 3, 5 and 10 |LIM) 
of jacaric acid at 37°C. Drugs were removed and replaced by fresh culture medium at 
different time periods (16 or 24 hours after drug addition) and all cultures were 
incubated up to 48 hours after initial drug addition. The cells were treated with 30 
MTT solution for 2 hours. DMSO (50 fil) was added after removing the medium. 
Percentage of inhibition = (OD540 of control - OD540 of test sample)/ OD540 of control 
X 100% 
Each bar represents the mean 士 S.E. of quadruplicate cultures. 
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3.2.5 Synergistic Anti-proliferative Effect of Jacaric Acid with Vitamin Djand All 
Trans-Retinoic Acid (ATRA) on the Human Promyelocytic Leukemia HL-60 
Cells In Vitro 
Tritiated thymidine incorporation assay was chosen for determining the 
synergistic anti-proliferative effect of jacaric acid with vitamin D3 and ATRA due to 
the high sensitivity of the assay. The IC25 values for vitamin D3 and ATRA on the 
human promyelocytic leukemia HL-60 cells at 48 hours of incubation were 
predetermined to be 0.4 |iM and 0.25 \iM respectively (data not shown). Once the IC25 
values were found, HL-60 cells (1 x 10^ cells/ml) were co-incubated with different 
concentrations of jacaric acid and vitamin D3 or ATRA at their IC25 concentrations. As 
shown in Fig. 3.12，a synergistic anti-proliferative effect was observed at lower jacaric 
acid concentrations (< 2 |iM of jacaric acid). Combination of higher concentrations of 
jacaric acid with vitamin D3 or ATRA did not produce any synergistic or additive 
anti-proliferative effect. Our findings suggest that jacaric acid might act 
synergistically with vitamin D3 and ATRA at lower concentrations to inhibit the 
growth of HL-60 cells. 
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Fig. 3.12: Synergistic anti-proliferative effect of jacaric acid (8Z, lOE, 12Z CLN) 
with either vitamin D3 or all trans-retinoic acid (ATRA) on the human 
promyelocytic leukemia HL-60 cells as determined by the tritiated thymidine 
incorporation assay. HL-60 cells (1 x 10^ cells/ml) were incubated with different 
concentrations ( 0 - 5 \iM) of jacaric acid and vitamin D3 (0.4 jiM) or ATRA (0.25 |iM) 
o 
at 37°C for 48 hours. The cells were then pulsed with 0.5 jiCi of H-TdR for 6 hours. 
Radioactivity expressed as counts per minutes (cpm) was measured using a Beckman 
liquid scintillation counter. Results were expressed as percentage inhibition of 
^H-TdR incorporation, using untreated cells as a control. Each point represents the 
mean 士 S.E. of quadruplicate cultures. 
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3.2.6 Effect of Jacaric Acid on the Cell Cycle Profile of the HL-60 Cells In Vitro 
In order to proliferate, a cell has to double its DNA content, undergoes nuclear 
division and separation of cytoplasm to form two daughter cells. The cell that keeps 
dividing repeatedly is said to be within the “cell cycle". In the eukaryotic system, the 
cell cycle is composed of four phases: Gi, S, G2 and M phases and each phase is 
highly regulated by checkpoints before entering to the next phase (Shackelford et al., 
1999). Gi, S and G2 phases are collectively known as interphase, during that the cell 
carries out normal metabolic functions. M phase is the phase when the cell undergoes 
nuclear division (mitosis) and cytoplasmic division (cytokinesis). When the cell has 
exited the cell cycle and temporarily entered the state of quiescence, the cell goes to 
Go phase. Many cancers result in the abnormal regulation of the cell cycle, so 
controlling the checkpoint proteins of the cell cycle provides a novel opportunity for 
cancer therapy (de Career et al., 2007). 
In the present study, jacaric acid was tested to see whether it could modulate the 
cell cycle progression of the HL-60 cells to achieve growth inhibition. Different 
concentrations (2, 4, 6 and 8 |uM) of jacaric acid were used in the experiment. Our 
results show that jacaric acid very slightly increased the percentage of cells in Gq/Gi 
phase dose-dependently when compared with the untreated cells (Fig. 3.13). 
Therefore, jacaric acid might inhibit HL-60 cell proliferation through triggering cell 
cycle arrest at the Gq/Gi phase. 
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Concentration of % of cells at* 
jacaric acid (juM) Gq/Gi phase S phase G2/M phase 
0 4 6 . 5 5 土 6 . 4 1 3 9 . 7 3 士 2 . 1 1 1 3 . 7 3 ± 8 . 5 3 
2 4 8 . 9 9 土 6 . 0 7 3 8 . 3 6 ± 0 . 0 3 1 2 . 6 6 ± 6 . 0 4 
4 51.97 土 2 . 8 1 38.38 士 0 . 5 3 9 . 6 7 ± 3 . 3 4 
6 5 4 . 2 3 ± 3 . 7 0 3 5 . 1 6 士 1 . 1 0 1 0 . 6 4 士 4 . 7 7 
8 5 6 . 0 4 士 2 . 9 1 3 3 . 3 1 士 0 . 4 0 1 0 . 2 6 士 3 . 8 7 
Fig. 3.13: Effect of jacaric acid on the cell cycle profile of human promyelocytic 
leukemia HL-60 cells. HL-60 cells (1 x 10^ cells/ml) were incubated with different 
concentrations ( 0 - 8 |LIM) of jacaric acid at 37°C for 30 hours. The jacaric 
acid-treated cells were fixed by ethanol and stained by PI staining solution. The PI 
stained cells were analyzed for fluorescence intensity using the FACS Canto flow 
cytometer. Cell cycle distribution was calculated by the MODFIT program. 
* Not significantly different from the control 
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3.2.7 Effect of Jacaric Acid on the In Vivo Tumorigenicity of the HL-60 Cells 
Since jacaric acid was found to inhibit the growth of the human promyelocytic 
leukemia HL-60 cells in vitro, therefore, it was interest to find out whether similar 
effect might be seen in vivo. HL-60 cells were incubated with different concentrations 
(5 and 10 |iM) of jacaric acid at 37°C for 16 hours. The cells were collected, washed 
and 3 X 10^ viable cells were injected subcutaneously into the back of each nude 
mouse in groups of five. The tumor size was continuously monitored at a 2 to 4 day 
interval up to one month. The width and length of the tumor were measured by a 
vernier caliper, in order to estimate the tumor size. As shown in Fig 3.14，the in vivo 
tumorigenicity of jacaric acid-pretreated HL-60 cells was significantly reduced in the 
nude mice at the first 3 weeks after tumor implantation. However, the effect could not 
be demonstrated when a lower concentration (5 |LIM) of jacaric acid was used after 3 
weeks of tumor implantation. 
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Fig. 3.14: Effect of in vitro pre-treatment of the human promyelocytic leukemia 
HL-60 cells with jacaric acid (8Z, lOE, 12Z CLN) on their tumorigenicity in nude 
mice. HL-60 cells (1 x 10^  cells/ml) which either pre-treated with solvent control or 
with two different concentrations of jacaric acid (8Z, lOE，12Z CLN) for 16 hours at 
37°C. The cells were washed once with RPMI medium. Viable HL-60 cells (3 x 10^ 
cells/ 150 jil) were injected subcutaneously on the back of each nude mouse in groups 
of five. The tumor size (the width and length of the tumor were measured to estimate 
the tumor size) were monitored at a 2 to 4 day interval up to one month. 
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3.3 Discussion 
In this chapter, the anti-proliferative effect of the four CLN isomers, 
a-eleostearic acid {cis-9, trans-11, trans-\3 CLN isomer), /^-eleostearic acid (Jrans-9, 
trans-11, trans-13 CLN isomer), y^-calendic acid {trans-^, trans-lO, trans-12 CLN 
isomer) and jacaric acid (cw-8, trans-10, cis-12 CLN isomer), on the human 
promyelocytic leukemia HL-60 cells was first evaluated. It was found that the growth 
of the HL-60 cells was suppressed dose-dependently by all the four CLN isomers. The 
estimated IC50 values of a-eleostearic acid, y5-eleostearic acid, y^-calendic acid and 
jacaric acid were 7.5 |LIM, 4 |LIM, 4 jiiM and 2 |LIM respectively at 48-hour incubation. 
Similar growth-inhibitory effects of the four CLN isomers were demonstrated in 
another human promyelocytic leukemia cell line NB-4. Among the four CLN isomers 
tested, jacaric acid showed the most potent anti-proliferative effect on these two cell 
lines, therefore, this CLN isomer was further examined for its anti-tumor effect on 
other human leukemia and lymphoma cell lines of different lineages and 
developmental stages, including the acute promyelocytic leukemia (HL-60/MX2), 
eosinophilic leukemia (EoL-1), chronic myelogenous leukemia (K562) and histiocytic 
lymphoma (U-937). Once again, jacaric acid showed similar anti-proliferative 
potency on different cell lines. Moreover, when compared to its parental fatty acids, 
alpha linolenic acid (ALA) and gamma linolenic acid (GLA), jacaric acid exhibited 
much more potent inhibitory effect on the proliferation of leukemia cells. At the IC50 
value of jacaric acid (2 j i iM), ALA and GLA showed less than 5% growth inhibition 
on the HL-60 cells. Even when the concentration of ALA and GLA was increased to 
40 |LIM, less than 20% inhibition of HL-60 cell proliferation was observed. Our results 
agree with the previous studies of other researchers. It has been reported CLN 
produced by alkali isomerization of linolenic acid showed potent anti-tumor effect on 
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a wide range of human cancer cells, including hepatoma (HepG2), lung 
adenocarcinoma (A549), breast adenocarcinoma (MCF-7), stomach tubular 
adenocarcinoma (MKN-7) and colon carcinoma (DLD-1) (Igarashi and Miyazawa, 
2000). Similarly, 9, 11, 13-octadecatrienoic acid isomers isolated from pomegranate, 
tung seed and catalpa oils were also found to be cytotoxic towards mouse tumor and 
human monocytic leukemia cells (Suzuki et al., 2001). For ALA and GLA, they are 
well-known cc>-3 and co-6 fatty acids that play many imperative roles in our bodies. 
However, they demonstrated insignificant, if any, anti-proliferative effect on the 
human myeloid leukemia HL-60 cells under similar experimental conditions of CLN. 
ALA lowers plasma triacylglycerol level in rats by suppressing the hepatic synthase 
(Kim, 2004). Some studies also suggest that ALA alone has beneficial 
electrophysiological and anti-arrhythmic effects, so it can protect against 
cardiovascular diseases and reduce coronary death (Landmark and Aim, 2006). GLA 
is a precursor of arachidonic acid, which in turn is a major precursor of several classes 
of signaling molecules in our bodies, including prostaglandins, prostacyclins, 
thromboxanes, and leukotrienes. In the present study, the observed differential 
anti-proliferative effect of the CLN isomers and their parental fatty acids (ALA and 
GLA) is possibly caused by the presence of the conjugated double bond system in the 
CLN isomers. This speculation is in line with some earlier investigations on the 
anti-proliferative effect of other conjugated fatty acids. Igarashi and Miyazawa (2000) 
had shown that conjugated EPA and conjugated DHA caused apoptosis in various 
cancer cell lines. Lui et al. (2005) also found that trans-XQ, cis-\2 CLA isomer but not 
linoleic acid demonstrated strong growth-inhibitory effect on a wide range of murine 
leukemia and lymphoma cells in vitro. 
Suzuki et al. (2001) had studied how the positions of the conjugated double 
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bonds of the CLN isomers might affect their cytotoxic effects on human monocytic 
leukemia cells. The cytotoxicity of three 9, 11, 13 CLN isomers, including 
a-eleostearic acid (9Z, HE, 13E CLN), punicic acid (9Z, HE, 13Z CLN), catalpic 
acid (9E, HE, 13E CLN) was compared with one 8，10, 12 CLN isomer, namely the 
a-calendic acid (8E, lOE, 12Z CLN). Their results suggest that the 9，11, 13 CLN 
isomers are generally more potent than the 8，10, 12 CLN isomer. On the contrary, our 
present results showed that the 8, 10, 12 CLN isomers generally had slightly stronger 
anti-proliferative effect than the 9, 11, 13 CLN isomers. We found that y^-calendic acid 
(8E, lOE, 12E CLN) and jacaric acid (8Z, lOE, 12Z CLN) had the estimated IC50 
values of 4 |iM and 2 |iM respectively at 48-hour incubation for the HL-60 cells while 
a-eleostearic acid (9Z, HE, 13E CLN) and y^-eleostearic acid (9E, HE, 13E CLN) 
had the estimated IC50 values of 7.5 |LIM and 4 piM respectively. The apparent 
discrepancy in our results with that of Suzuki et al. (2001) remains as yet unclear, 
perhaps it may be due to difference in the CLN isomers, leukemia cell lines and 
biological assay systems used in these two studies. Further experiments are needed to 
resolve this issue. Moreover, another factor that may influence the biological activity 
of conjugated fatty acids is the cis-/trans- configuration of their double bonds. Yasui 
et al. (2006) had checked the importance of cis-/trans- configuration by comparing 
a-eleostearic acid (9Z, HE, 13E CLN), y^-eleostearic acid (9E, HE, 13E CLN), 
a-calendic acid (8E, lOE, 12Z CLN) and y^-calendic acid (8E, lOE, 12E CLN) for 
their anti-tumor effects on the colorectal cancer. They concluded that the all-trans 
CLN isomers generally exert greater growth-inhibitory effect. On the other hand, 
Suzuki et al. (2001) showed that the cis/trans configuration of 9, 11, 13 CLN isomers 
had little effect on their cytotoxic activity. Our findings indicate that though jacaric 
acid (8Z, lOE, 12Z CLN) is not a all-trans CLN isomer, it showed the strongest 
anti-proliferative effect (with an estimated IC50 value of 2 |iM) on the HL-60 cells. 
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The estimated IC50 values of two all-trans CLN isomers, y^-eleostearic acid (9E, HE, 
13E CLN) and y^-calendic acid (8E, lOE, 12E CLN), were found to be 4 j^ iM, which 
are two fold higher than that of jacaric acid. Although the position of the conjugated 
double bonds and their cis-/trans- configuration seem to play certain roles in the 
biological activities of CLN isomers, more CLN isomers should be tested in various 
biological assay systems before definitive conclusions can be drawn. 
In order to determine whether the observed anti-proliferative activity of jacaric 
acid was due to its cytotoxic or cytostatic effect, the trypan blue exclusion assay was 
carried out to test for its direct cytotoxicity. Our results show that jacaric acid, up to 
the concentration of 5 exhibited no apparent cytotoxicity on the HL-60 cells 
following incubation for 24, 48 and 72 hours. In addition, it was demonstrated that the 
growth-inhibitory effect of jacaric acid was not due to the solvent effect, since the 
highest concentration of ethanol (0.02% v/v) used in our study exhibited insignificant, 
if any, growth-inhibitory effect on the HL-60 cells after 48-hour incubation. Moreover， 
to ensure the safety of a novel medication for clinical trials, the cytotoxicity of jacaric 
acid on normal cells was also checked. Our results indicate that jacaric acid exhibited 
minimal, if any, cytotoxic effect on normal cells, including the thioglycollate-elicited 
murine peritoneal macrophages, murine bone marrow cells, human hepatocyte-like 
WRL 68 cells and human foreskin fibroblast Hs68 cells. 
Kinetic study of the anti-proliferative effect of the four CLN isomers on the 
HL-60 cells showed that the conjugated trienoic fatty acids inhibited the cancer cell 
proliferation time- and dose-dependently. Another interesting result was that the 
anti-proliferative activity of the CLN isomer jacaric acid was partially reversible 
when the HL-60 cells were exposed to jacaric acid for short incubation periods (16 to 
- 1 2 4 -
Chapter 3 A nti-proli ferative Effects 
24 hours). These results suggest that jacaric acid might exert its growth-inhibitory 
effect on the HL-60 cells within the first 24 hours and longer incubation time would 
result in an irreversible inhibitory effect. 
In this study, attempts were made to study the combination effect of CLN with 
other physiological agents on the inhibition of leukemia cell proliferation. Our results 
showed that a synergistic anti-proliferative effect occurred at lower concentrations 
(1-3 j^M) of jacaric acid with vitamin D3 and all trarts-xQimoic acid (ATRA) on the 
HL-60 cells. The anti-proliferative effect was not enhanced at higher concentrations 
(4-5 jiM) of jacaric acid with vitamin D3 or ATRA. These findings suggest that jacaric 
acid might be used in conjunction with vitamin D3 and ATRA to enhance their 
therapeutic effect on the human myeloid leukemia cells. 
Many cancers result in the abnormal regulation of the cell cycle, so modulating 
the checkpoint proteins of the deregulated cell cycle provides a novel opportunity for 
the treatment of cancer (de Career et al., 2007). Cyclin-dependent kinases (cdks) are 
often upregulated in human cancers because of overexpression of their cyclin partners 
or inactivation of the cdk inhibitors. Some cdk inhibitors that possess high clinical 
values have already been studied in details, such as p i6 and p21, which coordinate 
both internal and external signals and affect proliferation of cancer cells at several key 
checkpoints (Johnson and Walker, 1999). Other serine-threonine protein kinases, for 
example the Aurora proteins (mostly Aurora A and B) and Polo-like kinases, are also 
potential candidates for regulating cell cycle (de Career et al., 2007). Other mitotic 
kinases, such as MPSl (monopolar spindle-1), BUB (budding uninhibited by benomyl) 
and NEK (NIMA-related kinases) proteins might also be new targets for cancer 
therapy due to their regulatory roles in mitotic progression and spindle checkpoints 
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(de Career et al., 2007). Some of the currently used chemotherapeutic agents also 
modulate cell cycle at different phases. DNA damaging agents like cisplatin, nitrogen 
mustard, cyclophosphamide and chlorambucil cause cell cycle arrest at both the Gi 
phase and the G2/M phase (Johnson and Walker, 1999). It has been reported that some, 
but not all, CLA isomers can trigger cell cycle arrest and trans-10, cis-\2 CLA isomer 
is more effective than cis-9, trans-\\ CLA isomer in the induction of G\ phase cell 
cycle arrest in the leukemia and breast cancer cells (Kemp et a/.,2003; Lui et al., 
2005). Until now, the ability of CLN isomers to induce cell cycle arrest has not yet 
been reported. In the present study, we found that 30-hour treatment of HL-60 cells 
with jacaric acid increased the percentage of the leukemia cells in Gq/Gi phase 
dose-dependently and this was accompanied by a decrease in the percentage of cells 
in S and G2/M phases, when compared to control. 
Since jacaric acid was found to exhibit potent anti-proliferative effect and 
triggered Gq/Gi phase cell cycle arrest in the HL-60 cells, it was interest to investigate 
the tumor suppressive effect of jacaric acid on the HL-60 cells in xenogeneic BALB/c 
nude mice. Our results show that pre-treatment of HL-60 cells in vitro with jacaric 
acid could reduce the in vivo proliferation of the leukemia cells dose-dependently in 
the nude mice. The results are in line with the effect of CLA isomers. Lui et al (2005) 
had reported that CLA-pretreated murine myeloid leukemia WEHI-3B JCS cells had 
lower in vivo proliferative rate than that of the control in syngeneic BALB/c mice. 
However, more studies should be carried out to show the mechanisms by which CLN 
can exert its anti-tumor activity in vivo, which is essential before CLN isomers can be 
used for the clinical trials in cancer therapy. 
In conclusion, this Chapter demonstrated that jacaric acid and other CLN isomers 
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possess strong anti-proliferative effect on the human myeloid leukemia HL-60 cells. 
Induction of Gq/Gi cell cycle arrest is one of the possible mechanisms that may 
contribute to their growth-inhibitory activity. Other possible mechanisms, such as 
induction of apoptosis and differentiation of the leukemia cells, and involvement of 
different signaling pathways would be addressed in Chapter 4 and 5 respectively. 
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Chapter 4 Apoptosis- and Differentiation-inducing Effects 
4.1 Introduction 
Cell death is a vital cellular process which is essential for regulating cell survival and 
controlling multicellular development. There are two well-known forms of cell death and they 
are apoptosis and necrosis. Apoptosis, an active and highly regulated form of cell death, plays 
a central role to enable individual cells to commit suicide via a series of well-defined 
morphological changes (Kerr et al., 1972; Wyllie, 1980). Changes include cytoplasmic 
shrinkage, plasma membrane blebbing and nuclear membrane breakdown, chromatin 
condensation, DNA fragmentation and release of small membrane-bound apoptotic bodies 
(Hail et al.’ 2006). The apoptotic bodies are phagocytosed by macrophages and neutrophils 
after apoptosis. Thus, the intracellular components will not be released into the extracellular 
environments where they may cause deleterious effects to the neighboring cells. In contrast, 
necrosis is a form of passive cell death triggered by diverse stimuli such as extreme 
temperatures, infections, toxins and hypotonic conditions (Majno and Joris, 1995). Cells that 
undergo necrosis swell, burst and release their intracellular contents, which frequently cause 
inflammation. 
Yet, the above oversimplified classification does not satisfy for all cases and some 
scientists proposed other types of cell death. For example, the "apoptosis-like PCD" is 
characterized by less compact chromatin condensation and phosphatidylserine exposure, but 
without caspase activation. On the other hand, "necrosis-like PCD" is characterized by the 
absence of both chromatin condensation and caspase activation (Leist and Jaattela, 2001; 
Kroemer and Martin, 2005). Autophagy is characterized by cytoplasmic vacuolization and 
degradation of cellular components via the lysosomal pathway (Lee et al.’ 2001; Kondo and 
Kondo, 2006). Some cell death pathways are believed to be restricted to certain cell types, 
like ‘‘paratosis,，and ‘‘dark cell death" (Sperandio et al., 2000; Turmaine et cd., 2000). 
As mentioned previously, apoptosis is essential for the development of organisms. For 
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example, it contributes to the deletion of the tail in developing human embryos, it regulates 
the number of neurons in human nervous system and controls the size of different body parts 
during development (Conlon et al., 1999). It has been demonstrated that the abnormal human 
embryos in pre-implantation stage are eliminated via apoptosis (Hardy, 1999). Loss of 
apoptosis brings some disastrous results to organisms, including cancer. Therefore, 
reactivation of apoptosis in tumor cells is an excellent way to treat cancer (Reed et al., 2005). 
Apoptosis can be divided into two central pathways, namely the intrinsic pathway and 
the extrinsic pathway (Chowdhury et al., 2006). The intrinsic apoptotic pathway begins when 
an injury occurs within a cell, like a cell in response to oxidative stress, ionizing radiation and 
DNA-damaging agents. The damaged mitochondria lose the mitochondrial membrane 
potential (Avj;m) and release Cytochrome c (Cyt c) to cytosol to activate caspase-9 and 
ultimately caspase-3 (Reed, 1997; Green and Reed, 1998). Second mitochondria-derived 
activator of caspases/direct inhibitors of apoptosis protein binding protein with low pi 
(Smac/DIABLO) and high-temperature requirement protein A2 (HtrA2/0mi) are also some 
proteins that leaked from the mitochondria. They promote the intrinsic pathway by 
counteracting the effect of inhibitor of apoptosis proteins (lAPs) (Mishra and Kumar, 2005). 
Activated caspase-3 cleaves specific substrates, including poly (ADP-ribose) polymerase 
(PARP), resulting in morphological and biochemical changes of apoptosis. 
The extrinsic pathway of apoptosis is usually initiated by the unfavorable extracellular 
environments, yet it also eliminates the unwanted cells during development, educates the 
immune system and triggers the immune-system-mediated tumor removal (Boatright et al., 
2003). Activation of the extrinsic pathway requires the ligation of the death receptor Fas in the 
plasma membrane. Fas is a member of the so-called "death receptor" family, which includes 
the TNF receptor (Locksley et al., 2001). Binding of Fas ligand (FasL/CD95L) to the 
Fas/CD95 activates the clustering of receptors and initiates the pathway (Yuan, 1997; Wallach 
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et al., 1999). The clustering recruits an adaptor molecule called Fas-associated protein with 
death domain (FADD) and procaspase-8 to the complex, which in turn activates caspase-8, 
and ultimately activates caspase-3. 
Reactive oxygen species (ROS) trigger both the intrinsic and extrinsic apoptotic 
pathways. ROS are well recognized for playing a deleterious role, which induce apoptosis by 
building up the oxidative stress within cells (Valko et al., 2007). Mitochondrion is a major 
source of ROS, so the organelle becomes the target site for triggering apoptosis when the 
‘‘redox homeostasis" in mitochondrion is disrupted by the overproduction of ROS (Droge, 
2002). Cyt c is released from the damaged mitochondria and apoptosis is resulted. Moreover, 
some studies have shown that ROS may induce the overexpression of Fas and FasL in certain 
cell types (Alcouffe et al., 2004; Huang et al., 2003). 
Previous work had shown that conjugated linolenic acid (CLN) exhibited potent 
cytotoxic effect on various cultured human tumor cells in vitro (Igarashi and Miyazama, 
2000). Mechanistic studies indicated that a-eleostearic acid (9Z, HE, 13E CLN), which can 
be isolated and purified from bitter gourd seed oil and tung seed oil, displayed a stronger 
anti-tumor effect than CLA in cultured cell lines, as it induced DNA fragmentation, increased 
caspase activity and increased expression of caspase mRNA in the human colon cancer 
DLD-1 cells (Tsuzuki et al., 2004). Moreover, free fatty acid prepared from bitter gourd seed 
oil and rich in a-eleostearic acid may induce apoptosis in the human colon cancer Caco-2 
cells through up-regulation of GADD45 mRNA, p53 mRNA and PARP mRNA and protein 
expression (Yasui et al., 2005). These earlier results suggest that a-eleostearic acid is a CLN 
isomer that may have potential as a natural product in the chemotherapy and chemoprevention 
of colon cancer. In Chapter 3, jacaric acid (8Z, lOE, 12Z CLN) was found to possess the 
strongest anti-proliferative effect on the human myeloid leukemia HL-60 cells. However, its 
anti-leukemic mechanisms have not been elucidated. In the first part of this Chapter, the 
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apoptosis-inducing ability of the CLN isomer, jacaric acid (8Z, lOE, 12Z CLN), on the human 
promyelocytic leukemia HL-60 cells was investigated by detecting DNA fragmentation using 
gel electrophoresis and quantified by the cell death ELISA kit. To reveal the mechanism of 
apoptosis, several experiments were carried out to detect the molecular changes in different 
parts of the cell, including the localization of phospholipids in cell membrane, mitochondrial 
membrane potential change and the release of cytoplasmic proteins in the jacaric acid-treated 
cells. The cell membrane integrity and its phospholipid orientation were detected by the 
annexin V-GFP-PI double staining method. The change of mitochondrial membrane potential 
was detected by the JC-1 dye staining method. Detection of caspases-3, -8 and -9 activities 
was achieved by using specific fluorometric substrates and their corresponding inhibitors. 
Moreover, the production of ROS may be associated with CLN-induced apoptosis. ROS 
production was detected by the flow cytometry and the free radical scavengers 
N-acetylcysteine (NAC) and superoxide dismutase (SOD) were used to counteract the effect 
of ROS. This helps to confirm the apoptosis-inducing effect of ROS in the jacaric 
acid-induced apoptosis. 
On the other hand, differentiation therapy is another novel approach to treat cancers. One 
of the most well-known cases is the treatment of human acute promyelocytic leukemia (APL) 
by the all-rra/7^-retinoic acid (ATRA) (Fenaux et al., 2001; Tallman et al., 2002; Fenaux et al., 
2007). The ATRA treatment reduces the co-repression activity and allows transcription of 
genes for differentiation to take place (de The et al., 1991; Grignani et al., 1998; He et al., 
1998; Melnick and Licht, 1999;). Nowadays, ATRA therapy is further combined with other 
commonly used chemotherapeutic drugs, like daunorubicin and anthracycline, for the 
treatment of APL as it is uniquely sensitive to the combination of differentiation and cytotoxic 
therapy. The therapy significantly reduces recurrence of malignancies and rarely shows initial 
drug resistance (Lo et al., 2002; Zelent et al., 2005). 
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Myeloid leukemia is the neoplastic proliferation of the myeloid progenitor cells that have 
lost the ability to undergo differentiation. Differentiation therapy can trigger the immature 
myeloid leukemia cells to become more mature using a wide range of differentiation-inducing 
agents. Terminal differentiation of the cancer cells is usually accompanied by the cessation of 
cancer cell proliferation (Leszczyniecka et al, 2001; Leung et al., 2005). Table 4.1 lists some 
common differentiation inducers used in clinical trials for hematologic malignancies (Miller 
and Waxman, 2002). 
It had been reported that some CLA isomers induced the monocytic differentiation in 
murine myeloid leukemia cells (Lui et al., 2005). Thus it is possible that CLN can also induce 
leukemic cell differentiation because they also have conjugated double bonds. In this study, 
the differentiation-inducing ability of jacaric acid on the acute promyelocytic leukemia HL-60 
cells was investigated by several assay systems, which measured the morphological, 
phenotypic and functional changes of the jacaric acid-treated HL-60 cells. The leukemia cells 
were stained after cytocentrifugation as described in Chapter 2 for the morphological studies. 
Quantitative analysis of the cell size and granularity was carried out by flow cytometry. 
Phenotypic changes of jacaric acid-treated HL-60 cells were evaluated by detecting the 
expression of cell surface markers of monocytic differentiation. 
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Table 4.1; Common differentiation inducers used in clinical trials for hematologic 
malignancies. 
Differentiation Inducers Examples 




Cyclic AMP analogs 8-Chloro-cyclic adenosine 3，,5 ’ monophosphate 
(8-Cl-cAMP) 
Demethylating agents Aza-cytidine 
Histone deacetylase Depsipeptide 
inhibitors Sodium phenylbutyrate (NaPB) 
(HDACi) Suberoylanilide hydroxamic acid (SAHA) 
Hematopoietic cytokines Erythropoietin (EPO) 
Granulocyte-colony stimulating factor (G-CSF) 






Short-chain fatty acids 
Sodium butyrate 
PKC agonists and Bryostatin 
antagonists Tetradecanoylphorbol acetate (TPA) 
Polar-planar compounds Hexamethylene bisacetamide (HMBA) 
Vitamin analogs Retinoids 
Vitamin D derivatives 
(Modified from Miller and Waxman, 2002) 
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4.2 Results 
4.2.1 Induction of Apoptosis in the Human Promyelocytic Leukemia HL-60 Cells by 
Jacaric Acid 
One of the most distinguishable changes that occurs during apoptosis is DNA 
fragmentation (Gerschenson and Ratello, 1992). In this study, DNA fragmentation in the 
jacaric acid-treated human promyelocytic leukemia HL-60 cells was detected by agarose gel 
electrophoresis. Fig. 4.1 and 4.2 show that jacaric acid induced DNA fragmentation in HL-60 
cells dose- and time-dependently. At the IC50 value (2 juM) of jacaric acid at 48-hour 
incubation, this CLN isomer triggered DNA fragmentation after 48 hours of incubation in a 
dose-dependent response manner (Fig. 4.1). At the IC75 value (3 jiM) of jacaric acid at 
48-hour incubation, jacaric acid triggered DNA fragmentation within 24 hours and a 
time-dependent response was detected (Fig. 4.2). To measure the jacaric acid-induced 
apoptosis in a more quantitative way, the cell death ELISA kit was used. Moreover, 
co-treatment of HL-60 cells with a pan-caspase inhibitor and jacaric acid counteracted the 
initiation of apoptosis (Fig. 4.3). The results suggest that jacaric acid-induced apoptosis is 
largely based on the caspases-associated pathways. 
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Fig. 4.1: Dose response study of DNA fragmentation induction in the human 
promyelocytic leukemia HL-60 cells treated with jacaric acid (8Z, lOE, 12Z CLN). 
HL-60 cells (1 x 10^  cells/ml) were cultured with different concentrations ( 0 - 5 |LIM) of 
jacaric acid (8Z, lOE, 12Z CLN) (Lane 2 to Lane 5) for 48 hours at 37�C. Apoptotic DNA 
fragments were extracted by mild detergent IGEPAL CA-630 lysis buffer, and analyzed by 
electrophoresis on 2% agarose gel stained with ethidium bromide. 
Lane 1: 100 bp DNA markers 
Lane 2: Untreated HL-60 cells 
Lane 3: HL-60 cells treated with 2 |aM jacaric acid 
Lane 4: HL-60 cells treated with 3 jacaric acid 
Lane 5: HL-60 cells treated with 5 i^M jacaric acid 
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Fig. 4.2: Kinetic study of DNA fragmentation induction in the human promyelocytic 
leukemia HL-60 cells treated with jacaric acid (8Z, lOE, 12Z CLN). HL-60 cells (1 x 
105 cells/ml) were cultured with 3 |iM jacaric acid (8Z, lOE, 12Z CLN) (Lane 2 to Lane 4) for 
different time periods (12, 24 and 48 hours) at 37°C. Apoptotic DNA fragments were 
extracted by mild detergent IGEPAL CA-630 lysis buffer, and analyzed by electrophoresis on 
2% agarose gel stained with ethidium bromide. 
Lane 1: 100 bp DNA markers 
Lane 2: HL-60 cells treated with 3 jacaric acid treated for 12 hours 
Lane 3: HL-60 cells treated with 3 i^ M jacaric acid treated for 24 hours 
Lane 4: HL-60 cells treated with 3 )AM jacaric acid treated for 48 hours 
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Fig. 4.3: Dose response study of apoptosis induction in the human promyelocytic 
leukemia HL-60 cells treated with jacaric acid (8Z, lOE, 12Z CLN) as determined by the 
cell death ELISA kit. HL-60 cells (1 x 10^  cells/ml) were cultured with different 
concentrations ( 0 - 5 jiM) of jacaric acid (8Z, lOE, 12Z CLN) with or without the 
pan-caspase inhibitor III for 4 hours at 37°C. Cytoplasmic histone-associated-DNA-fragments 
were extracted by the lysis buffer, and detected by adding anti-DNA-POD and ABTS 
substrate solution for colour development in dark. By measuring at 405 nm against ABTS 
solution as a blank (with reference wavelength of 490 nm) using a microplate reader, the 
colour change was analyzed. The degree of apoptosis expressed as enrichment factor was 
described in detail in Chapter 2. 
* Significantly different from the solvent control, p < 0.05 
** Significantly different from the solvent control, p < 0.005 
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4.2.2 Apoptosis-inducing Effect of Jacaric Acid on the Human Promyelocytic Leukemia 
HL-60 Cells as Detected by the Annexin V-GFP PI Double Staining Method 
In the early stages of apoptosis, one of the morphological features is the loss of 
membrane asymmetry. Phosphatidylserine (PS) translocates from the inner side of the cell 
surface membrane to the outer layer. Annexin V can be used as a sensitive probe for detecting 
early apoptosis. It is a 35 kDa, Ca^^-dependent phospholipid-binding protein that has high 
affinity for the PS that is exposed at the external surface of the cell (Vermes et al., 1995; 
Zhang et al., 1997). Annexin V can be conjugated to biotin or to a fluorochrome such as 
fluorescein isothiocyanate (FITC) and green fluorescent protein (GFP). Identification of cells 
can be done by flow cytometry. Annexin V conjugated with GFP was used in this study. A dye 
such as 7-amino-actinomycin D (7-AAD) or propidium iodide (PI) is commonly used with 
Annexin V, which binds to nucleic acids when it penetrates to the breached plasma membrane. 
It is because cells will lose their membrane integrity in the later stages of apoptosis or in 
necrosis. In the present study, PI was used in conjunction with Annexin V-GFP. 
HL-60 cells were cultured with jacaric acid (1 and 3 )iM) for 8 and 24 hours. The jacaric 
acid-treated cells were stained by Annexin V-GFP and PI in dark. The stained cells were 
analyzed by the FACSCanto flow cytometer. The percentage of cells at the lower right 
quadrant, which indicated early apoptosis, was increased dose- and time-dependently (Fig. 
4.4). Apoptosis was observed as early as 8 hours after incubation with 3 juM jacaric acid, and 
17% early apoptotic HL-60 cells were detected at the lower right quadrant after the treatment 
(Fig. 4.4A). On the other hand,�20o/o early apoptotic cells were observed at 24 hours after 
treatment with 3 |iM jacaric acid (Fig. 4.4B). 
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Fig 4.4: Induction of early apoptosis in the human promyelocytic leukemia HL-60 cells 
treated with jacaric acid (8Z, lOE，12Z CLN) as determined by the annexin V-GFP-PI 
doubling staining method. HL-60 cells (1 x 10^ cells/ml) were treated with two different 
concentrations (1 |uM and 3 |iM) of jacaric acid (8Z, lOE, 12Z CLN) for (A) 8 and (B) 24 
hours at 37°C. The cells were washed once with PBS. HL-60 cells were resuspended by the 
reaction buffer containing Annexin V-GFP and PI and incubated for 15 minutes at 4°C in dark. 
The stained cells were subjected to flow cytometric analysis using BD FACSCanto flow 
cytometer. FL-1 and FL-2 were measured simultaneously. 
* Significantly different from the solvent control, p < 0.05 
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4.2.3 Effect of Jacaric Acid on the Mitochondrial Membrane Potential in the Human 
Promyelocytic Leukemia HL-60 Cells 
Mitochondrial damage initiates the intrinsic pathway. Cyt c released from damaged 
mitochondria activates various cytoplasmic proteins to cause apoptosis and overcomes the 
effect of anti-apoptotic proteins (Reed, 1997; Green and Reed, 1998). Mitochondrial 
membrane depolarization of the damaged mitochondria is a hallmark of the intrinsic apoptosis 
pathway and the phenomenon can be measured by the 5,5',6,6'-tetrachloro-1,1 ',3,3'-
tetraethylbenzimidazolyl-carbocyanine iodide (JC-1 dye) (Reers et al., 1995; Salvioli et al., 
1998). JC-1 is a lipophilic and cationic fluorescent dye that selectively accumulates in 
mitochondria. It forms J-aggregates in the intact polarized mitochondrial membrane and emits 
red fluorescence at 590 nm upon excitation at 488 nm. When the mitochondrial membrane is 
depolarized, the dye will accumulate in the mitochondrial membrane in monomeric form and 
emits green fluorescence at 525 nm upon the same excitation wavelength. Thus, 
depolarization of mitochondrial membrane is indicated by a fluorescence emission shift from 
red (590 nm- J-aggregate form) to green (525 nm- monomeric form) or simply determined by 
the reduction of the red versus green fluorescence intensity ratio. 
In this study, HL-60 cells treated with jacaric acid (1, 3 and 5 |LIM) for different time 
periods (5, 10 and 20 hours) were stained by JC-1 dye. The red and green fluorescence signals 
were then measured by the FACSCanto flow cytometer. Fig. 4.5 shows that the mitochondrial 
membrane potential of the HL-60 cells was depolarized dose- and time-dependently. 
Significant depolarization was observed after 20 hours of incubation with 5 juM jacaric acid, 
and �50o/o HL-60 cells were depolarized under these conditions. A similar trend was observed 
when the leukemia NB-4 cells were treated with jacaric acid (data not shown). 
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Fig. 4.5: Effect of jacaric acid (8Z, lOE, 12Z CLN) on the mitochondrial membrane potential in 
the human promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^ cells/ ml) were treated with 
different concentrations ( 0 - 5 ^iM) of jacaric acid (8Z, lOE, 12Z CLN) for (A) 5, (B) 12 and (C) 20 
hours at 37°C. The cells were also incubated with «-linolenic acid or y-linolenic acid as negative 
controls for 20 hours. HL-60 cells were resuspended in the working JC-1 solution and incubated for 15 
minutes at 37°C. The stained cells were subjected to flow cytometric analysis using the BD 
FACSCanto flow cytometer. The excitation wavelength was 488 nm and the emission wavelengths of 
red (590 nm) and green (525 nm) fluorescence were measured simultaneously. Top left quadrant 
represented cells with normal polarized mitochondrial membrane that emitted red fluorescence. 
Bottom right quadrant represented cells with depolarized mitochondrial membrane that emitted green 
fluorescence. 
* Significantly different from the control, p < 0.05 
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4.2.4 Effects of Jacaric Acid on the Caspase Activities in the Human Promyelocytic 
Leukemia HL-60 Cells 
Caspases are the IL-ip-converting enzyme family proteases. Fourteen caspases have been 
identified so far and they share many common properties (Fan et al., 2005). They are 
aspartate-specific cysteine proteases with a conservative pentapeptide active site "QACXG" 
(X can be R, Q or D). Their precursors are zymogens, also known as procaspases. The 
N-terminal of procaspase prodomain contains a highly diverse structure for caspase activation. 
They are able to auto-activate and activate downstream caspases. 
There are three caspase subtypes: apoptotic "initiator" caspases (caspases-2, -8, -9 and 
-10), apoptotic "effector" caspases (caspases-3, -6 and -7) and inflammatory mediator 
(caspases-1, -4, -5, -11, -12, -13 and -14) (Paroni et al, 2002; Morishima et al., 2003; Sattar et 
al., 2003; Johnson and Jarvis, 2004; Fan et al., 2005; Launay et al., 2005). The "initiator" 
caspases are activated by oligomerization and self-cleavage of their monomeric procaspases. 
The "effector" caspases are activated by proteolytic cleavage of their inactive procaspases 
into active caspases by the upstream activated "initiator" caspases. Two apoptotic pathways 
are activated by different "initiator" caspases: caspases-8 and -10 are the common "initiator" 
caspases of the extrinsic pathway while caspase-9 is an "initiator" caspase for the intrinsic 
pathway. Caspase-3 is the most well-known "effector" caspase as both caspases-8 and -9 
funnel their apoptosis signals to this common effector (Chowdhury et al, 2006). 
In this study, specific caspase substrates (Ac-DEVD-AMC, Ac-IETD-AMC and 
Ac-LEHD-AFC are substrates for caspases-3, -8 and -9 respectively) and caspase inhibitors 
(Ac-DEVD-CHO, Ac-IETD-CHO and Ac-LEHD-CHO are inhibitors for caspases-3, -8 and 
-9 respectively) were used to measure the caspases-3, -8 and -9 activities. As shown in Fig. 
4.6, 4.7 and 4.8, the activities of caspases-3 and -9 were significant enhanced in the jacaric 
acid-treated HL-60 cells, while the caspase-8 activity was not changed. The activation of 
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caspases-3 and -9 by jacaric acid was dose-dependent, and the activities of caspases-3 and -9 
in HL-60 cells were increased by 76% and 65% respectively after incubation with 5 |iM 
jacaric acid for 16 hours (Fig. 4.6 and Fig. 4.8). Moreover, caspase inhibitors markedly 
suppressed the activities of caspases in all cases, which confirmed that the apoptotic effect 
was specifically linked with caspase activation. 
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Fig. 4.6: Induction of caspase-3 activity in the jacaric acid (8Z, lOE, 12Z CLN)-treated 
human promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^  cells/ml) were either 
incubated with solvent (0.005% ethanol) or with two different concentrations (2.5 jiiM and 5 
|LIM) of jacaric acid (8Z, lOE, 12Z CLN) at 37�C for 16 hours. HL-60 cells treated with 
actinomycin D (50 |iM) were served as a positive control. The proteins of each sample were 
extracted and incubated with caspase-3 specific substrate (Ac-DEVD-AMC) with or without 
its specific inhibitor (Ac-DEVD-CHO). The samples were excited at 430 nm and the 
fluorescence emitted at 465 nm was measured by the fluorescence plate reader Polarizon 
(Tecan). The AMC release unit was estimated by comparing sample AMC fluorescence units 
with the standard curve of free AMC molecules. The caspase 3 activity was correlated to the 
amount of AMC release. 
* Significantly different from the solvent control, p < 0.05 
*** Significantly different from the solvent control, p < 0.001 
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Fig. 4.7: Analysis of caspase-8 activity in the jacaric acid (8Z, lOE, 12Z CLN)-treated 
human promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^  cells/ml) were either 
incubated with solvent (0.005% ethanol) or with two different concentrations (2.5 jiiM and 5 
|LIM) of jacaric acid (8Z, lOE, 12Z CLN) at 37�C for 16 hours. HL-60 cells treated with 
actinomycin D (50 |iM) were served as a positive control. The proteins of each sample were 
extracted and incubated with caspase-8 specific substrate (Ac-IETD-AMC) with or without its 
specific inhibitor (Ac-IETD-CHO). The samples were excited at 430 nm and the fluorescence 
emitted at 465 nm was measured by the fluorescence plate reader Polarizon (Tecan). The 
AMC release unit was estimated by comparing sample AMC fluorescence units with the 
standard curve of free AMC molecules. The caspase 8 activity was correlated to the amount of 
AMC release. 
*** Significantly different from the solvent control, p < 0.001 
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Fig. 4.8: Induction of caspase-9 activity in the jacaric acid (8Z, lOE, 12Z CLN)-treated 
human promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^ cells/ml) were either 
incubated with solvent (0.005% ethanol) or with two different concentrations (2.5 |iM and 5 
luM) of jacaric acid (8Z, lOE, 12Z CLN) at 37�C for 16 hours. HL-60 cells treated with 
actinomycin D (50 |iM) were served as a positive control. The proteins of each sample were 
extracted and incubated with caspase-9 specific substrate (Ac-LEHD-AFC) with or without 
its specific inhibitor (Ac-LEHD-CHO). The samples were excited at 430 nm and the 
fluorescence emitted at 535 nm was measured by the fluorescence plate reader Polarizon 
(Tecan). The AFC release unit was estimated by comparing sample AFC fluorescence units 
with the standard curve of free AFC molecules. The caspase 9 activity was correlated to the 
amount of AFC release. 
* Significantly different from the solvent control, p < 0.05 
*** Significantly different from the solvent control, p < 0.001 
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4.2.5 Effects of Jacaric Acid and Antioxidants on the ROS production in the Human 
Promyelocytic Leukemia HL-60 Cells 
ROS are known to trigger both the intrinsic and extrinsic apoptotic pathways. Normally, 
ROS are generated by tightly regulated enzymes, such as NO synthase and NAD(P)H oxidase 
isoforms. However, overproduction of ROS can arise by either electron leakage from 
mitochondrial electron transport chain or excessive stimulation of NAD(P)H. For example, 
superoxide (O2') is produced when an electron is captured by molecular oxygen (Hileman et 
al., 2004). By building up the oxidative stress within cells, ROS are well recognized for 
playing a deleterious role to induce apoptosis (Valko et al., 2007). As mitochondrion is a 
major source of ROS, this organelle triggers apoptosis when its "redox homeostasis" is 
disrupted by overproduction of ROS (Droge, 2002). Cyt c released from the damaged 
mitochondria can induce apoptosis. Some studies have also shown that ROS might induce the 
overexpression of Fas and FasL in certain cell types (Huang et al., 2003; Alcouffe et al., 
2004). Nevertheless, the mechanism of how ROS initiate apoptosis remains unclear until now. 
In the present study, the ROS production in jacaric acid-treated HL-60 cells was analyzed. 
Intracellular ROS level was monitored by a fluorescent dye 2',7'-dichlorodihydrofluorescein 
diacetate (H2DCFDA). It was found that jacaric acid promoted the ROS production in the 
HL-60 cells after 48-hour treatment in a dose-dependent manner (Fig. 4.9). Moreover, the 
effect of antioxidants was investigated. When the HL-60 cells were pre-treated with 
antioxidants such as NAC or SOD for 3 hours, the ROS level in the jacaric acid-treated cells 
was significantly dropped (Fig. 4.9). The results suggest that the antioxidants can abolish the 
ROS-generating ability of jacaric acid in HL-60 cells. 
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Fig. 4.9: Effects of jacaric acid (8Z，lOE，12Z CLN) and antioxidants (NAC and SOD) on 
the reactive oxygen species (ROS) generation in the human promyelocytic leukemia 
HL-60 cells. HL-60 cells (1 x 10^ cells/ml) were divided into two groups: one group was 
treated with different concentrations (0 - 5 \xM) of jacaric acid at 37°C for 48 hours and 
another group was first pre-incubated with 15 mM N-acetyl-L-cysteine (NAC) or 200 
units/ml superoxide dismutase (SOD) for 3 hours before treatment. Total cells (1 x 10^) were 
collected in each sample and resuspended in 0.5 ml staining solution containing 10 |LXM 
oxygen radical sensor H2DCFDA at 37°C for 30 minutes. The BD FACS Canto flow cytometer 
was used to measure the green fluorescence intensity. The excitation wavelength was 488 nm 
and the emission wavelength was 590 nm. 
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4.2.6 Effect of N-acetyl-L-cysteine on the Apoptosis-inducing Activity of Jacaric Acid in 
the Human Promyelocytic Leukemia HL-60 Cells 
As demonstrated in Section 4.2.5, the antioxidants SOD and NAC completely abolished 
the ROS-generating ability of jacaric acid in the HL-60 cells. It was of interest to know 
whether antioxidants could also affect the DNA fragmentation in the HL-60 cells induced by 
jacaric acid. Fig. 4.10 shows that NAC completely blocked the jacaric acid-induced DNA 
fragmentation, suggesting that the apoptosis of HL-60 cells triggered by jacaric acid might be 
mediated through the ROS-related pathways. 
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Fig. 4.10: Effect of N-acetyl-L-cysteine (NAC) on the induction of DNA fragmentation in 
the human promyelocytic leukemia HL-60 cells triggered by jacaric acid (8Z, lOE, 12Z 
CLN). HL-60 cells (1 x 10^ cells/ml) were pre-treated with or without 15 mM 
N-Acetyl-L-Cysteine (NAC) for 3 hours at 37°C, after which the cells were incubated with 3 
jiM jacaric acid for 24 hours at 37°C. The apoptotic DNA fragments were extracted by mild 
detergent IGEPAL CA-630 lysis buffer, and analyzed by electrophoresis on 2% agarose gel 
stained with ethidium bromide. 
Lane 1: 100 bp DNA markers 
Lane 2: Untreated HL-60 cells 
Lane 3: HL-60 cells treated with 3 jiM jacaric acid 
Lane 4: HL-60 cells treated with 3 |j,M jacaric acid and 15mM NAC 
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4.2.7 Morphological Studies on the Jacaric Acid-treated Human Promyelocytic 
Leukemia HL-60 Cells 
The morphological changes of the human promyelocytic leukemia HL-60 cells after 
treatment with jacaric acid were examined. The HL-60 cells were first incubated with jacaric 
acid (2 and 3 jiM) for 72 hours. The cells were collected and centrifuged onto microscopic 
slides and stained by the Hemacolor 1, 2 and 3 solutions. Fig. 4.1 IB and Fig. 4.1 IC show that 
the jacaric acid-treated HL-60 cells did not have the typical macrophage-like morphology, like 
a large cytoplasm versus nucleus ratio and the presence of vacuolation in the cells. The jacaric 
acid-treated cells (Fig. 4.1 IB and Fig. 4.11C) only showed immature blast cell morphology 
which was similar to the solvent control and LN control groups (Fig. 4.11A, D and E). These 
results suggest that jacaric acid did not induce terminal differentiation of the HL-60 cells 
under the prescribed experimental conditions. 
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Fig. 4.11: Morphology of the jacaric acid (8Z, lOE, 12Z CLN)-treated human 
promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^  cells/ml) were treated with (A) 
solvent control (0.005% ethanol), (B) 2 |iM jacaric acid, (C) 3 [ lM jacaric acid, (D) 3 [iM 
oc-linolenic acid and (E) 3 jiM y-linolenic acid (D and E were linolenic acid controls) at 37�C 
for 72 hours. The cells (5 x lO"^  cells) were cytocentrifuged onto microscopic glass slides and 
stained with Hemacolor solutions. (Magnification: 400 X; scale bars shown represent 20 |Lim) 
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4.2.8 Cell Size and Granularity of the Human Promyelocytic Leukemia HL-60 Cells 
after Treatment with Different CLN Isomers 
To further examine the differentiation-inducing ability of different CLN isomers, 
quantitative analysis of the cell size and granularity was carried out by flow cytometric 
studies. The forward scatter (FSC) on the x-axis indicates the cell size while side scatter (SSC) 
on the y-axis indicates the granularity of cells. As shown in Fig. 4.12, the well-known 
characteristics of differentiated cells, including increases in cell size (FSC) and internal 
complexity (SSC), were not observed in the CLN-treated HL-60 cells. Similar results were 
obtained using another acute promyelocytic leukemia cell line NB-4 (data not shown). The 
results indicate that CLN had little, if any, ability to trigger differentiation of the human 
myeloid leukemia cells. 
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Fig. 4.12: Cell size and granularity of the CLN-treated human promyelocytic leukemia 
HL-60 cells. HL-60 cells (1 x 10^ cells/ml) were treated with (A) solvent control (0.005% 
ethanol), (B) 3 |iM a-eleostearic acid (9Z,11E,13E CLN), (C) 3 |LIM /?-eleostearic acid 
(9E,11E,13E CLN), (D) 3 jiM y^-calendic acid (8E,10E,12E CLN) or (E) 3 jiiM jacaric acid 
(8Z,10E,12Z CLN) at 37°C for 72 hours. The cells were fixed with paraformaldehyde and 
analyzed for FSC and SSC using the BD FACSCanto flow cytometer. (The percentage of cells 
in the top left quadrant which displayed differentiation characteristics was also indicated in 
the figure.) 
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4.2.9 Expression of Differentiation-Related Cell Surface Markers in the Human 
Promyelocytic Leukemia HL-60 Cells after Treatment with Jacaric Acid 
During myeloid leukemia cell differentiation, the morphological changes are often 
accompanied by phenotypic changes, such as the expression of certain lineage-specific 
differentiation antigen markers. In this study, the cell surface markers (CDl lb and CD 14) of 
monocytic differentiation were examined on the jacaric acid-treated HL-60 cells. The HL-60 
cells were treated with jacaric acid (1 i^M and 1.5 |iM) for 4 days. Longer incubation time was 
chosen to ensure that the differentiation-inducing effect, if any, could be detected. Vitamin D3, 
a well-known differentiation-inducing agent for the HL-60 cells, was also used as a positive 
control (Yoshida et al., 1995). It can be seen that jacaric acid failed to induce the expression 
of CDl lb and CD 14 markers on HL-60 cells when compared with the negative isotypic 
control and the solvent control (Fig. 4.13 and Fig. 4.14). In contrast, vitamin D3 markedly 
induced the expression of CD l i b and CD 14 in HL-60 cells (Fig. 4.13 and Fig. 4.14). 
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Fig. 4.13: Analysis of the expression of surface antigen C D l l b in the jacaric acid (8Z, 
lOE, 12Z CLN)-treated human promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^ 
cells/ml) were treated with solvent control (0.005% ethanol), 1 jiiM jacaric acid, 1.5 juM 
jacaric acid or 0.4 |aM vitamin D3 (positive control) at 37°C for 4 days. The cells were then 
stained with mouse monoclonal antibodies to C D l l b antigen as the primary antibody 
followed by FITC-conjugated anti-mouse IgG as the secondary antibody. Fluorescence 
intensity was analyzed using the BD FACSCanto flow cytometer. 
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Fig. 4.14: Analysis of the expression of surface antigen CD14 in the jacaric acid (8Z, lOE, 
12Z CLN)-treated human promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^ 
cells/ml) were treated with solvent control (0.005% ethanol), 1 |iM jacaric acid, 1.5 jiM 
jacaric acid or 0.4 |iM viamin D3 (positive control) at 37�C for 4 days. The cells were then 
stained with mouse monoclonal antibodies to CD 14 antigen as the primary antibody, followed 
by FITC-conjugated anti-mouse IgG as the secondary antibody. Fluorescence intensity was 
analyzed using the BD FACSCanto flow cytometer. 
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4.3 Discussion 
Apart from viewing cancer as a disease of deregulated cell proliferation, it has been 
proposed that cancer can be due to the aberrant control of apoptosis in cells (Cheung et al., 
2006). With increasing understanding of the underlying molecular mechanisms of how cancer 
cells escape the tightly regulated processes of apoptosis, it may offer a new hope in cancer 
therapy (Johnson and Walker, 1999). Until now, several studies have shown that certain CLN 
isomers, especially a-eleostearic acid (9Z, HE, 13E CLN), are able to initiate apoptosis in the 
human colon cancer cells both in vitro and in vivo (Igarashi and Miyazawa, 2000; Kohno et 
al.’ 2002; Suzuki et al., 2006; Yasui et al., 2006). 
In this Chapter, the apoptosis-inducing ability of the CLN isomer, jacaric acid (8Z, lOE, 
12Z CLN), in the human promyelocytic leukemia HL-60 cells was investigated. It was found 
that jacaric acid induced DNA fragmentation in the HL-60 cells dose- and time-dependently, 
and DNA fragmentation could be detected following 24-hours of treatment. To measure 
apoptosis quantitatively, the cell death ELISA kit was used. The kit detects the degree of 
apoptosis based on the quantitative sandwich-enzyme-immunoassay using monoclonal 
antibodies that specifically quantify the presence of mono- and oligo-nucleosomes in the 
cytoplasmic fraction of the cell lysates. Using the cell death ELISA kit, it can be seen that 
co-treatment of HL-60 cells with the pan-caspase inhibitor and jacaric acid counteracted the 
occurrence of apoptosis, suggesting that jacaric acid-induced apoptosis largely depends on the 
caspases-associated pathways. 
Annexin V is a phospholipid-binding protein which has high affinity for the PS that is 
exposed at the external surface of the cells. PS externalization is one of the major 
characteristics of early apoptosis, and hence annexin V can be used as a sensitive probe for 
detecting early apoptosis (Vermes et al., 1995; Zhang et al., 1997). As PS translocation also 
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occurs in necrosis, Annexin V is not an absolute marker of apoptosis. Other dyes such as 
7-amino-actinomycin D (7-AAD) or propidium iodide (PI) should be used with Annexin V to 
confirm the apoptosis induction. The dyes bind to nucleic acids only when they penetrate the 
breached plasma membrane. In the present study, the combination of Annexin-GFP and PI 
staining showed that jacaric acid induced PS externalization in a time- and dose-dependent 
manner. 
Mitochondrial membrane potential changes could be detected as early as 5 hours after 
treatment of HL-60 cells with 5 |iM jacaric acid, and nearly 50% of the treated cells had 
become depolarized at 20 hours of treatment. Interestingly, the parental fatty acids without 
conjugated double bonds, ALA and GLA, did not trigger any loss of mitochondrial membrane 
potential in HL-60 cells. One of the possible causes to initiate the loss of mitochondrial 
membrane potential is due to the Bax-dependent mitochondrial permeability transition (MPT) 
formation. The detailed expression of the apoptosis-associated proteins will be discussed in 
Chapter 5. 
Among the fourteen caspases that have been identified in animal cells, the "initiator" 
caspases (caspases-2, -8，-9 and -10) and apoptotic ‘‘effector，，caspases (caspases-3, -6 and -7) 
play major essential roles in mediating the downstream of apoptotic pathways (Fan et al., 
2005; Launay et al., 2005). The "initiator" procaspases are characterized by their long 
prodomain. They exist as monomeric form in animal cells and are activated by dimerization 
or oligomerization and self-cleavage of the procaspases occurred. However, some scientists 
suggested that "initiator" caspase activation can occur in the absence of any proteolytic 
cleavage in certain animal systems (Salvesen and Abram, 2004). The "effector" procaspases 
are characterized by their short prodomain. They exist as dimers in living cells and they are 
activated by proteolytic cleavage at their internal aspartate residues to generate two large and 
two small subunits for heterodimerization by the upstream activated "initiator" caspases 
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(Laiinay et al., 2005). The activated "effector" caspases cleaved inactive procaspases and 
other cellular proteins, including DNA repairing enzymes, p53 inhibitor MDM2, lamin, 
gelsolin and protein kinase C5 (Strasser et al., 2000). In short, caspases not only directly 
cause apoptosis, but also demolish cell survival pathways and disrupt important architectural 
components of cellular framework (Earnshaw et al., 1999). 
Caspase-8 is a well-known mediator of the extrinsic pathway while caspase-9 is an 
essential factor of the intrinsic pathway. The apoptotic signals of the caspases of both 
pathways funnel to activate caspase-3 (Chowdhury et al., 2006). In the present study, the 
activation of caspases-3, -8 and -9 in HL-60 cells by jacaric acid was examined. It was found 
that the activities of the “initiator，’ caspase-9 and "effector" caspase-3 in the jacaric 
acid-treated HL-60 cells were enhanced while no significant change in the caspase-8 activity 
was observed. These results suggest that the caspase-dependent apoptosis in jacaric 
acid-treated HL-60 cells is mainly mediated by the intrinsic pathway but not the extrinsic 
pathway. Interestingly, Lui et al (2005) had reported that 9E, H E CLA isomer induced both 
the extrinsic and intrinsic apoptotic pathways in the murine myeloid leukemia cells in vitro. 
The reasons why CLA and CLN isomers trigger different apoptotic pathways in myeloid 
leukemia cells remain as yet unclear, but these findings indicate that different CFA might 
initiate apoptosis in leukemia cells via different signaling mechanisms. 
ROS is a collective term of free radicals, for examples, superoxide anions (O2'), hydroxyl 
radicals (OH.) and some non-radical oxygen derivatives, such as hydrogen peroxide (H2O2). 
Normally, ROS are generated by tightly regulated enzymes, such as NO synthase and 
NAD(P)H oxidase isoforms, but overproduction of ROS can arise by either electron leakage 
from mitochondrial electron transport chain or excessive stimulation of NAD(P)H. In general, 
cancer cells are more active in O2' production and are more sensitive to intrinsic oxidative 
stress than normal cells, and thus cancer cells are more vulnerable to the damage by the 
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ROS-generating agents (Hileman et al,, 2004). Some ROS-generating agents hinder 
mitochondrial electron transport chain and strengthen the O2" production (Pelicano et al., 
2003). Thus, by building up the oxidative stress within cancer cells, ROS are well recognized 
for playing a deleterious role to induce apoptosis and may provide therapeutic value for 
cancer chemotherapy (Valko et al., 2007). It has been reported that O2" and H2O2are the main 
ROS that build up oxidative stress and can induce apoptosis in both myeloid and lymphoid 
leukemia cells (Zhou, et al., 2003; Nakazato et al., 2005; Kizaki, et al., 2006). The 
ROS-inducing apoptotic therapy using natural compounds such as green tea catechin is 
believed to be safer and with lesser side effects than the current chemotherapy of leukemia 
(Nakazato et al., 2005; Kizaki et al., 2006). In this study, jacaric acid was found to trigger 
ROS production in the HL-60 cells after 16-hours of incubation in a dose-dependent manner. 
Our results are in accordance with previous studies by other groups who have targeted on the 
CLA isomers and conjugated EPA and DHA, as they have shown that some conjugated fatty 
acids can enhance oxidative stress accumulation in cancer cells (Basu et al., 2000; Igarashi 
and Miyazawa, 2000; Bergamo et al. 2004; Lui et al 2005). 
Mitochondrion is a major site for the ROS-metabolizing enzymes, so apoptosis is 
triggered when the "redox homeostasis" in mitochondrion is disrupted by overproduction of 
ROS (Droge, 2002). In the present study, antioxidants such as SOD and NAC were used to 
pre-treat the HL-60 cells, so as to study the role of ROS in jacaric acid-induced apoptosis in 
the leukemia cells. SOD catalyzes the dismutation of O2" to H2O2 and molecular oxygen and 
against the effects of oxygen radicals (McCord and Edeas, 2005). NAC is a strong antioxidant 
and act as a precursor of the intracellular reduced glutathione (GSH) synthesis (Swamy and 
Huat, 2003; Flora, 2007). GSH is an important antioxidant to quench ROS and regulates the 
redox state of cells as well as keeping the enzyme GSH peroxidase in the reduced form (Sies, 
1999). GSH depletion leads to mitochondrial membrane depolarization, ROS accumulation 
and ultimately caspase activation and apoptosis (Swamy and Huat, 2003). Our results showed 
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that SOD and NAC greatly reduced the jacaric acid-induced ROS generation and NAC also 
suppressed DNA fragmentation triggered by jacaric acid in the HL-60 cells. Therefore, it 
could be speculated that the jacaric acid-induced ROS generation was closely linked with the 
inhibition of the intracellular antioxidant defense system. Our speculation agrees with 
previous studies by other groups who demonstrated that CLA caused GSH depletion and 
reduced GSH peroxidase activity in the leukemia Jurkat T cells (Bergamo et al. 2004). 
Nevertheless, the mechanisms of ROS generation in leukemia cells can be further studied by 
pre-treating HL-60 cells with NADPH oxidase inhibitor or protein kinase C (PKC) inhibitor 
to see whether this can suppress the jacaric acid induced-apoptosis of the leukemia cells or 
not. 
Differentiation therapy is regarded as a novel and targeted approach to leukemia 
treatment (Leung et al., 2005). The acute promyelocytic leukemia HL-60 cell line was chosen 
as an in vitro model for studying the differentiation-inducing effect of CLN in this project as 
this cell line is well characterized and can be induced to differentiate along the monocytic 
lineage and granulocytic lineage by various biological or chemical agents, such as vitamin D3， 
ATRA and arsenic trioxide (Kwong et al, 2001; Miller and Waxman, 2002; Tallman et al., 
2002). 
Our preliminary findings showed that jacaric acid (0.5-3 |iM) could not trigger terminal 
differentiation in the HL-60 cells under the prescribed experimental conditions. 
Morphological studies demonstrated that jacaric acid did not increase the cytoplasm versus 
nucleus ratio and vacuolation in the HL-60 cells, indicating that the leukemia cells did not 
differentiate into the more matured monocytic or granulocytic lineage cells. The general 
differentiation-inducing properties of other CLN isomers were also examined, a-eleostearic 
acid-, y^-eleostearic acid-, y^-calendic acid- and jacaric acid-treated HL-60 cells were analyzed 
by flow cytometry for their forward scatter (FSC) and side scatter (SSC). The results 
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demonstrated that the SSC and FSC of the leukemia cells were more or less the same after 
treatment with these four CLN isomers. Based on these preliminary results, there is limited 
evidence to support that CLN isomers can trigger differentiation in the human myeloid 
leukemia cells. Interestingly enough, CLA isomers, such as 9Z, H E CLA, lOE, 12Z CLA and 
9E, HE CLA, were found to induce morphological changes in the murine WEHI-3B JCS 
cells with macrophage-like characteristics (Lui et al., 2005). This implies that CLN and CLA 
isomers have differential differentiation-inducing abilities on myeloid leukemia cells, though 
the underlying mechanisms have yet to be resolved. 
In the phenotypic study, the expression of the monocytic differentiation cell surface 
markers C D l l b and CD 14 on jacaric acid-treated HL-60 cells was examined. CD l ib , also 
known as aM integrin chain, aM-pl , C3biR, CR3, Mac-1 and Mo 1, is mainly expressed in 
granulocytes, monocytes, NK cells and certain subsets of T cells and B cells (Cabanas and 
Sanchez-Madrid, 1999). It is associated with a wide range of ligands (such as iC3b, 
fibrinogen, factor X, FcR and ICAM) to carry out various cellular functions, for examples, 
interaction between neutrophils (or monocytes) and stimulated endothelium, phagocytosis of 
iC3b- or IgG-coated particles and neutrophil respiratory burst or degranulation triggered by 
FcR or C5a (Brown, 1991; Springer, 1994; Stewart et al., 1995; Elangbam et al, 1997). On 
the other hand, CD 14, also known as LPS receptor, is highly expressed in monocytes, 
macrophages and weakly expressed in granulocytes. The ligands and molecules associated 
with CD 14 include endotoxin lipopolysaccharide (LPS), lipoteichoic acid and phosphatidyl 
inositol (Wright et al., 1990; Hailman et al., 1994; Yu et al., 1997). LPS binds to its receptor 
CD 14 directly or binds to the serum LPS-binding protein which enhances the binding of LPS 
to CD 14 to stimulate monocytes and neutrophils (Hailman et al., 1994). The activated cells 
release cytokines, like tumor necrosis factor (TNF) and up-regulate the expression of 
adhesion molecules (Pugin et cd., 1995). In this study, jacaric acid did not induce a significant 
expression of C D l l b and CD 14 on the HL-60 cells. Only the positive control (vitamin D3) 
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induced C D l l b and CD 14 expression. These findings further support that jacaric acid has 
very limited, if any, differentiation-inducing effect on the HL-60 cells. 
Based on the results so far obtained, unlike the CLA isomers, CLN can induce apoptosis 
but not differentiation in the human myeloid leukemia cells. Therefore, in Chapter 5 we will 
focus our study mainly on apoptosis-associated proteins and signaling pathways in an attempt 
to understand the underlying molecular mechanisms by which CLN can trigger apoptosis in 
the leukemia HL-60 cells. 
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5.1 Introduction 
In Chapter 4, we have shown that the human promyelocytic leukemia HL-60 
cells could be triggered by jacaric acid to undergo apoptosis but not differentiation. In 
this Chapter, the modulatory effects of jacaric acid on the expression of 
apoptosis-related proteins and the signaling pathways that might be involved in the 
jacaric acid-induced apoptosis of HL-60 cells were investigated. 
Firstly, our results in Chapter 4 clearly indicate that jacaric acid could activate 
both caspase-9 and caspase-3 but not caspase-8 in the human promyelocytic leukemia 
HL-60 cells. This suggests that jacaric acid mainly triggers the intrinsic rather than the 
extrinsic apoptotic pathway in HL-60 cells. It is known that the extrinsic apoptotic 
pathway is activated by tumor necrosis factor (TNF)-family receptors. Fas/CD95 is 
one of the well-known death receptor containing Death Domain (DD) in its cytosolic 
tail (Wallach et al., 1999). It has been reported that binding of Fas with FasL or 
cross-linking of Fas with the agonistic antibodies activates apoptosis in Fas-bearing 
cells. When the Fas ligand binds to Fas on plasma membrane, the trimeric receptor 
recruits adapter molecule FADD and either procaspase-8 or -10 in cytosol to form a 
death-inducing signaling complex (DISC) to trigger caspase-8/-10 dependent 
apoptosis (Schwarz et al., 2007). These caspases have death effector domains (DED) 
in their N-terminal prodomains that bind to a corresponding DED in FADD. To 
ascertain that the extrinsic apoptotic pathway plays a minimal role in the action 
mechanism of jacaric acid, the effects of jacaric acid on the protein expression of Fas 
and FasL were examined in this Chapter. 
Secondly, the possible involvement of the intrinsic pathway in jacaric 
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acid-induced apoptosis of HL-60 cells was also examined. It is known that 
caspase-dependent intrinsic pathway is started at the damaged mitochondria. 
Normally, a variety of apoptotic proteins are located at the mitochondrial 
inter-membrane space in an inactive form. The permeability of the mitochondrial 
outer membrane is regulated by the Bcl-2 family members. Bcl-2 proteins have 
regions of amino acid sequence similarity called Bcl-2 homology (BH) domains. 
Bcl-2 proteins can be classified into 2 types, the anti-apoptotic and pro-apoptotic 
Bcl-2 proteins. Anti-apoptotic Bcl-2 member proteins, such as Bcl-2 and BC1-XL, 
protect against outer membrane permeabilization. They have four domains (BHl, 
BH2, BH3 and BH4) and the BH4 domain is responsible for the anti-apoptotic effect 
(Daniel et al,, 2003; Armstrong, 2006; Schwarz et al., 2007). Pro-apoptotic proteins, 
such as Bak and Bax, trigger the release of pro-apoptotic factors from mitochondria 
(Gottlieb, 2000; Daniel et al., 2003). They have only three BH domains (BHl, BH2 
and BH3) and the BH3 domain is responsible for the pro-apoptotic effect. Bak tightly 
anchors on the outer mitochondrial membrane in a complex with the 
voltage-dependent anion channel (VDAC2) (Cheng et al, 2003). Pro-apoptotic Bcl-2 
proteins, which contain only the BH3 domain, such as Bid and Bim, initiate 
oligomerization of Bax and Bak. Other pro-apoptotic Bcl-2 proteins which contain 
only the BH3 domain, such as Bad and Bik, can bind to Bcl-2 and displace 
sequestered Bid-like proteins (Chen et al., 2005; Schwarz et al, 2007). The structures 
of different Bcl-2 family members are shown in Fig. 5.1. 
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Fig. 5.1: The structural features of anti-apoptotic and pro-apoptotic BcI-2 
proteins 
(Modified from Cory and Adams, 2002; Burlacu, 2003) 
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Since the equilibrium between the anti-apoptotic and pro-apoptotic Bcl-2 
proteins can influence the susceptibility of cells in response to a death signal such as 
jacaric acid, therefore, the effects of jacaric acid on the expression of these Bcl-2 
family proteins in HL-60 cells were studied. Moreover, the intrinsic apoptotic 
pathway is also mediated by many apoptotic factors and one of the key players is 
Cytochrome c (Cyt c). Once Cyt c is leaked to the cytosol, it binds to and triggers 
oligomerization of apoptotic protease-activating factor-1 (Apaf-1) to form 
apoptosome that binds and activates procaspase-9 (Cain e t a l , 2002). Therefore, the 
ability of jacaric acid in triggering the release of Cyt c from the mitochondria of 
HL-60 cells had also been investigated in the present study. 
Thirdly, in order to dissect out the underlying molecular mechanisms by which 
jacaric acid can exert its anti-leukemic effect on the HL-60 cells, attempts had been 
made to study the ability of jacaric acid in activating a number of intracellular 
signaling pathways in HL-60 cells. The mitogen-activated protein kinase (MAPK) 
signaling pathway is one of the most well characterized intracellular signaling 
pathways. The kinases in this signal transduction system sense the stress signals that 
arise both intracellularly or from outside of the cells. Examples for these stimuli 
include oxidative stress caused by chemotherapeutic drugs, UV-radiation, binding of 
inflammatory cytokines to cell surface receptors etc. (Mak et al., 2007). MAPK 
belong to a large family of the serine-threonine kinases regulating cellular processes 
like proliferation, apoptosis, differentiation, transformation and development. At least 
three MAPK subfamilies have been characterized for their functions and mechanisms. 
They are the extracellular signaling-regulated kinases (ERK), C-Jun N-terminal 
kinase (JNK/SAPK) and p38 MAPK (Zhang and Liu, 2002; Fang and Richardson, 
2005). MAP kinases work together to construct kinase cascades and each cascade 
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consists of at least three enzymes: a MAPK kinase kinase (MAPKKK), a MAPK 
kinase (MAPKK) and a MAP kinase (MAPK) (Fig. 5.2). The cascades amplify and 
integrate signals from different sources and elicit various cellular responses. In this 
study, the activation of ERK and JNK in jacaric acid-treated HL-60 cells was 
investigated. 
Activation of the transcription factor NF-KB is another imperative mechanism 
coordinating different physiological responses. It regulates both innate and adaptive 
immune responses. Moreover, a wide range of genes that are regulated by NF-KB 
include cytokines (IL-1, IL-2, IL-6, IL-12, TNF-a, and GM-CSF etc.), chemokines 
(IL-8, MlP- la and MCP-1 etc.), adhesion molecules (ICAM, VCAM and E-selectin), 
acute phase proteins (e.g. SAA) and inducible effector enzymes (iNOS and COX-2 
etc.) (Nakano et al., 2006). NF-KB is a collective term for a group of structurally 
related and evolutionary conserved proteins, with five members: Rel (c-Rel), Rel-A 
(p65), Rel-B, NF-KB 1 (p50 and its precursor PI05) and NF-KB2 (p52 and its 
precursor p i00) (Ghosh et ah, 1998; Ghosh and Karin, 2002). NF-KB/RCI proteins 
exist as either homo- or hetero-dimeric form. The proteins share a highly conserved 
N-terminal Rel homology domain (RHD) that is responsible for DNA binding, 
dimerization and association with the IKB inhibitory proteins. Most NF-KB/Rel dimers 
are bound to IKB in cytoplasm in resting cells. Many signal transduction pathways can 
activate specific IKB kinase (IKK) (Karin and Ben-Neriah, 2000). IKK phosphorylates 
the N-terminus of IKB and this induces rapid degradation of IKB through 
polyubiquitination. Thus, NF-KB is free and able to enter the nucleus for DNA 
binding and then activates transcription. In this Chapter, the activation of NF-KB by 
jacaric acid in HL-60 cells was also examined. 
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Fig. 5.2: Three major MAP kinase cascades in mammalian cells 
(Modified from Zhang and Liu, 2002) 
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5.2 Results 
5.2.1 Expression of Fas and Fas Ligand Proteins in the Jacaric Acid-treated 
Human Promyelocytic Leukemia HL-60 Cells 
In this study, the modulatory effects of jacaric acid on the Fas and FasL protein 
expression in the human promyelocytic leukemia HL-60 cells were investigated by 
the Western blot analysis. The HL-60 cells were either untreated, or treated with 3 [iM 
or 5 |iM jacaric acid for 24 hours. The amount of protein product was normalized with 
respect to the house-keeping gene product, P-actin. Fig. 5.3 shows that jacaric acid did 
not increase the expression of Fas and Fas ligand proteins in the human promyelocytic 
leukemia HL-60 cells. Therefore, the extrinsic pathway does not seem to play a 
significant role in the jacaric acid-induced apoptosis of HL-60 cells. 
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Concentrations of jacaric acid 
Control 3 [iM 5 |uM 
F a s 铺/卜誓 參‘‘，‘ 4 8 k D a 
1.000 0.863 士 0.026 0.795 ± 0.057 
Fas L 40 kDa 
1.000 1.095 ±0.106 1.042 ±0.082 
P-actin 42 kDa 
Fig. 5.3: Effects of jacaric acid (8Z, lOE, 12Z CLN) on the expression of Fas and 
Fas ligand proteins in the human promyelocytic leukemia HL-60 cells. HL-60 
cells (2 X 10^ cells) were treated with different concentrations (0 - 5 j^M) of jacaric 
acid for 24 hours at 37°C. The proteins of each sample were extracted and analyzed 
by Western blot as described in Chapter 2. The extracted proteins (20 jug per sample) 
were electrophoresed on a polyacrylamide gel and then transferred onto a PVDF 
membrane for probing with specific primary antibody followed by horseradish 
peroxidase-conjugated secondary antibody. Then ECL detection assay was carried out 
in order to generate visible signal by exposing the membrane to X-ray films. The 
relative intensity of each protein band was normalized with respect to P-actin. 
* Significantly different from the control, p < 0.05 
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5.2.2 Expression of Bcl-2 Family Member Proteins in the Jacaric Acid-treated 
Human Promyelocytic Leukemia HL-60 Cells 
In the present study, the modulatory effects of jacaric acid on the 
apoptotic-regulatory protein expression in the human promyelocytic leukemia HL-60 
cells were investigated by the Western blot analysis. The HL-60 cells were either 
untreated, or treated with 3 |LIM or 5 |IM jacaric acid for 24 hours. The amount of 
protein product was normalized with respect to the house-keeping gene product, 
(3-actin. Fig. 5.4 shows that the expression levels of pro-apoptotic proteins Bak and 
Bad were significantly increased while the expression levels of anti-apoptotic proteins 
Bcl-2 and BC1-XL were decreased. These results indicated that the intrinsic apoptotic 
pathway was clearly involved in the jacaric acid-induced apoptosis of HL-60 cells. 
Moreover, the Bid protein was found to be cleaved after treatment of HL-60 cells with 
jacaric acid for 24 hours (Fig. 5.4). 
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Concentrations of jacaric acid 
C o n t r o l 3 | i M 5 ^iM 
Bad , 會 gMMWP^  23 kDa 
1 . 0 0 0 1 . 3 0 0 ± 0 . 1 2 0 1 . 8 4 1 ± 0 . 0 9 3 
氺 
Bak _,養 ‘‘‘ 講 30 kDa 
1 . 0 0 0 1 . 0 1 0 士 0 . 0 1 1 1 . 6 4 1 ± 0 . 0 6 5 
氺 
Bcl-2 ： ： ： 26 kDa 
1 . 0 0 0 0 . 8 5 1 ± 0 . 0 0 6 0 . 3 3 5 ± 0 . 0 2 7 
氺 
BCI-XL “ 30 kDa 
1 . 0 0 0 0 . 6 8 4 ± 0 . 4 3 8 0 . 7 1 6 士 0 . 0 7 0 
Bid � � ’ � / 22 kDa 
1 • � … � � � � “ � … ’ … K 、 、 ： � 15 kDa 
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1 . 0 0 0 1 . 0 3 5 士 0 . 0 3 5 0 . 9 4 7 ± 0 . 0 2 8 
1 . 0 0 0 1 . 3 7 5 ± 0 . 0 6 6 1 . 6 1 1 ± 0 . 0 2 4 
氺 
B-actin ' f ^ ^ m 42 kDa 
Fig. 5.4: Effect of jacaric acid (8Z, lOE，12Z CLN) on the expression of Bcl-2 
family proteins in the human promyelocytic leukemia HL-60 cells. HL-60 cells (2 
X 10^ cells) were treated with different concentrations (0 - 5 juM) of jacaric acid for 24 
hours at 37°C. The proteins of each sample were extracted and analyzed by Western 
blot as described in Chapter 2. The extracted proteins (20 jug per sample) were 
electrophoresed on a polyacrylamide gel and then transferred onto a PVDF membrane 
for probing with specific primary antibodies followed by horseradish 
peroxidase-conjugated secondary antibody. Then ECL detection assay was carried out 
in order to generate visible signal by exposing the membrane to X-ray films. The 
relative intensity of each protein band was normalized with respect to P-actin. 
* Significantly different from the control, p < 0.05 
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5.2.3 Cytochrome c Release in the Jacaric Acid-treated Human Promyelocytic 
Leukemia HL-60 Cells 
The intrinsic pathway is triggered by an apoptotic stimulus, which induces 
mitochondrial membrane permeabilization (MMP) and leads to the release of Cyt c 
from the mitochondrial intermembrane space (Cain et al., 2002). In the present study, 
the human promyelocytic leukemia HL-60 cells were either untreated, or treated with 
3 jiM or 5 jiM jacaric acid for 24 hours. The mitochondrial fraction and cytosolic 
fraction were isolated separately, as described in Chapter 2, and the proteins were 
analyzed by the Western blotting using Cyt c specific antibody. Fig. 5.5 shows that 
Cyt c was released from mitochondria dose-dependently after 24-hour treatment. This 
finding is in line with the activation of pro-apoptotic Bcl-2 members in jacaric 
acid-treated HL-60 cells as shown previously. 
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Concentrations of jacaric acid 
Control Control 3 i^M 3 |LIM 5 |uM 5 ^M 
\ 麵 igmiiiiiii^� 
• • ‘ , 賺 • 看 — _ 
1 . 0 0 0 1 . 7 3 0 士 0 . 2 5 7 2 . 0 3 5 ± 0 . 0 6 6 
* 
2 . 5 0 7 士 0 . 0 3 5 1 . 5 6 8 ± 0 . 0 8 7 0 . 8 2 5 ± 0 . 0 3 7 
氺 
C M C M C M 
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C/M ratio 0.399 1.103 2.467 
M: Mitochondrial fraction 
C: Cytosolic fraction 
Fig. 5.5: Effect of jacaric acid (8Z, lOE, 12Z CLN) on the release of cytochrome c 
proteins in the human promyelocytic leukemia HL-60 cells. HL-60 cells (2 x 10^ 
cells) were treated with different concentrations ( 0 - 5 juM) of jacaric acid for 24 
hours at 37°C. The proteins of each sample were extracted and analyzed by Western 
blot as described in Chapter 2. The extracted proteins (20 jug per sample) were 
electrophoresed on a polyacrylamide gel and then transferred onto a PVDF membrane 
for probing with specific primary antibody followed by horseradish 
peroxidase-conjugated secondary antibody. Then ECL detection assay was carried out 
in order to generate visible signal by exposing the membrane to X-ray films. The 
relative intensity of each protein band was normalized with respect to P-actin and 
C/M ratio was calculated. 
* Significantly different from the control, p < 0.05 
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5.2.4 Cleavage of Poly(ADP-ribose) Polymerase (PARP) in the Jacaric 
Acid-treated Human Promyelocytic Leukemia HL-60 Cells 
Poly(ADP-ribosyl)ation is an immediate DNA-damage-dependent post-
translational modification of histories and other nuclear proteins that regulate cell 
survival or cell death. Poly(ADP-ribose) polymerase-1 (PARP-1) is responsible for 
more than 90% of the poly(ADP-ribosyl)ating capacity of the cells. Mild genotoxic 
stimuli may activate PARP-1 and facilitate DNA repair and cell survival. However, 
early PARP activation in apoptosis may assist the apoptotic cascade by stabilizing p53 
and mediating the translocation of AIF from the mitochondria to the nucleus (Virag, 
2005). Moreover, caspases cause cleavage of PARP during apoptosis to stop any 
anti-apoptotic functions of PARP. 
In this study, the human promyelocytic leukemia HL-60 cells were either 
untreated, or treated with 3 jiM or 5 jiiM jacaric acid for 24 hours. The amount of 
protein product was normalized with respect to the house-keeping gene product, 
p-actin. Fig. 5.6 shows that PARP was cleaved after 24-hour treatment. The result is 
consistent with the activation of caspases, as shown in Chapter 4. 
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Concentrations of jacaric acid 
Control 3 jiM 5 i^M 
’ “ ’ 广 丄 1 1 6 kDa 
1 . 0 0 0 0 . 8 1 6 士 0 . 1 1 7 0 . 7 6 1 ± 0 . 0 9 8 
PARP i , z kDa 
底 • (Cleaved rorm) 
1.000 1.075 ± 0.077 1.468 ±0.047 
氺 
旅 _ _ , , : � 25 kDa 
V 一 (Cleaved form) 
1.000 1.122 士 0.076 1.728 土 0.054 
氺 
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Fig. 5.6: Effect of jacaric acid (8Z，lOE，12Z CLN) on the cleavage of PARP 
protein in the human promyelocytic leukemia HL-60 cells. HL-60 cells (2 x 10^ 
cells) were treated with different concentrations (0 - 5 jiM) of jacaric acid for 24 
hours at 37°C. The proteins of each sample were extracted and analyzed by Western 
blot as described in Chapter 2. The extracted proteins (20 jug per sample) were 
electrophoresed on a polyacrylamide gel and then transferred onto a PVDF membrane 
for probing with specific primary antibody followed by horseradish 
peroxidase-conjugated secondary antibody. Then ECL detection assay was carried out 
in order to generate visible signal by exposing the membrane to X-ray films. The 
relative intensity of each protein band was normalized with respect to p-actin. 
* Significantly different from the control, p < 0.05 
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5.2.5 Phosphorylation of ERK in the Jacaric Acid-treated Human Promyelocytic 
Leukemia HL-60 Cells 
There are three protein kinases in the ERK pathway: ERK-1 (p44MAPK), ERK-2 
(p42MAPK) and the alternative spliced form ERK-1 (口40_卩民)Tj^ese three isoforms 
have a high degree of similarity and ERK-1 and -2 show limited difference in 
substrate specificity. They can be activated by a wide range of growth factors and 
mitogens. The kinases are activated by phosphorylation of threonine and tyrosine 
residues in a -TXY- motif that is common in all the MAPK. The substrates of ERK 
are 90RSK, MNKI / 2 , Ets, Elkl, Myc, STAT 1/3 and ER. The cellular responses include 
development, differentiation and proliferation (Seger and Krebs, 1995; Zhang and Liu, 
2002). 
In the present study, the human promyelocytic leukemia HL-60 cells were treated 
with 5 |LIM jacaric acid for a short period of time (0, 0.5, 1, 1.5, 2 and 3 hours) so as to 
investigate the changes in the levels of the phosphorylated ERK. The total ERK 
fraction and phosphorylated ERK fraction were collected, as described in Chapter 2, 
and the proteins were analyzed by the Western blotting using specific antibodies. The 
antibodies used would bind to both ERK-1 and -2. Fig. 5.7 shows that the 
phosphorylated ERK but not the total ERK decreased time-dependently in the 3-hour 
treatment period, indicating that the ERK pathway might not be activated by jacaric 
acid in HL-60 cells. 
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5 |LIM jacaric acid 
Hour (s) 0 0.5 1 1.5 2 3 
1.000 0.976 1.052 1.015 1.103 0.995 
士 0.044 士 0.182 士 0.002 士 0.054 ±0.012 
Total ERK � ^ ^ ^ ^^m ^ ^ ^ 漆 4 4 kDa 
Phosphorylated ： � 夠 ^ kU^ 
1.000 1.221 0.465 0.358 0.351 0.179 
±0.156 士 0.006 士 0.057 士 0.018 士 0.051 
氺 氺 氺 氺 
Fig. 5.7: Effect of jacaric acid (8Z, lOE, 12Z CLN) on the phosphorylation of 
ERK protein in the human promyelocytic leukemia HL-60 cells. HL-60 cells (2 x 
10^ cells) were treated with 5 |iM jacaric acid for 0, 0.5, 1, 1.5, 2 and 3 hours at SV '^C. 
The proteins of each sample were extracted and analyzed by Western blot as 
described in Chapter 2. The extracted proteins (20 i^ g per sample) were 
electrophoresed on a polyacrylamide gel and then transferred onto a PVDF membrane 
for probing with specific primary antibody followed by horseradish 
peroxidase-conjugated secondary antibodies. Then ECL detection assay was carried 
out in order to generate visible signal by exposing the membrane to X-ray films. The 
relative intensity of each protein band was normalized with respect to P-actin. 
* Significantly different from the control, p < 0.05 
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5.2.6 Phosphorylation of JNK in the Jacaric Acid-treated Human Promyelocytic 
Leukemia HL-60 Cells 
The JNK cascade is activated by various stresses, including growth factors, 
cytokines, UV irradiation and even osmolarity. The mammalian JNK family is 
composed of three separate gmes, jnkl, jnk2 and jun3, which are able to form twelve 
isoforms by alternative splicing. The phosphorylated JNK phosphorylates c-Jun, 
ATF2 and Elkl by increasing their transcriptional activities. In contrast, 
phosphorylation of NFAT4 by JNK suppresses its transcriptional activity. The cellular 
fates include apoptosis, differentiation and proliferation (Basu and Kolesnick, 1998; 
Zhang and Liu, 2002). 
In this study, the induction of phosphorylation of JNK by jacaric acid in the 
human promyelocytic leukemia HL-60 cells was studied by the FACE™ JNK ELISA 
kit. The kit determined JNK phosphorylation by specific phospho-JNK antibody and 
total-JNK antibody. Fig 5.8 shows that the ratio of phosphorylated JNK to total JNK 
at 5, 15, 30, 60 and 120-minutes after treatment of HL-60 cells with jacaric acid. It 
was found that JNK was activated and the phosphorylated JNK level was significantly 
elevated at 60-120 minutes of incubation. The results suggest that the JNK pathway is 
probably one of the pathways that might be involved in jacaric acid-induced apoptosis 
of HL-60 cells. 
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Fig. 5.8: Induction of phosphorylation of JNK by jacaric acid (8Z, lOE，12Z CLN) 
in the human promyelocytic leukemia HL-60 cells using FACE^"^ JNK ELISA kit. 
The kit determined JNK phosphorylation relative to the total JNK protein found in 
cells. After fixing the jacaric acid (8Z, lOE, 12Z CLN)-treated HL-60 cells (1 x 10^ 
cells/ml), the phospho-JNK antibody and the total-JNK antibody were added. A 
comparison of the ratio of phosphorylated JNK to total JNK at each time point was 
determined. 
* Significantly different from the control, p < 0.05 
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5.2.7 Phosphorylation of NF-KB Protein in the Jacaric Acid-treated Human 
Promyelocytic Leukemia HL-60 Cells 
In the present study, the induction of NF-KB phosphorylation by jacaric acid in 
the human promyelocytic leukemia HL-60 cells was studied by the F A C E ™ NF-KB 
p65 profiler. The kit determined NF-KB phosphorylation by two specific 
phospho-NF-KB antibodies and one total-NF-KB antibody. Fig 5.9 shows that the ratio 
of phosphorylated NF-KB (at 468 and 536 amino acid residues) to total NF-KB at 15, 
30, 60, 120 and 180-minutes after treatment of HL-60 cells with jacaric acid. The 
results show that NF-KB was activated and the phosphorylated NF-KB level was 
increased gradually after 60-minutes of incubation. 
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Fig. 5.9: Induction of phosphorylation of NF-KB by jacaric acid (8Z, lOE, 12Z 
C L N ) in the human promyelocytic leukemia HL-60 cells using F A C E ™ NF-KB 
p65 profiler. The kit determined NF-KB phosphorylation relative to the total NF-KB 
protein found in cells. After fixing the jacaric acid (8Z, lOE, 12Z CLN)-treated HL-60 
cells (1 X 10^ cells/ml), the phospho-NF-KB antibodies and the total NF-KB antibody 
were added. A comparison of the ratio of phosphorylated NF-KB to total NF-KB at 
each time point was determined. 
* Significantly different from the control, p < 0.05 
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5.3 Discussion 
In this Chapter, the possible involvement of the extrinsic and intrinsic apoptotic 
pathways in the action mechanisms of jacaric acid (8Z, lOE, 12Z CLN) on the human 
promyelocytic leukemia HL-60 cells was studied. In particular, the modulatory effects 
of jacaric acid on the expression of the apoptosis-regulatory proteins such as Fas, 
FasL, Bcl-2 family member proteins, Cyt c and PARP proteins were examined. 
Moreover, some of the well known intracellular signaling pathways, including the 
MAPK and NF-KB pathways, by which jacaric acid might exert its anti-tumor actions 
on the leukemia HL-60 cells, had also been elucidated. As depicted in Fig. 5.10, the 
caspases-dependent intrinsic and extrinsic apoptotic pathways as well as the MAPK 
pathways are well-characterized mechanisms associated with programmed cell death. 
-185 -
Chapter 5 Apoptosis-associated Proteins and Signal ins: Pathways 
Extrinsic pathway Intrinsic pathway M A P K cascades 
� f n 门 TNF receptors 
Cel n n 
( T N F R l , Fas’ S t r e s s 
membrane ^ ^ � 
J V l J Trail R l , Trail R2) ^ ^ \ 
二 XAX z \ = 
/ \ Pro-apoptotic Bcl-2 members \ 
D D M D D \ n \ 
Cytosol FADD 广 、 
V T y f 年 Smac/DIABLO, > M A P K K K 
“ / \ C y t c • • • 
I / rr 
\ l i p I Apaf- l I i 
(caspase-8/-10 ； \ \ ( Caspase-9 ) M A P K K 
j\\ y 
Cleavage of ^ ^ 
PARP ^ 
t M A P K 
N F - K B pathway „ 
N F - K B — , N K , p 3 8 ) 
一 一 ^ ^ ^ ^ ^ “ Up-regulation of pro-apopi^ li^ ^^^^^^^^^^^^^^^^^^^^^^^^^ ^ ^ 
Nucleus Bcl-2 members, death receptors etc. 
Fig. 5.10: An overview of apoptosis-associated pathways and the proteins that are 
involved. (Modified from Klener e t a l , 2006) 
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Based on the results so far obtained and among the mechanisms shown in Fig 
5.10, the intrinsic apoptotic rather than the extrinsic pathway is most likely to be 
involved in triggering apoptosis in the jacaric acid-treated HL-60 cells. It is known 
that the caspase-dependent extrinsic pathway is activated by the tumor necrosis factor 
(TNF)-family receptors. Eight out of the 30 known members of the TNF family 
contain the Death Domain (DD) in their cytosolic tails. Tumor necrosis factor receptor 
l(TNFRl), Fas/CD95, death receptor 4/TNF-related apoptosis-inducing ligand 
receptor 1 (DR4/TrailRl) and death receptor 5/TNF-related apoptosis-inducing ligand 
receptor 2 (DR5/TrailR2) are the DD-containing TNF-family receptors that use 
caspase-activation as a signaling mechanism (Yuan, 1997; Wallach et al., 1999). Fas 
ligand triggers trimerization of Fas and the trimerized cytoplasmic region of the 
receptor recruits the adaptor molecule FADD and transduces death signal to the cells 
(Schwarz et al., 2007). In this study, neither the expression of Fas nor Fas ligand was 
elevated in the jacaric acid-treated HL-60 cells as measured by Western blot analysis. 
This suggests that the extrinsic pathway may not play a significant role in the jacaric 
acid-induced apoptosis of HL-60 cells. 
The inactive Bcl-2 family member proteins are membrane proteins that localize 
to the outer mitochondrial membrane, as well as nuclear envelope and endoplasmic 
reticulum, whereby their N-terminal facing towards the cytosol (Burlacu, 2003). Bcl-2 
proteins have a hydrophobic domain at C-terminal (TM-domain) which allows the 
proteins to insert into the intracellular membrane (Nguyen et al., 1993). For example, 
Bak tightly anchors on the outer mitochondrial membrane in a complex with the 
voltage-dependent anion channel (VDAC) and Bax is loosely attached to the outer 
mitochondrial membrane (Cheng et al., 2003). 
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As Bcl-2 family member proteins are able to form homodimers or heterodimers, 
thus they can work independently or co-operationally to regulate apoptosis. A 
speculative model about how the Bcl-2 proteins regulate apoptosis has been proposed 
(Sato et al” 1994). Homodimerization of Bax protein produces an apoptotic death 
signal. Bax changes its conformation and undergoes oligomerization to form pores on 
the outer mitochondrial membrane to allow the apoptotic factors to leak out 
(Korsmeyer et al., 2000; Daniel et al.’ 2003). Moreover, the BH3 domains of the 
Bcl-2 family BH-3-only proteins, such as Bid and Bim, directly activate Bax (Kuwana 
and Newmeyer, 2003; Kuwana et al, 2005). To counteract the death signal, it is 
believed that Bcl-2 acts as a main inhibitor of Bax. The pro-apoptotic function of Bax 
can be abolished when Bcl-2 binds to Bax to form a heterodimer (Sato et al., 1994). 
However, Bcl-2 is in turn regulated by other Bcl-2 family members. 
Heterodimerization of Bcl-Xs with Bcl-2 prevents Bcl-2 to neutralize the 
pro-apoptotic function of Bax, It has been reported that the Bcl-Xs/Bcl-2 
heterodimerization is much stronger than the Bcl-2/Bcl-2 homodimerization (Sato et 
al., 1994). Pro-apoptotic Bcl-2 proteins which contain only the BH3 domain also play 
some roles in modulating the cell death signal. For example, Bid and Bim enhance the 
oligomerization of Bax and Bak to form pores on the mitochondria (Chen et cd.’ 2005; 
Schwarz et al, 2007). The presence of different Bcl-2 protein dimers may explain the 
existence of active and inactive Bcl-2 members. The equilibrium between these anti-
and pro-apoptotic Bcl-2 family members influences the susceptibility of cells in 
response to a death signal and controls the upstream apoptosis. Thus, the pore 
formation is triggered by the co-operation of different subtypes of the Bcl-2 family 
members. The phenomenon results in the release of other mediators for apoptosis, 
such as Cyt c, into the cytosol from the external membrane of the damaged 
permeabilized mitochondria (Reed, 1997; Green and Reed, 1998). 
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In the present study, it was found that jacaric acid exerted significant modulatory 
effects on the expression of some apoptosis-related proteins in the human 
promyelocytic leukemia HL-60 cells. For example, the expression levels of the 
pro-apoptotic proteins such as Bale and Bad were clearly upregulated while the 
anti-apoptotic proteins such as Bcl-2 and BC1-XL were downregulated in the HL-60 
cells. Interestingly, the Bid protein was found to be cleaved in the jacaric acid treated 
HL-60 cells. It has been reported that proteolytic cleavage of the BH3-only molecule 
Bid can induce apoptosis. Normally, cytosolic Bid with a long flexible loop is 
harmless to cells. However, when the extrinsic pathway-associated caspase-8 is 
activated by death ligands, such as Fas and TNF-a, the loop of Bid will be removed 
(Li et al., 1998). Bid can also be cleaved by caspase-3 in the apoptotic intrinsic 
pathway or granzyme B, which do not associate with any external death ligand 
stimulations (Barry e t a l , 2000; Blomgren e t a l . , 2001). Cleavage of amino-terminal 
domain of p22 Bid produces p i5 Bid, or truncated Bid (tBid), which then translocates 
to the mitochondria. The activated Bid interacts with various mitochondrial proteins 
and induces apoptosis. For example, it has been proposed that tBid can bind to Bax 
and induces its conformational change, so as to facilitate the pore formation on the 
mitochondria membrane and enhances apoptosis (Desagher e t a l , 1999). In this study, 
it was found that jacaric acid did not trigger extrinsic apoptotic pathway but Bid was 
cleaved after incubation of the HL-60 cells with jacaric acid. These results suggest 
that the Bid cleavage is most likely to be linked with the intrinsic apoptotic pathway. 
The intrinsic pathway is mediated by many apoptotic factors and one of the key 
players is Cyt c. In our study, we showed that Cyt c was released from the 
mitochondria to cytosol dose-dependently when the HL-60 cells were treated with 
jacaric acid. Once the Cyt c is released into the cytosol, apoptotic protease-activating 
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factor-1 (Apaf-1) recruits procaspase-9 by its N-terminal caspase-activation 
recruitment domain (CARD). Apaf-1 is a compact molecule in the quiescent state. In 
the presence of ATP, Cyt c displaces the CARD domain, which allows the compact 
structure of Apaf-1 to stretch out into a more linear molecule to activate procaspase-9 
and forms the apoptosome (Cain et al., 2002). This leads to auto-cleavage of 
procaspase-9 to form active caspase-9. Caspase-9 then cleaves and activates the 
"effector" procaspase-3 to caspase-3. 
There are 18 members in the Poly(ADP-ribose) polymerase (PARP) enzyme 
family which respond to synthesis of poly(ADP-ribose) (PAR). Mild genotoxic 
stimuli may activate PARP-1 and facilitate DNA repair and cell survival. However, 
early PARP activation may act as cytotoxic mediator in apoptosis, which assists the 
apoptotic cascade by stabilizing p53, by mediating the translocation of AIF from the 
mitochondria to the nucleus or by inhibiting early activation of DNases (Virag, 2005). 
Moreover, caspases cause cleavage of PARP during apoptosis to stop any 
anti-apoptosis functions of PARP. When cells under the most severe oxidation stress 
conditions, excessive DNA damage leads to over-activation of PARP-1, which 
triggers the switch of cell death mode from apoptosis to necrosis (Virag, 2005). In this 
study, PARP in the HL-60 cells was cleaved after 24-hours of incubation with jacaric 
acid. One possibility is that caspase-3 cleaved PARP and abolished the DNA repairing 
and genotype stabilizing functions of PARP. Further experiments are needed to test 
this hypothesis. 
The mitogen-activated protein kinases (MAPK) are known to play a vital role in 
regulating diverse cellular processes like proliferation, apoptosis, differentiation and 
transformation of cells. At least 14 MAPKKK, 7 MAPKK and 12 MAPK have been 
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identified in mammalian cells (Widmann et al., 1999). MAPK pathways relay, 
amplify and integrate signals from different sources and elicit various cellular 
responses (Zhang and Liu, 2002). 
Raf-MEK-ERK pathway is one of the best characterized MAPK signaling 
pathways. The stimulation of tyrosine kinase receptors (RTK) activates MAPK in 
multi-steps. The cascade of protein kinase starts at MAPKKK (C-Raf-1). MAPKK are 
MEKl and MEK2. MEK activate ERK-1 ERK-2 or the 
alternative spliced form ERK-1 (p40Mapk) xhe kinases are activated by 
phosphorylation of threonine and tyrosine residues in a -TXY- motif that is common 
in the MAPK. The activated ERK translocate to the nucleus and transactivate 
p c 
transcription factors and modulating gene expression, including 90 , MNKl/2, Etsl, 
ternary complex factor Elkl, c-Myc and Tal etc. (Seger and Krebs, 1995; Zhang and 
Liu, 2002). The is known to be an intracellular checkpoint for cellular 
mitogenesis. At the post-translational level, the ERK pathway regulates the assembly 
of cyclin Dl-Cdk4/6 complexes. The complexes phosphorylate the Rb protein leading 
to the activation of E2F transcription factors which regulate the transcription of genes 
associated with Gj/S transition (Ewen, 2000). In the present study, jacaric acid 
suppressed the expression of ERK proteins in the HL-60 cells. The significance of this 
finding is unclear, but it indicates that the ERK pathway might not be involved in the 
apoptosis triggered by jacaric acid in the HL-60 cells. 
Several MEKKK have been reported to activate the JNK pathway, including the 
members o fMEKK group, the ASK group, TAKl and Tpl2 (Davis, 2000). JNK binds 
to the N-terminal activation domain of c-Jun and phosphorylates its residues Ser-63 
and Ser-73. Transactivation of c-Jun causes an increase in expression of genes that 
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have AP-1 sites in their promoters, for example c-jun gene itself. Therefore, a positive 
feedback loop is initiated. JNK also increases the transcriptional activity of its 
substrates, including activating transcription factor 2 (ATF2), Elkl and p53 (Widmann 
et al, 1999). JNK pathway is known to be involved in both the cell death and cell 
survival signaling. It has been reported that the UV-induced apoptosis in fibroblasts 
requires JNK activation for Cyt c release from the mitochondria (Tournier et al., 
2000). JNK also transduces differentiation signals for the hematopoietic system and is 
probably involved in embryonic development (Basu and Kolesnick, 1998; Zhang and 
Liu, 2002). In this study, an induction of phosphorylation of JNK by jacaric acid in 
the HL-60 cells was observed, suggesting that the JNK pathway might play a role in 
the jacaric acid-induced apoptosis of the HL-60 cells. 
NF-KB activation has a survival function and it suppresses both apoptosis and 
necrosis. Rel-A subunit of NF-KB is an essential element for the survival of liver cells 
in embryonic mice and provides a protective role by inhibiting the TNFRl-mediated 
apoptosis (Doi e t a l . , 1999). It was also shown to suppress apoptosis and necrosis in 
the liver of adult mice (Lavon e t a L , 2000; Chaisson e t a l . , 2002). As a transcription 
factor, NF-KB is able to initiate the expression of several pro-survival proteins, 
including BC1-XL, cellular inhibitor of apoptosis (c-IAP), X chromosome-linked 
inhibitor of apoptosis (XIAP) and TNFR-associated factors (TRAFs) etc. (Karin and 
Lin, 2002; Kucharczak et aL, 2003). 
Interestingly, NF-KB activation may also induce apoptosis in a stimulus- and cell 
type-dependent manner (Luo et al., 2005). NF-KB might mediate the 
doxorubicin-induced cell death in the N-type neuroblastoma SH-SY5Y and IMR32 
cells (Bian et al., 2001). It is also required for the anti-CD3-induced apoptosis in the 
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murine double-positive thymocytes (Hettmann et al., 1999). An in vitro study had 
shown that epotoside- and 1 -P-D-arabinofuranosylcytosine triggered NF-KB 
activation in the HL-60 cells within 1 hour and induced apoptosis within 3 to 4 hours 
(Bessho et al., 1994). It has been proposed that downregulation of NF-KB can prevent 
the human melanoma cells to undergo UV radiation-induced apoptosis (Ivanov et al, 
2000). Recently, NF-KB has shown to act as a repressor of anti-apoptotic genes in the 
UV light- or doxorubicin-induced apoptosis. It is believed that the "surprising" 
pro-apoptotic functions of NF-KB are triggered without the involvement of TNF-a. 
In this study, NF-KB phosphorylation was induced by jacaric acid in the HL-60 
cells within 3 hours. As a previous study had shown that HL-60 cells triggered by 
certain chemotherapeutic agents to undergo apoptosis required NF-KB activation 
(Bessho et al,, 1994), it is reasonable to believe that the jacaric acid-induced apoptosis 
in HL-60 cells also involves NF-KB activation. Our results suggest that NF-KB may 
have pro-apoptotic functions and can mediate apoptosis under certain conditions. Yet, 
the pathophysiological relevance of these observations remains to be determined. 
In conclusion, based on the results shown in Chapter 4 and 5, a hypothetical 
model by which jacaric acid may exert its apoptotic activity on the HL-60 cells can be 
proposed as follows. Jacaric acid can activate the intrinsic pathway by upregulating 
the pro-apoptotic Bcl-2 family members, such as Bak, Bad, and downregulating the 
anti-apoptotic Bcl-2 family members, such as Bcl-2 and BCI-XL. The imbalance 
between the pro-apoptotic and the anti-apoptotic Bcl-2 family members triggers the 
formation of mitochondrial permeability transition (MPT). Mitochondrial pore 
formation leads to the loss of A\\jm and ultimately the release of Cyt c into cytosol. 
Cyt c binds to Apaf-1 and recruits cytoplasmic procaspase-9 to form a complex called 
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apoptosome. Autocatalytic activation of procaspase-9 is initiated to produce active 
caspase-9. Caspase-9 then cleaves and activates procaspase-3 to give an important 
effector caspase, caspase-3, to signal other downstream apoptotic mechanisms. The 
extrinsic pathway plays an insignificant role, if any, in the jacaric acid-induced 
apoptosis. Neither Fas, FasL nor caspase-8 are activated in the jacaric acid-treated 
HL-60 cells. Apoptosis is also triggered by oxidative stress by the ROS-dependent 
cell death pathway. In addition, activation of the apoptosis-associated JNK pathway, 
but not the differentiation-associated ERK pathway, also gives more hints to the 
apoptotic mechanisms. Finally, activation of NF-KB pathway may play a role in 
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Chapter 6 Conclusions and Future Perspectives 
Conjugated linolenic acid (CLN) is a group of positional and geometrical 
conjugated trienoic isomers of C-18 linolenic acid, which are the major components 
of some plant seeds. They cannot be synthesized by mammals and must be isolated 
from plants. There are seven major CLN isomers found in nature: punicic acid (cis-9, 
trans-11, cis-\3 CLN), a-eleostearic acid {cis-9, trans-11, transCLN), 
y^-eleostearic acid {trans-9, trans-11, trans-\3 CLN), catalpic acid {trans-9, trans-\\, 
cis-13 CLN), a-calendic acid (trans-^, trans-10, cis-12 CLN), /?-calendic acid (jrans-名, 
trans-XO, trans-12 CLN) and jacaric acid {cis-^, trans-W，cis-12 CLN). Researchers 
have also tried to produce CLN directly by bacterial biosynthesis. However, the yield 
and purity are unsatisfactory. Recent studies have revealed that CLN isomers, such as 
a-eleostearic acid, catalpic acid and punicic acid, have chemopreventive activity in 
the early phase of colon carcinogenesis in rats (Kohno et al., 2002; 2004; Suzuki et al., 
2006). Apart from colorectal cancer cells, CLN isomers also possess potent anti-tumor 
effect on a wide range of cancer cells, including hepatoma (HepG2), lung 
adenocarcinoma (A549), breast adenocarcinoma (MCF-7) and stomach tubular 
adenocarcinoma (MKN-7) (Igarashi and Miyazawa, 2000). Yet, the mechanisms 
behind the anti-proliferative effect of CLN isomers are still unclear; they may serve as 
cytotoxic or cytostatic mediators to various human cancer cell lines. 
As shown in Chapter 3, CLN isomers (a-eleostearic acid, y^-eleostearic acid, 
y^-calendic acid and jacaric acid) could inhibit the proliferation of human 
promyelocytic leukemia HL-60 and NB-4 cells dose-and time-dependently. Similar 
effect has been demonstrated in other human leukemia cell lines, including 
HL-60/MX2, EoL-1, K562 and in a human lymphoma cell line U-937. Moreover, the 
four conjugated trienoic acids that we had chosen for our studies, but not their 
parental fatty acids (a-linolenic acid and y-linolenic acid), showed strong 
-195 -
Chapter 6 Conclusions and Future Perspectives 
anti-proliferative effect on the HL-60 cells. This indicates that the conjugated double 
system is essential for the anti-proliferative activity of the conjugated trienoic acids. 
Among the four CLN isomers, jacaric acid was found to be more potent than the other 
three CLN isomers in inhibiting the proliferation of the leukemia HL-60 cells in vitro, 
so subsequent experiments had been done on this CLN isomer to elucidate the 
mechanisms behind the anti-leukemic effects of jacaric acid. The observed 
anti-proliferative effect of jacaric acid is most likely to be due to its cytostatic, but not 
cytotoxic, effect on the HL-60 cells as shown by the trypan blue exclusion assay. In 
addition, our results also indicate that jacaric acid exhibited little, if any, cytotoxicity 
on normal cells, such as murine peritoneal macrophages, murine bone marrow cells, 
human hepatocyte-like WRL 68 cells and human foreskin fibroblast Hs68 cells. As 
different CLN isomers showed differential anti-proliferative activity on the two acute 
promyelocytic leukemia cell lines (the HL-60 and the NB-4 cells), it is conceivable 
that the positions of conjugated double bonds and the trans- and cis- configurations of 
the double bonds in the CLN isomers might play certain roles on the anti-proliferative 
effect (Suzuki et al., 2001). Though the detailed structure-function relationship of 
different CLN isomers has not been elucidated in this project, it is worthy for future 
investigations once more CLN isomers can be isolated from natural sources or 
become available commercially. 
To elucidate the mechanisms by which jacaric acid could suppress the growth of 
HL-60 cells in vitro, the effects of this CLN isomer on cell cycle progression, 
apoptosis and differentiation of the HL-60 cells were investigated. Our findings 
revealed that jacaric acid could trigger cell cycle arrest at the GQ/GI phase. It is known 
that the checkpoints of cell cycle are regulated by the cyclin-dependent kinases (cdk) 
and cyclins. Moreover，the Gi/S-phase transition is regulated by two families of G\ 
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cyclins, the D-type cyclins (cyclin Dl , D2 and D3) and the E-type cyclins (cyclin El 
and E2), and their cyclin-dependent kinases (cdk-4, -6 and -2). The activities of the 
cdk are also regulated by two families of cyclin-dependent kinase inhibitors (CKI): 
the Cip/Kip family and and the INK4 family (plS!巡4b， 
pl6iNK4a, pi8iNK4c and (Myatt and Lam, 2007). Therefore, the expression of 
cell cycle-regulatory genes and proteins in the jacaric acid-treated HL-60 cells can be 
investigated using the RT-PCR and Western blotting techniques respectively in the 
future. 
As jacaric acid exhibited growth-inhibitory effect and triggered cell cycle arrest 
of the HL-60 cells in vitro, the suppressive effect of jacaric acid on the tumorigenicity 
of the HL-60 cells in BALB/c nude mice was also examined. Our results show that 
the pre-treatment of HL-60 cells in vitro with jacaric acid could significantly inhibit 
the in vivo growth of leukemia cells in nude mice dose-dependently. Obviously, more 
studies should be carried out in the future using in vivo tumor models to show that 
CLN administered in vivo by various routes can prevent leukemia formation in the 
animals or can suppress the growth of established tumor in the leukemia-bearing 
mice. 
In addition to cell cycle arrest, another possible mechanism leading to the growth 
inhibition of leukemia cells is the induction of apoptosis. Our results clearly show that 
jacaric acid could induce apoptosis in the HL-60 cells in a dose- and time-dependent 
manner, as demonstrated by the DNA fragmentation assay using gel electrophoresis 
and cell death ELISA kit. To follow the apoptosis-associated changes in different parts 
of the leukemia cells, various assays had been carried out to examine the changes in 
the cell surface membrane, mitochondrial membrane potential and cytoplasmic 
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protein expression, after the HL-60 cells were cultured with jacaric acid for various 
time periods. One of the well-known signs of early apoptosis, the translocation of 
phosphatidylserine from the inner side of the plasma membrane to the outer layer, was 
detected in the jacaric acid-treated HL-60 cells by the Annexin V-GFP PI double 
staining method. Moreover, the mitochondrial membrane potential of the jacaric 
acid-treated HL-60 cells was depolarized dose- and time-dependently, suggesting an 
involvement of the intrinsic apoptotic pathway, but not necrosis, in the jacaric 
acid-treated HL-60 cells. The expression of a number of proteins that are involved in 
apoptosis was also investigated by the Western blot analysis. The intrinsic apoptotic 
pathway activation was confirmed by the elevated expression of pro-apoptotic Bcl-2 
family member proteins Bak and Bad and the reduced expression of anti-apoptotic 
proteins Bcl-2 and BC1-XL in the jacaric acid-treated HL-60 cells. Our results also 
show that Cyt c, an imperative mediator of apoptosis, was released from mitochondria 
to cytosol in the jacaric acid-treated HL-60 cells in a dose-dependent manner. It is 
conceivable that Cyt c possibly binds to Apaf-l and recruits procaspase-9 to form an 
apoptosome but this awaits further investigations. The cleavage of PARP protein also 
supported the involvement of the caspase-dependent apoptotic pathway. Interestingly, 
jacaric acid did not increase the expression of Fas and Fas ligand proteins in the 
jacaric acid-treated HL-60 cells. Therefore, the extrinsic pathway seems not to be 
involved in the jacaric acid-induced apoptosis. 
Specific caspase substrates (Ac-DEVD-AMC, Ac-IETD-AMC and 
Ac-LEHD-AFC are substrates for caspase-3, -8 and -9 respectively) and caspase 
inhibitors (Ac-DEVD-CHO, Ac-IETD-CHO and Ac-LEHD-CHO are inhibitors for 
caspase-3, -8 and -9 respectively) were used to measure the caspases-3, -8 and -9 
activities during jacaric acid-induced apoptosis of the HL-60 cells. An "initiator" 
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caspase of the intrinsic pathway, caspase-9, and its "effector" caspase, caspase-3, were 
activated after treatment of the HL-60 cells with jacaric acid. However, an "initiator" 
caspase of the extrinsic pathway, caspase-8, was not activated, confirming that the 
intrinsic apoptotic pathway is a major pathway to mediate the jacaric acid-induced 
apoptosis of the HL-60 cells. 
Apart from the intrinsic apoptotic pathway, jacaric acid initiated oxidative stress 
in the HL-60 cells and induced apoptosis through the ROS-dependent cell death 
pathway. In our studies, we found that jacaric acid enhanced ROS production in the 
HL-60 cells. Interestingly, pre-treatment of the HL-60 cells with antioxidants such as 
SOD or NAC significantly suppressed the ROS production and blocked apoptosis in 
jacaric acid-treated HL-60 cells. Over-production of ROS in jacaric acid-treated 
HL-60 cells may damage the cells by lipid peroxidation, DNA fragment formation 
and enzyme oxidation and inactivation, and all these events may cause death of the 
leukemia cells. It would be of interest to see whether pre-treatment with NADPH 
oxidase inhibitor or protein kinase C (PKC) inhibitor can suppress the jacaric acid 
induced-apoptosis in HL-60 cells. This may give us more hints if the jacaric acid 
induced oxidative stress is mediated by the NADPH/PKC oxidase pathway (Bergamo 
et al. 2004). Moreover, the jacaric acid-induced apoptosis may also involve other 
pathways, such as the endoplasmic reticulum (ER) stress-induced apoptotic pathway 
and lysosomal-dependent (cathepsin B/D-regulated) apoptotic pathway (Chwieralski, 
et al., 2006; Boelens et al., 2007). Involvement of other novel caspases or 
caspase-independent factors is still unknown in the jacaric acid-induced apoptosis. 
Future investigations of all these mechanisms are eagerly awaited. 
p53 plays significant roles in many processes related to apoptosis because of its 
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tumor suppressor activity (Yee and Vousden, 2005). p53 transcriptionally 
transactivates or transrepresses many genes which are involved in both the intrinsic 
and the extrinsic pathway (Hussain and Harris, 2006). It interferes with the balance 
between the pro-apoptotic and the anti-apoptotic Bcl-2 member proteins by 
transactivating Bax, Puma, Noxa and Bid genes, so as to initiate the mitochondrial 
membrane depolarization (Oda et al., 2000). It also transactivates Apaf-1 to promote 
the intrinsic pathway. Moreover, it also transactivates Fas, DR4 and DR5 to trigger 
the extrinsic pathway (Mueller et al., 1998). Oxidative stress may also be associated 
with the p53-mediated apoptosis as some of the p53-inducible genes are redox-related 
genes (Polyak et al., 1997). p53 also induces upregulation of manganese superoxide 
dismutase (MnSOD) which imbalances the antioxidant enzyme mechanism and leads 
to oxidative stress and ultimately apoptosis (Hussain et al., 2004). 
Transcription-independent p53-associated apoptotic mechanisms have also been 
proposed. p53 has a direct apoptogenic role on the mitochondria by acting as a 
functional homologue of the BH3-only protein which directly inhibits Bcl-2 and 
BC1-XL and induces the Cyt c release (Mihara et al, 2003; Yee and Vousden, 2005). In 
this project, the effects of jacaric acid on the expression of p53 in HL-60 cells have 
not been determined. Whether jacaric acid can affect the p53 gene expression at the 
transcriptional or translational level is an intriguing aspect that is worthy of future 
investigations. 
We demonstrated that jacaric acid did not exhibit differentiation-inducing effect 
in the HL-60 cells, as judged by a number of criteria such as morphological, 
phenotypic and functional changes in the jacaric acid-treated HL-60 cells. The typical 
morphology of differentiated cells, including an increase in cell size and internal 
complexity, could not be observed in the jacaric acid-treated HL-60 cells. This is 
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supported by the fact that there was little, if any, increase in the expression of the cell 
surface markers of monocytic differentiation C D l l b and CD 14 on the jacaric-acid 
treated HL-60 cells. Collectively, our results indicate that induction of leukemic cell 
differentiation is unlikely to be responsible for the observed anti-proliferative effect of 
jacaric acid on the leukemia HL-60 cells. 
By unravelling the signaling pathways by which jacaric acid can exert its effects 
on the myeloid leukemia cells, it is hoped that novel targets for the treatment of 
leukemia can be identified. Our results show that jacaric acid activated the 
apoptosis-associated JNK pathway, but not the differentiation-associated ERK 
pathway of the MAPK pathways. Jacaric acid also triggered the NF-KB pathways, 
which probably play certain roles, including inducing or regulating apoptosis in the 
HL-60 cells. Nevertheless, the possible involvement of other signaling pathways such 
as p38 MAPK pathway, JAK/STAT pathway and PI3K pathway, in the jacaric 
acid-induced apoptosis of HL-60 cells have not been examined. In addition, the 
correlation and cross-talk among these different signaling mechanisms in the action 
mechanisms of jacaric acid have yet to be demonstrated. Further investigations using 
selective pharmacological agents or specific inhibitors which can interfere or block 
these signaling pathways may provide better insights into the roles of various 
signaling molecules in the anti-leukemic action of jacaric acid. 
In conclusion, CLN or its isomers such as jacaric acid are natural products which 
have the potential to be developed as chemotherapeutic agents with high efficacy and 
low toxicity for the treatment of myeloid leukemia. However, more evidence should 
be provided on the safety and efficacy of using CLN as a drug for the therapeutic 
treatment of leukemia in humans in vivo. It is obviously that more in-depth 
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investigations are needed to reveal the molecular and signaling mechanisms 
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